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Abstract 
 
Jung Ho Jun, Ph. D 
Department of Chemistry, October 2013 
University of Kansas 
 
Sulfur containing compounds have become increasingly important in the development of 
biological agents for pharmaceutical and industrial use.  Cyclic sulfamides, in particular, have 
been found to be useful as cancer, HIV protease inhibitors and other therapeutic treatments.  As 
the need for new and improved inhibitors is warranted by the serious cancer disease, the search 
for new synthetic pathways to access novel sulfamides is ongoing.  To this end, the work 
discussed herein focuses on the synthesis of newly developed sulfamides utilizing the reductive 
amination and Mitsunobu reaction to generate novel chiral amino ester containing sulfamide 
compounds.  These compounds are being screened for their biological activities as Tyrosyl-DNA 
phosphodiesterase 1 (Tdp 1) inhibitors and anti-cancer drugs. Initially, reductive amination, CSI 
coupling, and Mitsunobu reaction were employed to generate piperidinyl sulfamides, and these 
compounds were screened for Tdp1 inhibition.  These compounds were submitted to Dr. 
Pomier’s group at NIH to carry out the gel study to select active compounds.  We also checked 
the binding effect through the protein docking study.  In addition, these sulfamide compounds 
were screened from NCI 60-cancer cell lines to check the bioactivity and in vitro cytotoxicity 
evaluation.  To understand anti-cancer activity of cyclic sulfamides, symmetric and unsymmetric 
seven-membered sulfamides compounds were tested in 60 cancer cell line from the National 
Cancer Institute.  These compounds were made when I studied for the Master degree at the 
University of Kansas.  RCM was employed to generate symmetric seven-membered cyclic 
sulfamides similar in structure to known active HIV protease inhibitor DMP 323.  
iv 
 
Functionalization of these compounds employing “robust S-linchpins” in conjunction with RCM 
yields an array of new S-heterocycles.  Further work in sulfamides employed a combination of 
RCM with different coupling routes to generate unsymmetric seven-membered cyclic sulfamides 
with varied substitution in their P1/P1' and P2/P2' periphery in attempts to broaden the scope of 
this chemistry and to generate new biologically active compounds. 
 
 
 
 v
 
 
 
 
 
 
 
 
 
 
 
 
To my friend and wife 
To my love 
 
JungRim Moon 
 
My soul mate and intimate prayer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi
 
 
 
 
 
 
 
 
 
 
 
 
To my family with love 
 
My father and mother 
My daughter, Talia Jun 
My sister’s family 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii
Acknowledgements 
 
First of all, I would like to thank the Lord for guiding my way, and my eternal friend, 
lovely wife and soul mate, Jungrim Moon.  As I always mentioned, you are a 
precious gift from God.  You always give me lots of ideas of how to endure 
torrential life and go straight toward our promised future with God.  You have 
shown your love and support to me every single day and every moment.  I sincerely 
appreciate your prayer that you always hope my life goes well.  I love you and will 
love you forever. 
 
My daughter, Talia.  You are the greatest gift and an angel for me and your mom 
from the Lord.  I still remember the first day when your mom gave birth to you.  I 
enjoyed holding you in my arm as my first and only daughter.  You were so cute and 
pretty!!!  When you held my finger with your hand for the first time, I cried with joy 
and grace.  The very first day of your walking, your mommy and daddy were so 
excited and proud of you.  Now you are already the first grade student.  Talia, I 
pray to God that you always enjoy your life and journey, and be in his graceful 
guidance.     
 
My family, father, mother, my younger sister’s family, and my father-in-law family.  
All of you are the Lord’s greatest gift to me.  I am entirely blessed to have you 
always praying on my behalf.  Dad, you are my hero and master of my adventurous 
sailing.  Whenever I needed your wisdom and experience, you always constantly 
encouraged and supported me.  Dad, I will never forget memories of us climbing the 
mountains together every New Year’s Day.  Mom, thank you for always supporting 
my efforts and for being my best friend.   You have been a major part of my life for 
so long.  I will pray for your health and pleasure.  My younger sister, Jungrim Jun, 
you are my lovely friend and I hope you are always happy with your son, Jinho.  
Without your thoughtful consideration of my life, it would have been impossible to 
achieve this goal.  Jinho, you will be remembered always as my cute nephew and I 
want you to grow like Joseph with BIG DREAM!  My mother-in-law and father-in-
law, thank you for your continuous prayer for my family.  My wife’s sister family, 
Misuk and Jaesung.  I won’t forget all of the memories that we had last summer. It 
was really great time with you.  
 viii
 
Paul, it is a great honor to have been a member of your group at KU.  It is really 
hard to say how much I appreciate your endless support for everything.  I have 
enjoyed the past four years at KU very much and five years as an out-of state student.  
Well, it is hard to count how many years I have been studied as your student.  I still 
remember that you always give us small gifts such as balloons, screwdrivers, stirring 
bars, etc. that bring joy to us every time.  You are a great chemist and you advised 
me with all stimulating knowledge of chemistry.  You always suggest thinking on 
the lighter side that I really appreciate.  I thank you for every little but important 
thing you have done for me.  You are a truly selfless, gifted advisor who cares of his 
group members like they are his own kids.   
 
Yumi nuna (“nuna” means older sister in Korean)!  I thank you all of your support 
and advise.  Without your help, I couldn’t even start my American life in the very 
beginning of study.  I am very curious why I feel this way, but as I call you “nuna”, I 
feel sometimes Paul is my brother-in-law or BIG Brother!  Thank you so much for 
being a group MOM!!  We really appreciate your endless support and love to all 
group members.  Paul and Yumi nuna!!  I will pray for you and your family. 
 
To the rest of my committee: I would like to thank Dr. Richard Givens, Dr. Jon Tunge, 
Dr. Minae Mure, and Dr. Thomas Prisinzano for your guidance in my career, and your 
lesson in Wednesday Night Problem Sets.  Professor Givens, I really enjoyed to read 
your warm and sincere e-mails.   
 
Sanjay (a.k.a. S. V. Malhotra), you are my co-advisor and manager.  I enjoyed many 
events and projects with you as your group member at SAIC-Frederick.  Thank you 
for discussing with me many times about my Ph.D. project and I learned a lot about 
managing and networking skills from you.  I also appreciate your investment in my 
career. 
 
Many thanks to all of the other professors who have contributed to my intellectual 
and personal development:  Dr. Robert Carlson, Dr. Helena, Malinakova, Dr. David 
Benson, Dr. Jeffrey Aube, Dr. Andrew Borovik, and Dr. Brian Blagg. I thank you all.  
 
 ix
I want to thank all of Hanson group members who are in my memory.  Don, Matt, 
Joel, Joe, Andy, Poon, Rusty, Shubashish, Mianji, Punitha, Alan, Steve, Maria, Josh, 
Thiwanka, and so on.  I really miss the fun we had and lots of memories with you 
guys!!  I do not think I will ever have an experience as enjoyable as I had working 
with you guys. I hope to see you all at Paul’s 60th Birthday Party!!!! (It will come 
very soon). 
 
Vineet, my previous colleague at SAIC-Frederick.  I enjoyed every moment last five 
years with you as LSC group member.  I have many memories with you from setting 
our lab to the renovation and more.  I hope we keep in touch and I will be watching 
your career from afar.  You are my good friend!  
 
Many current Hanson group members.  Even if we never work together in a lab, I 
feel like we’ve been worked altogether for a long time.  Naeem, Pradip, Qin, Saqib, 
Joanna, Jana, Soma, Rambabu, Salim, Kyu Ok, Susanthi, Moon Young, and more.  
Thank you for listening my Skype- presentation at group meeting and reading my 
thesis.  Kyu Ok, I will continuously watch your next steps as a young chemist.  
Naeem, I appreciate your time and effort to set up seminar schedules for me. Moon 
Young, I appreciate your technical support for each time.  Guys! Remember this. 
One day you will move on leaving DOOMSDAY behind forever and ever. The day 
will come, the sun will rise, and we’ll be fine! 
 
Finally, I would like to thank Dr. Changkiu Lee and Dr. Insook Han-Lee, my former 
advisors and organic chemistry professors at the Kangwon National University in 
Korea.  Your enthusiasm for organic chemistry encouraged many students including 
me to step up to higher field and to study abroad to explore new and advanced 
academic area.  You introduced me a new life view to plan and help to educate next 
generation.  I am forever grateful for your commitment to me.  I hope you continue 
to harvest a greater research result every year.      
 
 
 
 x 
 
Table of Contents 
Title Page         i 
Acceptance page       ii 
Abstract        iii 
Dedication         v 
Acknowledgments        vii 
Table of Contents       x 
Thesis Explanation       xiii 
Abbreviations        xiv 
 
 
 
Chapter 1 Biologically Active Sulfamides and Synthetic Approaches to 
Sulfamides        1 
  
1.1. Introduction       2 
1.2. Methods for generation of acyclic sulfamides   6 
1.3. Methods to generate cyclic sulfamide    17 
1.4. Sulfamide catalysts      30 
1.4.1. Hydroaminoalkylation and hydroamination   31 
1.4.2. Aldol reaction       32 
1.4.3. Conjugate addition      33 
1.4.4. Michael addition       35 
1.4.5. Mitsunobu-like coupling     37 
1.4.6. Utilization of cyclic sulfamide as chiral auxiliaries   39 
1.5. Conclusion       41 
1.6. Reference        43 
 
 
 xi 
Chapter 2 Newly Developed Piperidinyl Sulfamides as Tyrosyl-DNA 
phosphodiesterase 1 (Tdp 1) Inhibitors    57 
 
2.1. Abstract        58 
2.2. Introduction       58 
2.3. Topoisomerase I (Top1) and Tyrosyl-DNA  
phosphodiesterase 1 (Tdp1)     59 
2.4. Chemistry       64 
2.4.1. Initial Gel Study       67 
2.4.2. Protein docking Study      68 
2.4.3. Synthesis of Piperidinyl Sulfamides     70 
2.5. Biology         74 
2.5.1. Expression and Purification of Tdp1     74 
2.5.2. Tdp1 Gel-Based Assay       75 
2.6. Molecular Modeling of Piperidinyl Sulfamide Derivatives   76 
2.6.1. Preparation of ligand structures      76 
2.6.2. Molecular Docking       77 
2.7. Conclusion          77 
2.8. Reference        78 
 
 
Chapter 3 Study of Anticancer Activity of Piperidinyl Sulfamides Derivatives  
Using the USA National Cancer Institute 60 Human Cancer Cell 
Line (NCI 60) Screening       84 
 
3.1. Introduction       85 
3.2. NCI 60 Cell Line Screening      86 
3.2.1. In vitro anticancer activity      89 
3.2.2. Five dose assay       94 
3.3. Conclusion        107 
3.4. References        107 
 
 xii 
 
Chapter 4  Study of Anticancer Activity of Seven-membered Cyclic Sulfamide 
Analogs Using the USA National Cancer Institute 60 Human 
Cancer Cell Line (NCI 60) Screening       109 
 
4.1. Introduction        110 
4.2. Summary of the synthesis of cyclic sulfamide compounds  113 
4.3. Anticancer drug discovery 60 cell line screening at the  
National Cancer Institute (NCI)     122 
4.3.1. One dose assay       122 
4.3.2. Five dose assay       131 
4.4. Conclusion        145 
4.5. References        146 
 
Chapter 5  Experimental Data       153 
 
5.1. General Methods       154 
5.2. Experimental Procedure and data: Chapter 2   155 
5.3. Appendix A: Selected 1H and 13C NMR’s    203 
5.4. Appendix B: One and five dose experimental data from 60  
cell line - Tdp1 related compounds    239 
5.5. Appendix C: One and five dose experimental data from 60  
cell line - Cyclic sulfamide compounds    262 
5.6. References        307 
 
      
 
 
 xiii 
Thesis Explanation: 
 
This thesis is separated into three major parts and is set up to be easily perused by the 
interested reader. 
 
Chapter 1 consists of an introduction of biologically active sulfamides and synthetic 
approaches to sulfamides. 
 
Chapter 2 contains the synthesis of newly developed piperidinyl sulfamides as 
Tyrosyl-DNA phosphodiesterase 1 (Tdp 1) Inhibitors. 
 
Chapter 3 is the study of anticancer activity of piperidinyl sulfamides derivatives 
using the National Cancer Institute 60 human cancer cell line (NCI 60) screening.  
 
Chapter 4 is discussion about the anticancer activity of seven-membered cyclic 
sulfamide analogs using the Nnational Cancer Institute 60 human cancer cell line 
(NCI 60) Screening. 
 
Chapter 5 is the experimental section consisting of an explanation of all synthetic 
methods and selected 1H and 13C NMR spectra for new compounds that have been 
synthesized.  In spectral data for pertinent new compounds is reported. This section 
also contains the results of one and five dose experimental data from NCI 60 cell line. 
 
For the purpose of simplicity, Grubbs 1st generation catalyst and 2nd generation 
catalyst have been designated I and II, and refer to the structures listed below: 
Ru
PCy3
PCy3
Ph
Cl
Ru
PCy3
Cl
NN
ClCl
Grubbs 1st Generation Grubbs 2nd Generation
Ph
I II  
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CHAPTER 1 
Introduction:  
Biologically Active Sulfamides and Synthetic Approaches to Sulfamides 
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1.1. Introduction 
Over the past decade, the sulfamide (R2NSO2NR2) functionality has found extensive use 
in medicinal chemistry for the development of novel small molecule therapeutic agents and high 
affinity protein ligands.1,2  The synthesis of the first sulfamide was reported in 1892 by Traube, 
who prepared it from sulfuryl chloride and gaseous ammonia.3  
The utility of sulfamides can be attributed to the ability to variably substitute with up to 
four different substituents, which are distributed on the two nitrogen atoms, thus offering 
diversity.  Moreover, the sulfamide functional group can also act as a useful biosteric 
replacement for sulfonamide, sulfamate, urea, carbamate, ketoamide, ester, and amide 
functionalities when incorporated into putative pharmaceutical agents, as it has the potential to 
construct several electrostatic interactions with protein and other targets.4  
Notably, numerous compounds have been reported as marketed and investigational drugs 
in which the free or substituted sulfamide moiety plays a key role in dictating potent biological 
activity (Figure 1.1).  Doripenem (1.1), structurally related to penicillin, is an ultra-broad 
spectrum injectable antibiotic that was recently approved by the Food and Drug Administration 
(FDA) for the treatment of complicated intra-abdominal infections and complicated urinary tract 
infections.5  It is currently on market by Johnson & Johnson and is a beta-lactam that belongs to 
the subgroup of carbapenems.  Initially, it was launched in 2005 by the Shionogi Company of 
Japan under the brand name Finibax.  Quinagolide (Norprolac, 1.2), is a selective, dopamine 
receptor agonist that is used for the treatment of elevated levels of peptide hormone prolactin.6 
JNJ-26990990 (1.3), a primary sulfamide used for the treatment of epileptic seizures is reported 
to have entered phase II clinical trials as a broad-spectrum anticonvulsant drug.7  Macitentan 
(1.4), has currently entered phase III human clinical trials for pulmonary arterial hypertension. 
Famotidine (1.5), is a histamine-2 (H2) blocker, which is now on the market for the treatment of 
ulcers in the stomach. 
3 
 
 
Figure 1.1. Examples of sulfamide-containing drugs. 
Interestingly, sulfamides have also seen widespread utilization in early, and late-stage, 
drug discovery efforts in several therapeutic areas, such as glaucoma, cancer, obesity, epilepsy 
and other neurological disorders.8  In particular, the search for therapeutics for the treatment of 
cancer remains an ongoing endeavor with a World Health Organization (WHO) 9  survey 
revealing that approximately 7.6 million people worldwide died (around 13% of all deaths) from 
cancer in 2008. 
In this regard, several acyclic sulfamides have emerged as potential cancer drugs and are 
shown in Figure 1.2.  Compound 1.8 has undergone clinical investigation at Merck as an orally 
dosed c-Met (Mesenchymal epithelial transition factor, tyrosine kinase receptor) inhibitor which 
inhibits the expression of hepatocyte growth factor (HGF, scatter factor).10,1a  Aberrant activation 
of c-Met can increase the tumorigenicity and metastatic potential of tumor cells, so it is 
hypothesized that the inhibition of c-Met could suppress tumor aggressiveness and decrease the 
lethal disruptions to embryogenesis.11  Recently, kinesin spindle protein (KSP) has been the 
focus of intense interest as a novel biological target for anticancer therapy by 
GlaxoSmithKline.12  Further, biphenyl sulfamide 1.9 was found to exhibit potent inhibitory 
activity against kinesin spindle protein (KSP) with in vitro anti-proliferative activity against 
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human cells with mutant KSP (HCT116 D130V).11  Sulfamide compound 1.10 was rationally 
designed and tested for the steroid inhibition of glucose 6-phosphate dehydrogenase (G6PD) in 
HEK293T cells, with good activity, and was retained with this sulfamide compound.13  Moreover, 
a series of sulfamidocyclopropanecarboxylates 1.11 were discovered as potent, highly selective 
and orally bioavailable aggrecanase inhibitors in 2011.14  Aggrecanases are considered as 
possible drug targets for the treatment of osteoarthritis, a degenerative joint disease.  While other 
potent MMP compounds bear a hydroxamate zinc-binding group that tend to lack metabolic 
stability,15 and inhibit other MMPs such as MMP-3, MMP-9, and MMP-13 in broad range 
selectivity panel, 1.11 has a carboxylate zinc-binding group which has good oral bioavailability 
and was identified as highly selective aggrecanase-2 inhibitor.  It is widely admitted that a 
diversity of unacceptable hostile events, such as musculoskeletal disorder, that have been  
 
Figure 1.2. Biologically active acyclic sulfamide compounds in early- and late-stage drug-
discovery. 
clinically perceived with the use of broad spectrum MMP inhibitors arose from a lack of 
selectivity, and hence the identification of highly selective MMP inhibitors is greatly desired.  
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Cyclic sulfamides are an important class of compounds and can be found in a number of 
pharmaceutically useful compounds.  Notably, cyclic sulfamides have been reported to be 
general templates suitable for the design of inhibitors against a variety of biological targets 
including HIV, serine proteases, γ-secretase as shown in Figure 1.3.  Cyclic sulfamide compound 
1.11 was developed by Merck as a γ-secretase inhibitor16 as alternative motifs to the acyclic 
sulfonamide derivatives reported in 2005 for inhibiting γ-secretase.17  Compound 1.12 is a potent 
and orally-bioavailable Factor Xa inhibitor.18  Factor Xa (FXa) is a serine protease that plays a 
critical role in the sequence of blood coagulation cascade by catalyzing the proteolytic 
conversion of prothrombin to active thrombin.  Compound 1.13 was discovered as a potent 
inhibitor of Norwalk virus for viral gastroenteritis, and displayed enhanced binding, increased 
aqueous solubility, and better bioavailability.19  Fused cyclic sulfamide compound 1.14  
 
Figure 1.3. Representative examples of cyclic sulfamide compounds in clinical discovery. 
represents yet another example of γ-secretase inhibitors containing the sulfamide moiety and was 
developed by Merck for the treatment of Alzheimer’s disease (AD).20  The Korean Institute of 
Science and Technology (KIST) has reported the development of carbapenem compounds 
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comprising a pendant cyclic sulfamide such as in 1.15, which was found to exhibit potent 
antibacterial activity.21 
1.2. Methods for generation of acyclic sulfamides 
The significance of the sulfamide functional group is increasingly growing in bioactive 
small molecule, medicinal and supramolecular chemistry, yet surprisingly few selective synthetic 
methods are available for its elaboration.22,23  In this section, several selected general as well as 
efficient procedures are introduced for the generation of acyclic symmetric and asymmetric 
sulfamides. 
Leschinsky and co-workers have reported the construction of acyclic, non-symmetric 
substituted sulfamides as shown in Scheme 1.1.  Thus, sequential treatment of primary or 
secondary amines with chlorosulfonic acid and PCl5 provides the substituted chlorosulfonamides 
1.16.24  Treatment of the chlorosulfonamide with a second amine furnishes the desired di-, tri- or 
tetra-substituted sulfamides 1.17.25   
 
Scheme 1.1.  
 
Application of DABCO-bis(sulfur dioxide) [DABSO] as a convenient source of sulfur 
dioxide was reported for the preparation of sulfonamides and sulfamides (Scheme 1.2). 26  
DABSO was conveniently prepared from the direct combination of DABCO and SO2 in 
quantitative yield, and was reported to be a bench-stable solid reagent.  Treatment of two 
equivalents of DABSO with anilines and iodine allowed for the preparation of N,N’-
diarylsulfamide derivatives, in moderate yields.27 
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entry aniline yield entry aniline yield 
1 
 
63% 4 65% 
2 
 
73% 5 
 
51% 
3 60% 6 52% 
 
Scheme 1.2. Preparation of symmetric sulfamide using DABSO. 
 
Nonhazardous sulfamide derivatives such as 1.19 have also been reported for the 
synthesis of non-symmetric sulfamide 1.20 (Scheme 1.3).28  Chlorosulfonylisocyanate (CSI) was 
treated with 2-bromo or 2-chloroethanol to furnish the N-sulfamoyloxazolidinoes 1.18.  Addition 
of primary amine to the in situ generated chlorosulfonyloxazolidinone 1.18, in the presence of 
Et3N, afforded asymmetric intermediate 1.19 via the intermolecular SN2 displacement of the 
halide.  A second addition of primary amine to the oxazolidinone 1.19, with base in CH3CN, 
afforded a variety of sulfamides 1.20 in good yields as listed in the Table within Scheme 1.3.  It 
is noteworthy that the first amine addition has to be a primary amine, vide infra.  
DABCO + SO2 (g) NN SO2O2S
DABSO
(bench-stable, colorless solid)
DABSO +
NH2
R
I2 (1.5eq), MeCN
0 C to rt
H
N
R
S
H
N
O O
R
(2eq)
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entry R1 R2 R3 R4 Yield (%)
1 p-MePh H i-Pr H 74 
2 p-MeSO2Ph H i-Pr H 85 
3 p-MeSPh H i-Pr H 62 
4 p-ClPh H i-Pr H 84 
5 Ph H i-Pr H 87 
6 p-MeSO2Ph H p-MePh H 68 
7 i-Pr H t-amyl H 73 
 
Scheme 1.3. Preparation of ozaxolidinone and non-symmetric sulfamide. 
 
The postulated intermediate for the trans-sulfamoylation reaction is likely to involve the 
N-sulfamoylamine species 1.19d (Scheme 1.4).  This intermediate is formed via the 
deprotonation of the N-sulfamoyloxazolidinones 1.19 to generate species 1.19a, which is 
stabilized through either mesomeric forms 1.19b or 1.19c depending on the substituents present. 
Presumably, only the form 1.19b will lead to the formation of the sulfamide species via 1.19d.   
 
Scheme 1.4. Resonance effect involved in the formation of 1.19d.  
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In 2003, Burns and coworkers studied “primary amine effects” of the aforementioned 
trans-sulfamoylation reaction29 and reported that when a secondary cyclic amine such as 1,2,3,4-
tetrahydroisoquinalone was attached to a sulfamide, the oxazolidin-2-one group was not 
displaced by a primary amine, but rather resulted in ring-opening of the oxazolidinone ring to 
furnish sulfamide 1.22 (Scheme 1.5). 
 
Scheme 1.5.  
Burns and coworkers further investigated alternatives to the oxazolidin-2-one moiety for 
the preparation of non-symmetric sulfamides.29  Immidazolium salts are known to be a superior 
leaving groups for the synthesis of sulfamides.30  In this regard, N,N’-sulfuryldiimidazole 1.23 
was prepared by reacting an excess of imidazole with sulfuryl chloride. 31   The N,N’-
sulfuryldiimidazoles were then allowed to undergo sequential and selective monoalkylation, 
followed by subsequent displacement for the preparation of a variety of sulfonylureas, including 
both sterically-crowded and electronically-deactivated amines.  Thus, alkylation of 1.23 was 
carried out utilizing MeOTf in CH2Cl2 resulting in salt 1.24.  Precipitation and filtration of the 
imidazolium group of salt 1.24, and treatment with an amine generated the corresponding 
imidazoylsulfonylurea 1.25.  A second addition of MeOTf in CH2Cl2 generated salt 1.26, which 
was heated to 80 °C in CH3CN in the presence of a primary or secondary amine, to convert the 
triflate salt 1.26 to the desired sulfamide product 1.27 in moderate to good yield (Scheme 1.6). 
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Scheme 1.6. Immidazolium salts for the synthesis of a non-symmetric sulfamides. 
 
 
In 2001, Montero and coworkers reported the introduction of a new method for the 
synthesis of non-symmetric sulfamides utilizing Burgess-type reagents (Scheme 1.7). 32 
Treatment of chlorosulfonyl isocyanate (CSI) with tert-BuOH in CH2Cl2 afforded N-(tert-
butoxycarbonyl)-N-[4-(dimethylazaniumylidene)-1,4-dihydropyridin-1-ylsulfonyl]-azanide 1.28 
as a colorless crystal, which was non-moisture sensitive and stable at ambient temperature in 
good yield and which exists in the zwitterionic form similar to the Burgess reagent.33  
 
Scheme 1.7. Sulfamoylating agent: N-(tert-Butoxycarbonyl)-N-[4-(dimethylazaniumylidene)-1,4-
dihydropyridin-1-ylsulfonyl] azanide. 
 
Similarly, K. C. Nicolaou and coworkers explored the synthesis of non-symmetric, linear 
sulfamides from primary and secondary amines (Scheme 1.8).34  A Burgess reagent could be 
generated appropriately by the treatment of chlorosulfonyl isocyanate with an alcohol of interest 
and exposing to Et3N at 0 ºC.  Reactions of the Burgess reagent with starting amines furnished 
several linear sulfamides in high yields. This Burgess reagent provides a mild alternative, 
avoiding direct use of toxic and corrosive agents which contain traces of acid, such as HCl, 
making them incapable of associating with acid-sensitive functionality (Entry 3).35 
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Scheme 1.8. Synthesis of linear sulfamides. 
 
Entry Amine Product Yield (%) 
1 
 
83 
2 97 
3 
 
98 
4 
 
87 
 
Catechol-derived cyclic sulfates 1.29 have been established as a useful intermediate in 
the synthesis of sulfamide compounds.36  Until the mid-1990s, the procedures for the preparation 
of catechol sulfates suffered from low yield and lack of general applicability.37  In 1994, the 
Tickner group reported a high yielding and efficient synthesis of catechol cyclic sulfate (Scheme 
1.9),38 which is readily prepared by reacting the catechol component with 1,1’-sulfurylimidazole 
in the presence of KF in DMF at 85–90 °C.  There are several advantages to this method.  Firstly, 
the use of 1,1’-sulfurylimidazole avoids the competing ring chlorination which often occurs 
when sulfuryl chloride is employed.  Secondly, since this reaction is carried out under neutral 
conditions the potential oxidation of the starting catechol is circumvented.  Potassium fluoride 
serves as an effective non-nucleophilic base which is tolerated by most functionalities.   
Scheme 1.9. Synthesis of catechol sulfate and asymmetric linear sulfamides. 
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Fettes and co-workers have reported the preparation of 4-nitrophenyl chlorosulfates for 
the preparation of non-symmetric sulfamides (Scheme 1.10).39  Addition of sulfuryl chloride to a 
solution of 4-nitrophenol 1.30 and pyridine in Et2O at -78 °C for 4 h afforded 4-nitrophenyl 
chlorosulfate 1.31 in 83% overall yield as a stable crystalline solid.  1.31 was then reacted with 
amine 1.32 at room temperature or -78 °C to afford the symmetrical sulfamide 1.33 as the major 
product and 4-nitrophenyl sulfamate 1.35 as a minor product, with none of the sulfamoyl 
chloride 1.34 being isolated.  The mechanism of nucleophilic substitution reaction of 1.31 
includes nucleophilic attack at sulfur with either S-Cl or S-OAr bond scission with the S-OAr 
bond cleavage being the major reaction pathway.40  The authors note that if the major pathway is 
the S-OAr bond cleavage, the more active sulfamoyl chloride 1.34 is generated in situ and reacts 
with the amine 1.32 to give the unwanted dimerized compound 1.33.  Thus the less active  
4-nitrophenyl sulfamate 1.35 is probably derived via the S-Cl bond cleavage reaction pathway. 
To avoid the generation of unwanted symmetrical dimer 1.33, an excess of 4-nitrophenol and 
Et3N were added and 4-nitrophenyl sulfamoyl chloride 1.34 could be prepared in 68% yield.  
4-nitrophenyl sulfamide 1.35 was then treated with secondary amine 1.36 in CH2Cl2 to afford 
asymmetric sulfamide 1.37 in 83% yield. 
13 
 
 
Scheme 1.10.  
Recently, the Lubell group has reported an effective method to generate  
N-aminosulfamide using p-nitrophenylsulfamidate esters (Scheme 1.11).41  This method entailed 
the reaction of 4-nitrophenol 1.38, sulfuryl chloride, and pyridine in Et2O at -78 °C
39,42 to afford 
the desired product as a crystalline and relatively stable solid that can be stored for several month 
under an inert gas.  It must be noted that in order to prepare sulfamate 1.40, 2 equiv. of  
4-nitrophenol was required to avoid the formation of symmetric sulfamide as mentioned before. 
It is also noteworthy that microwave irradiation improved the formation of N-aminosulfamides 
1.41 to more than 80% yield as compared to 36% yield with conventional heating at reflux for 24 
h.  
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Scheme 1.11. Synthesis of p-nitrophenylsulfamidate esters and N-aminosulfamides. 
 
The Bolli group reported a new method to generate a sulfamide compound ACT-064992, 
(macitentan, 1.50) as an orally active, potent dual endothelin receptor antagonist for regulating 
blood pressure (Scheme 1.12).43  The procedure starts by reacting chlorosulfonyl isocyanate (CSI) 
with t-BuOH to provide the Boc-protected amino-sulfonyl chloride 1.42, which was 
subsequently added to n-propylamine to furnish 1.43.  Boc-deprotection using HCl in CH2Cl2 
solution afforded 1.44.  Generation of potassium salt 1.45 and addition of pyrimidine 1.46 
allowed the preparation of the desired sulfamide 1.47 via a nucleophilic aromatic substitution 
(SNAr).  Introduction of an ethylene glycol side-chain via a second SNAr reaction furnished the 
corresponding alcohol 1.48.  Attachment of 2-chloropyrimidine 1.49 afforded the final product 
1.50 in 88 % yield. 
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Scheme 1.12. Synthesis of sulfamide potassium salt and general route for the preparation of 
ACT-064992 (1.50).  
In 2001, Montero reported an efficient N-alkylation method for the generation of 
unsymmetric sulfamide using an alkyl bromide and a Mitsunobu betaine (Scheme 1.13).44  In this 
reaction, the Mitsunobu betaine intermediate 1.51 is produced in situ from PPh3 and an 
azodicarboxylate, which performs the role of a base to deprotonate the sulfamoyl carbamate NH.  
This reaction was employed in alkylation as well as glycosylation reactions utilizing two redox 
couples; (a) triphenylphosphine (TPP) and diisopropylazodicarboxylate (DIAD) and (b) tri-n-
butylphosphine (TBP) and 1,1’-(azodicarbonyl)-dipiperidine (ADDP), and the results are 
highlighted in Table 1.1. 
 
Scheme 1.13. N-alkylation method reported by Montero.44 
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Table 1.1. Reaction of 1.52 with alkyl bromide under Mitsunobu conditions using two different 
redox couples. 
entry R-Br TPP/DIAD TBP/ADDP 
1 37% 86% 
2  41% 88% 
3 37% 60% 
4 20% 45% 
5  32% 56% 
6 
 
(α-acetobromoglucose) 
35% 
β-anomer 
60% 
β-anomer 
7 
 
(α-acetobromogalactose) 
23% 
β-anomer 
44% 
β-anomer 
8 
 
(α-acetobromorhamnose) 
10% 
β-anomer 
45% 
β-anomer 
9 
 
(α-acetobromoribose) 
21% 
β-anomer 
42% 
β-anomer 
10 
20% 
β-anomer 
40% 
β-anomer 
 
The Vidal group reported the generation of mono- and di-substituted acyclic sulfamides 
using solid-support resins and sulfamoylating agent 1.28 (Scheme 1.14).45  Montero and co-
workers have described the preparation of a sulfamoylating agent 1.28 and its reactivity with 
various amines (vide infra).32  Vidal and coworkers employed the Burgess Type reagent 1.28 
O
Br
O
O O
O2N
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with polystyrene (PS)-supported benzylamine amine 1.55 to prepare Boc-substituted sulfamide 
1.56 by the reaction of excess of sulfamoylating agent 1.28 (3 equiv.) and PS-benzyl amine 1.55 
in DMF-CH2Cl2 at room temperature.  Utilization of TFA allowed simultaneous deprotection 
and cleavage from the resin to provide sulfamide 1.57.  On the other hand, Mitsunobu alkylation 
of 1.56 and subsequent cleavage in TFA-CHCl3-H2O (50:50:1) afforded the non-symmetric 
sulfamide 1.59. 
 
Scheme 1.14. Synthesis of acyclic sulfamides using solid-support resins and 1.28. 
 
1.3 Methods to generate cyclic sulfamide 
Exploratory studies related to the design and synthesis of functionalized cyclic 
sulfamides have been achieved for the invention of pharmaceutical compounds such as HIV 
protease inhibitors, virus inhibitor, and diabetes treatment.46  In this section, various methods for 
the generation of cyclic sulfamides are summarized. 
In 2000, Hanson and coworkers reported new methods employing ring-closing metathesis 
(RCM) to generate C2-symmetric sulfamides 1.60 and 1.61 and the asymmetric cyclic sulfamide 
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1.62 starting from from sulfuryl chloride (SO2Cl2) and chlorosulfonyl isocyanate (OCNSO2Cl) 
(Scheme 1.15).47 
 
Scheme 1.15.  
 
The synthetic route to the amino acid-derived C2-symmetric sulfamides is outlined in 
Scheme 1.16.  Condensation of amino ester with sulfuryl chloride generates sulfamide 1.63 in 
70–85% yield.  Diallylation to the sulfamide, and RCM using the first-generation Grubbs 
catalyst (G-I), 48  subsequently afforded the C2-symmetric cyclic sulfamide 1.60 in excellent 
yields. 
 
Scheme 1.16. Synthesis of C2-symmetric cyclic sulfamide. 
Next a route to afford the substituted, C2-symmetric sulfamide 1.61 is described in 
Scheme 1.17.  In this method, amine 1.64 obtained from amino ester via Swern oxidation and 
Wittig reaction, was coupled with sulfuryl chloride to furnish sulfamide 1.65 in 71% yield.  
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Subsequent RCM using 15 mol% of the G-I catalyst generated the desired sulfamide 1.61 in 69% 
yield. 
 
Scheme 1.17. Synthesis of C2-symmetric cyclic sulfamide. 
 
The Hanson group also developed a strategy to the unsymmetric cyclic sulfamide 
utilizing CSI chemistry as outlined in Scheme 1.18.  Starting substrate 1.66 was obtained by 
reacting chlorosulfonyl isocyanate (CSI), t-BuOH and an amino ester, and was subsequently 
utilized in a regioselective Mitsunobu reaction and deprotection to afford unsymmetric 
intermediate 1.68.  Subsequent diallylation and RCM produced the unsymmetric cyclic 
sulfamide 1.62 in excellent yield.  
 
Scheme 1.18. Synthesis of unsymmetric cyclic sulfamide.  
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second-generation Grubbs catalyst (G-II),48 and Boc-deprotection produced cyclic sulfamide 
1.72.  Benzylation afforded the desired trisubstituted cyclic sulfamide 1.73 in excellent yield. 
 
Scheme 1.19. Synthesis of tri- and tetra-substituted non-symmetric cyclic sulfamide compounds. 
In 2009, Oh and co-workers reported the preparation of substituted cyclic sulfamides 1.75 
via the condensation of the corresponding diamines 1.74 with sulfamide in refluxing pyridine 
(Scheme 1.20).21, 50   Their method was then employed for the preparation of 1β-
methylcarbapenems 1.78 which possess excellent in vitro antibacterial activity. 
 
 
Scheme 1.20. Synthesis of a substituted cyclic sulfamide. 
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Ahn and co-workers have described a component coupling reaction for the synthesis 
cyclic sulfamide 1.81 as shown in Scheme 1.21.46b  Intermediate 1.79 was synthesized via 
sequential addition of t-BuOH and the corresponding mustards to chlorosulfonyl isocyanate (CSI) 
in CH2Cl2 at 0 °C.  The N-Boc cyclic sulfamide 1.80 was then obtained simply by the treatment 
of the intermediate 1.79 with K2CO3 in DMSO.  
Scheme 1.21. Synthesis of cyclic sulfamide from chlorosulfonyl isocyanate (CSI). 
 
In 2005, Chemler and coworkers reported Cu(OAc)2 as an excellent promoter for the 
intramolecular diamination of inactivated olefins which have the sulfamide moiety (Scheme 
1.22).51  Acyclic sulfamide 1.82 was treated with Cu(OAc)2 (1.2 eq) in the presence of K2CO3 as 
a base at high temperature (90 °C) to provide the desired cyclic sulfamide 1.83 in up to 92%.  
Free diamine 1.84 can be furnished by the reduction of the sulfamide 1.83 with LiAlH4 in THF 
under refluxing conditions in 93% yield.  
 
Scheme 1.22. Intramolecular diamination of olefins. 
Table 1.2. 
entry substrate product Yield (%) 
1 
 
73 
2 
 
56 
Cl
S
N
OO
C
O
+ H2N
Cl
n
t-BuOH
DCM
HN
S
N
H
OO
Cl
Boc
n
N
S
HN
OO
Boc
n
K2CHO3
DMSO
1.79 1.80
N
S
N
O O
O
N
H
R1
R2
R3
1.81
NH
S
NHBn
O
O
N
S NBn
O O
3 eq of Cu(OAc)2, 
2 eq of K2CO3
DMF(0.1 M)/DMSO (10 eq)
90 °C, 48 h, 56%
LiAlH4
THF, reflux
93%
N
H NHBn
1.82 1.83 1.84
22 
 
3 
 
57 
4 
 
 
Selectivity = > 20 : 1
71 
5 83 
6 
 
Selectivity = 1.2 : 1
34 
 
The proposed mechanism suggests that intramolecular diamination is likely initiated by 
the engagement of Cu(OAc)2 to sulfamide nitrogen to deliver intermediate 1.82a (Scheme 1.23). 
Migratory insertion allows formation of the new sp3 N-C bond to furnish the intermediate 1.82b. 
The organocopper species 1.82b is then suggested to undergo ligand exchange with the 
remaining nitrogen, followed by reductive elimination to afford cyclic sulfamide 1.83.  
 
 
Scheme 1.23. Mechanism of diamination 
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carboxylate for the synthesis of cyclic sulfamides (Scheme 1.24).52  The organic soluble copper 
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in this regard was the use of microwave heating (120 °C for 20 min) to further reduce reaction 
times. 
 
Scheme 1.24. Intramolecular diamination 
 
The reaction mechanism for the copper (II) carboxylate-promoted intramolecular 
diamination is proposed in Scheme 1.25.  Ligand exchange of 1.84 with Cu(ND)2 generates the 
N–Cu bond, followed by syn-aminocupration via transition state 1.86, to stereoselectively 
generate cis-pyrrolidine 1.87.  The organocopper (II) intermediate 1.87 generates primary radical 
1.88 via C–N bond homolysis.  Since it is necessary to lose another electron from the substrate, 
copper needs to be involved in the second C–N bond forming process.  The resulting 
intermediate 1.89 then undergoes ligand exchange and reductive elimination or SN2 to afford the 
cyclized unsymmetric sulfamide compound 1.90. 
 
Scheme 1.25. Proposed diamination mechanism. 
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In 2004, the Groutas group explored the synthesis of cyclic sulfamides for the generation 
of potential inhibitors of human leukocyte elastase (HLE) (Scheme 1.26).53  Primary alcohol 1.91 
was formed via the reduction of the corresponding amino ester and subsequently utilized in an 
intramolecular Mitsunobu reaction to furnish a cyclized sulfamide 1.93.  
 
Scheme 1.26. Synthesis of the clinical potential HLE inhibitor 1.93. 
In 2003, the Montero group reported a two-step protocol starting from N-benzyl-N’-tert-
buthoxycarbonylsulfamide 1.94 to generate cyclic sulfamides 1.96 (Scheme 1.27). 54   Thus, 
regioselective N-alkylation of 1.94 was carried out using dibromoalkanes in the presence of 
K2CO3 in acetone to obtain 1.95 in moderate to good yield for n>3.  Alternatively, bromo-
alcohols were utilized in a Mitsunobu alkylation reaction for the preparation of 1.95.  Subjection 
of 1.95 to basic conditions under reflux furnished a variety of cyclic sulfamides 1.96.  Boc-
deprotection and the coupling with t-BuOH bromoacetate in the presence of DBU gave 1.97.  
Hydrogenation and peptidic coupling using BOP with N-Boc-protected valine, generated 
sulfamide 1.98 in good yield. 
 
Scheme 1.27. General synthesis of n-membered cyclic sulfamide. 
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A new heterocyclic class of cyclic sulfamides, 1,4,3,5-oxathiadiazepane-4,4-dioxanes 
were reported in 2012 as potential analogs of anti-HIV compounds (Scheme 1.28).55  The key 
reaction for the preparation of the cyclic sulfamide 1.103 was the condensation of 
hydroxysulfamide 1.102 with aldehydes.56  Sulfamoylation of amino acid methyl ester generated 
compound 1.99 which was then allowed to undergo a Mitsunobu alkylation with benzyl alcohol 
to afford 1.100.  Subsequent deprotection of the Boc group using TFA, followed by reduction of 
the ester using NaBH4, furnished 1.102. Hydroxysulfamide 1.102 was subjected to a 
cyclodehydration reaction by the treatment of a variety of substituted aromatic aldehydes in 
CH2Cl2 to afford cyclic sulfamide 1.103. 
 
Scheme 1.28. Synthesis of substituted amino alcohol sulfamides. 
In 2010, Stahl and co-workers reported the utilization of Pd-catalyzed hydroamination of 
allylic sulfamides 1.104 for the synthesis of cyclic sulfamides 1.105 as shown in Scheme 1.29.57  
Treatment of the allyl sulfamide with Pd(TFA)2 in the presence of sodium benzoate, catalytic 
DMSO and molecular oxygen allowed for an oxidative cyclization of allylic sulfamide to 
generate the desired cyclic sulfamide.  
 
Scheme 1.29. Aerobic oxidative cyclization of sulfamide. 
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There are two different possible mechanisms to explain this oxidative cyclization reaction 
(Scheme 1.30): (1) aminopalladation of the alkene followed by the β–hydride elimination or  
(2) formation of a π-allyl-palladium (II) intermediate via allylic C-H activation followed by the 
C-N coupling. 
 
 
Scheme 1.30. Possible mechanism for the palladium-catalyzed oxidative cyclization reaction. 
Ligand 1.106 and 1.107 which are known to facilitate allylic C-H activation were tested 
but only low yields of sulfamide products were observed (Figure 1.4).  A further study to 
distinguish these two mechanisms was carried out, whereby the homoallyl amine derivative 
1.108 was synthesized.  Cyclization of this substrate would provide evidence in favor of an 
allylic C–H activation pathway.  However, treating this substrate 1.108 under the optimized 
cyclization reaction conditions resulted in complete recovery of starting material after 24 hrs. 
Thus, it can be concluded that cyclization via allylic C–H activation does not occur.       
 
Figure 1.4. Ligands and homoallyl amine derivative. 
Employment of the optimized reaction conditions with a variety of sulfamides afforded 
an array of cyclic sulfamides in good to excellent yields (Table 1.3).  Substrates bearing both 
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aliphatic or aryl N-substituents were found to undergo cyclization efficiently (Table 1.3, 1.109–
1.114).  Quaternary C–N bond formation (1.115) stemming from the use of a tri-substituted 
alkene was found to occur in quantitative yield while employment of a silyloxy allyl amine 
furnished the corresponding silyloxy vinyl ether 1.116.  Allylic substituents larger than a methyl 
group delivered diastereomeric product in good to high yield (1.118–1.120, diastereomeric ratios 
> 29:1). 
Table 1.3. Aerobic oxidative cyclization of sulfamide. 
 
 
In 2007, the Girón group reported a new carboxamide series of 1,1-dioxo-1,2-dihydro-
1λ6-1,2,6-thiadiazine derivatives that have a cannabinoid (psychotropic constituent)-like 
molecular structure (Scheme 1.31).58  The general synthetic route for the formation of substituted 
1,2,6-thiadiazine 5-carboxamides employs a cyclocondensation with mono-substituted sulfamide 
and 2,4-dioxocarboxylic acid ethyl ester under the acidic conditions to furnish 1.121, and 
subsequent amination with an exogenous amine to afford 1.122 in high yield.  
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Scheme 1.31. Synthesis of 1,1-dioxo-1,2,6-thiadiazine compounds. 
In 2003, Hanson and coworkers reported a result of the synthesis of a variety of amino 
acid derived unsymmetric cyclic sulfamide compounds utilizing ring-opening metathesis (ROM) 
polymerization-derived oligomers as soluble supports (Scheme 1.32). 59   In this method, 
norbornenyl-tagged sulfonamide 1.123 60  was allowed to undergo sequential reactions with 
chlorosulfonyl isocyanate and amino acid methyl esters to afford the norbornenyl-tagged 
sulfamoyl carbamate 1.124, which was polymerized with 5 mol% of the G-II catalyst to generate 
the soluble oligomer.  Dissolving the oligomer in DMF, followed by bis-allylation (allyl bromide, 
NaI, K2CO3) furnished diene 1.125.  Upon precipitation with water, oligomer 1.125 was treated 
with 10 mol% of the G-I catalyst to afford the cyclized compound 1.126.  Cleavage by the TFA: 
CH2Cl2 (1:1) furnished unsymmetric cyclic sulfamide 1.127.  Overall, this method represents a 
chromatography-free method for the preparation of cyclic sulfamides using a soluble support. 
 
Scheme 1.32. Synthesis of cyclic sulfamide using ring opening metathesis (ROM) oligomers  
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In 2002, K. C. Nicolaou and coworkers explored the synthesis of nonsymmetric cyclic 
sulfamides from amino alcohols (Table 1.4).34   In this regard, a Burgess reagent-facilitated 
cyclic sulfamide synthesis was reported employing primary and secondary amino alcohols under 
optimized condition.  Initially, the reaction mixtures (1.0 equiv. of amino alcohol and 2.5 equiv. 
of the Burgess reagent) were heated for specified hours in THF to yield cyclic sulfamides  
  
Table 1.4. Synthesis of non-symmetric cyclic sulfamides from amino alcohols.  
 
Entry Starting amine Product Yield (%) 
1 
 
77[a] 
2 
 
89[b] 
3 
 
45[c] 
4 93[a] 
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81[a] 
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90[a] 
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then 25 ºC, 5 h 
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(entries 1, 2, and 3).  Non-benzylic alcohols were employed to explore a series of six-, seven-, 
and eight-membered ring analogues (entries 4, 5, and 6) under optimized reaction condition 
(THF, refluxing 2 h).  Utilizing primary aliphatic amines, in conjunction with secondary benzylic 
alcohols, the reaction mixture was commenced at 0 ºC and allowed to warm to 25 ºC for 5 h to 
produce compounds in high yields (entries 7 and 8). 
The proposed mechanistic conversion of amino alcohols into non-symmetric cyclic 
sulfamides using a Burgess-type reagent is shown in Scheme 1.33.  Thus, treatment of excess 
amounts of the Burgess reagent with an amino alcohol leads to a mono-protected, nonsymmetric 
cyclic sulfamide B through the SN2 reaction of the proposed intermediate A.  Potentially, 
deprotection of the carbamate B and substitution provides an array of pharmaceutically useful 
sulfamides such as high-affinity protein ligands61  and inhibitors of enzymes including HIV 
proteases.62 
 
Scheme 1.33. Proposed conversion of amino alcohols into cyclic sulfamides. 
 
1.4. Sulfamide catalysts 
Recently, asymmetric organocatalysis has emerged as a “third pillar” of enantioselective 
catalysts, together with biocatalysis and metal catalysis.63,64  Although the potential of proline-
catalyzed asymmetric intramolecular aldol reactions have been shown by Hajos and Wiechert in 
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aldol reactions by Barbas et al. opened a new gate of asymmetric organocatalysis.66,67  Since this 
seminal discovery, organocatalysis has accumulated the attention of the synthetic community.  In 
this section, various roles of sulfamide catalysts for several types of reactions are highlighted.  
1.4.1. Hydroaminoalkylation and hydroamination 
In 2012, Doyle group reported hydroaminoalkylation and hydroamination reactions using 
titanium complexes with sulfamide ligands as precatalysts (Scheme 1.34).68  Diphenylsulfamide 
1.129 was prepared from SO2Cl2 and aniline in the presence of pyridine.  Subsequently, 
sulfamide 1.129 was reacted with two equivalents of Ti(NMe2)4 at room temperature to furnish 
the dinuclear titanium complex 1.130 in 65% yield.  This sulfamide-titanium complex was used 
for catalyzing the hydroamination of olefins.  Thus, hydroaminoalkylation of 1-octene, 
allylbenzene and styrene with N-methylaniline was carried out in the presence of 5 mol% of 
complex 1.130 at 120 ºC for 48 hours in n-hexane to afford the desired product in moderate to 
good yield.  Catalyst 1.130 was also found to be useful for the intramolecular hydroamination of 
several aminoalkenes 1.134 and 1.136 under mild conditions employing 2.5 mol% of catalyst 
loading to produce cyclized amines 1.135 and 1.137.  To date, mechanisms for these reactions 
are yet to be reported. 
 
Scheme 1.34. Hydroaminoalkylation and hydroamination reactions using titanium complexes. 
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1.4.2. Aldol reaction  
A Ti-enolate-derived diastereoselective aldol reaction using a cyclic sulfamide chiral 
auxiliary for the preparation of syn-aldol products was reported in 1992 by Ahn and co-
workers.69  Chiral sulfamide auxiliary 1.140 was synthesized through the coupling reaction of 
propionyl chloride and cyclic sulfamide 1.139 which was obtained from the reaction of (1S,2S)-
diphenyl-1,2-diaminoethane (1.138) and sulfamide.  The titanium enolate of 1.140 was generated 
by the treatment of 1.140 with TiCl4 in the presence of DIEA in CH2Cl2 at -78 °C.  This enolate 
was treated with aldehyde at -78 °C for 5 minutes to afford the syn-aldol product in high yield 
(89–93%) (Table 1.5).  
Scheme 1.35. Synthesis of chiral sulfamide auxiliary 1.140 and aldol reaction. 
Table 1.5. Asymmetric aldol reactions of titanium enolate of 1.140. 
Entry R in RCHO Stereoselectivity Yield (%) 
1 Ph >96:4 91 
2 Me >97:3 90 
3 i-Pr >97:3 93 
4 (trans)-MeCH=CH >95:5 89 
 
Each of the absolute stereochemistries of the syn products were identified by comparing 
the optical rotation of 1.142 with reported data.70  The conversion of dialdol 1.141 into 1.142 and 
recovery of the sulfamide chiral auxiliary 1.139 are described in Scheme 1.36.  Treatment of 
1.141 with NaOMe generated aldol product 1.142 and sulfamide 1.143 in quantitative yield.  
Sulfamide 1.143 was, however, found to resist a second cleavage.  In order to circumvent this 
issue, Boc-protection of 1.143 and treatment with NaOMe produced 1.145 and 1.146.  
Subsequent treatment of reaction mixture with TFA furnished 1.147 and sulfamide chiral 
auxiliary 1.139. 
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Scheme 1.36.  
 
1.4.3. Conjugate addition  
Asymmetric conjugate addition of ketone or aldehyde to nitro-olefins is a very useful 
reaction to prepare chiral γ–amino acids.  In 2009, Chan and coworkers reported that chiral 
bifunctional sulfamides were highly efficient organocatalysts in the conjugate addition of 
aldehydes to trans-β–aryl-nitroethenes in the presence of base additives (Scheme 1.37).71  In this 
regard, the chiral cyclohexanediamine unit exerted high enantiofacial selectivity in this reaction.  
Sulfamide catalyst 1.140 was prepared via stepwise reaction of the corresponding amines and 
(1R,2R)-cyclohexane-1,2-diamine with catechol sulfate.72 
 
Scheme 1.37. Conjugate addition of aldehydes to β–aryl-nitroethenes catalyzed by chiral 
bifunctional sulfamide.  
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Entry R1 R2 R3 T (h) Yield (%) ee (%) 
1 Ph CH3 CH3 3 83 99 
2 4-MeO-Ph CH3 CH3 2 79 99 
3 4-Cl-Ph CH3 CH3 3 79 98 
4 4-NO2-Ph CH3 CH3 3 74 99 
5 PhCH=CH CH3 CH3 24 53 98 
6 2-furanyl CH3 CH3 6 94 98 
7 2-thiophenyl CH3 CH3 24 99 99 
8 Ph CH2(CH2)2CH2 23 41 91 
9 Ph H CH3 23 96 (2/1) 78/70 
10 Ph H CH2CH3 24 72 (2/1) 91/93 
11 Ph H Ph 21 90 (2/1) 82/80 
 
Table for Scheme 1.37. Conjugate addition of aldehydes to β–aryl-nitroethenes catalyzed by 
chiral bifunctional sulfamide.  
 
A catalytic mechanism of conjugate addition of aldehyde to nitro ethene using a chiral 
sulfamide catalyst is proposed in Scheme 1.38.  Initially, the catalyst and isobutyraldehyde 
generate the imine intermediate A.  Tautomerization of A is promoted by the base additive 
(DMAP or imidazole) and generates enamine B.  As is shown in Scheme 1.37, two hydrogen 
bonds are postulated to form between the nitro group of nitrostyrene and the sulfamide 
(intermediate C) to attenuate the electrophilic nature of nitrostyrene.  Attack of the enamine to 
the re-face of the nitrostyrene double bond provides intermediate D.  Consequent proton transfer 
and hydrolysis affords the desired chiral aldehyde product and regenerates the chiral sulfamide 
catalyst for an ensuing cycle.  
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Scheme 1.38. Proposed catalytic mechanism. 
 
1.4.4. Michael addition 
In 2011, the Nugent group reported a Michael addition using a sulfamide as a 
catalyst/hydrogen bond donor to generate enantioenriched quaternary carbon containing 
compounds (Table 1.6). 73   In this regard, reaction of isobutyraldehyde, 
cyclopentanecarboxaldehyde, and cyclohexanecarboxaldehyde with 2-substituted-nitroethanes in 
the presence of OtBu-L-threonine, DMAP and sulfamide as an H-bond donor afforded  
1.141–1.144 in high yield and high ee.  Addition of aldehyde with nonequivalent  
α,α‘-substituents to β-nitrostyrene provided the Michael products 1.145–1.147 containing a 
stereogenic quaternary carbons in good yield and excellent ee, albeit with moderate 
diastereomeric ratios.  
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Table 1.6. Various aldehyde additions to 2-substituted-nitroethenes. 
 
Entry Product T (h) Yield (%) dr ee (%) 
1 
 
7 97 - 98 
2 
 
24 98 - 96 
3 
 
7 89 - 97 
4 
 
48 88 - 91 
5 
 
12 84 70:30 97 
6 
 
12 71 78:28 91 
7 
 
12 70 77:23 98 
 
In 2009, Shea and coworkers reported a new type of H-bond catalysis using a sulfamide 
catalyst (Scheme 1.39).74  The sulfamide catalyst 1.149 can be readily synthesized from the 
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reaction of aniline 1.148 and SO2Cl2 in CH2Cl2 in 35% yield.  The Friedel-Craft reaction 
between β–nitrostyrene 1.150 and N-methyl indole 1.151 was carried out with 10 mol% of 
sulfamide 1.149 to provide 3-alkylated indole compound 1.152 in 20% yield.  The Baylis-
Hillman reaction was performed between methyl acrylate 1.153 and benzaldehyde 1.154 in the 
presence of the sulfamide catalyst 1.149 and DABCO as a co-catalyst to furnish the vinyl ketone 
1.155 in 73% of yield.   
 
Scheme 1.39. Fridel-Crafts reaction and Baylis-Hillman reaction using sulfamide catalysis. 
 
1.4.5. Mitsunobu-like coupling 
Sulfamides have been reported for the preparation of a Mitsunobu-type betaine for 
coupling between alcohols and carboxylic acids and imides (Figure 1.5).75  In 1994, Castro and 
coworkers isolated an unprecedented adduct 1.165 between triphenylphosphine and 3,3-
dimethyl-1,2,5-thiadiazolidine 1,1-dioxide 1.159, which was synthesized from diamine 1.161 
and sulfamide (SO2(NH2)2.  Interestingly, the initial study involved the preparation of 1.160 
using 1.156 or 1.157 with 1.158 or 1.159 for the identification of molecules for the treatment of 
migraine headaches (Figure 1.5).76  
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Figure 1.5.  
Under the standard Mitsunobu conditions, alcohol 1.156 and 1.157 failed to furnish the 
expected alkylated product when reacted with 1.159 (R1=R2= Me, R3= H), but afforded a white 
solid was identified as the betaine 1.165 (Figure 1.6).  It is important to note that when only one 
proton on the cyclic sulfamide (R1=R2= H, R3= Me) is available, the betaine cannot be generated. 
On the other hand, using acidic component HX with a lower pKa than that of betaine 1.165 
allows for the generation of ion pair 1.166.  Reaction with alcohol would then furnish the 
oxyphosphonium salt 1.167 and cyclic sulfamide 1.159.  Subsequent SN2 displacement with the 
nucleophilic component afforded the corresponding product 1.168 with inversion of chiral center. 
Summary of the reactions with various alcohols and carboxylic acids and imides are given in 
Table 1.7. 
 
Figure 1.6. Mechanism of coupling reaction through a Mitsunobu-like process. 
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Table 1.7. Utilization of betaine 1.165 in a Mitsunobu-like process. 
entry substrate HX conditions product 
Yield 
(%) 
1 
 
CH2Cl2, 
rt, 5 h 
 
89 
2 
 
CH2Cl2, 
rt, 64 h 
53 
3 
 
Toluene, 
rt, 17 h 
95 
4 
 
CH2Cl2, 
rt, 2.5 h 
 
98 
5 
 
 
CH2Cl2, 
rt, 65 h 
 
80 
 
 
1.4.6. Utilization of cyclic sulfamide as chiral auxiliaries 
Cyclic sulfamides have been employed as chiral auxiliaries for the production of chiral, 
non-racemic molecules.  In 2010, Dewynter and coworkers reported the application of an acyclic 
sulfamide as a chiral auxiliary for facilitating asymmetric aldol and alkylation reactions.77  Thus, 
N-propionyl sulfamide 1.174 was efficiently synthesized in five steps and shown in Scheme 1.40.  
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Scheme 1.40. Preparation of cyclosulfamide 1.173 as a chiral auxiliary. 
With this sulfamide in hand, the authors were able to accomplish a number of diasteroselective 
aldol reactions using chiral auxiliary 1.174 as represented in Scheme 1.41.  Reaction with 1.2 
equiv. of TiCl4 and 1.174 in CH2Cl2 at -78 °C for 30 min followed by the addition of  
N-diisopropyl ethylamine generated the titanium enolate of 1.174.  The enolate was then reacted 
with aldehyde at the same temperature for 4 hours, warmed to 0 °C, and stirred overnight to 
afford the aldol product as a single diastereoisomeric, syn-aldol product 1.175 (dr >99:1).  In this 
regard, a variety of aldehydes were used and the results are summarized in Table 1.7.  The aldol 
products were subsequently hydrolyzed with 3 equiv. of LiOH monohydrate in THF/H2O (1:1) at 
0 °C to afford the corresponding carboxylic acids 1.176, as well as the chiral auxiliary 1.173, 
without any loss of the stereochemical integrity (Table 1.8).  
 
Scheme 1.41. Diastereoselective aldol reactions. 
Table 1.8. 
Entry aldehyde dr % Yield Product Yield of recovery 1.173 % Yield Product
1 iPr-CHO >99:1 93% 1.175a 96% 95% 1.176a 
2 Ph-CHO >99:1 88% 1.175b 98% 96% 1.176b 
3 nPr-CHO >99:1 92% 1.175c 95% 94% 1.176c 
4 cHex-CHO >99:1 87% 1.175d 93% 93% 1.176d 
 
Chiral sulfamide 1.174 was also reported in asymmetric alkylation reactions.  Treatment 
of 1.174 with NaHMDS or LiHMDS and addition of benzyl bromide or allyl bromide allows for 
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generation of 1.177 and 1.178 (Scheme 1.42 and Table 1.9).  Removal of the chiral auxiliary 
1.173 using lithium hydroxide afford only one diastereomer in each case. 
 
 
Scheme 1.42. Stereocontrolled alkylation.  
Table 1.9. 
Entry R-X Base dr Yield Product Yield of recovery 1.173 Yield Product 
1 Bn-Br NaHMDS >99:1 30% 1.177 96% 95% 1.179 
2 Bn-Br LiHMDS >99:1 58% 1.177 97% 91% 1.179 
3 Allyl-Br NaHMDS >99:1 48% 1.178 98% 94% 1.180 
4 Allyl-Br LiHMDS >99:1 60% 1.178 97% 92% 1.180 
5 Allyl-I LiHMDS >99:1 78% 1.178 98% 96% 1.180 
 
1.5. Conclusions 
In conclusion, sulfamide compounds have been reported possessing a variety of 
biological activities for the treatment of life threating illnesses such as AIDS and cancers.  
Despite the indisputable utility of sulfamide compounds, existing routes for their construction 
were lacking in the literature.  With this essential need, synthetic approaches for acyclic and 
cyclic sulfamide compounds were summarized in this chapter.  Many methods from typical 
procedures to advanced innovative approaches for the synthesis of sulfamides have been 
developed by scientists featuring symmetric and non-symmetric sulfamides to serve as high 
affinity protein ligands and pharmaceutically useful agents.  There are several investigational and 
commercially available drugs containing sulfamide moiety in order to treat different types of 
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diseases.  In this regard, generation of new molecular structures and chemical methodologies to 
discover new pharmacophores are important to survey more pharmaceutically active sulfamide-
containing compounds.  Several technological advances will undoubtedly enable the formation 
of new, structurally unique sulfamides exhibiting biological potential.  Furthermore, advances in 
sulfamide organocatalysts will expand a pathway to develop and produce a powerful arsenal for 
both drug and reagent development. 
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CHAPTER 2 
 
Newly Developed Piperidinyl Sulfamides as  
Tyrosyl-DNA phosphodiesterase 1 (Tdp 1) Inhibitors 
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2.1. Abstract 
Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is an enzyme that catalyzes the hydrolysis of 
3'-phosphotyrosyl bonds.1  Such linkages form in vivo following the DNA processing activity of 
topoisomerase I (Top1).  For this reason, Tdp1 has been implicated in the repair of irreversible 
Top1-DNA covalent complexes, which can be generated by either exogenous or endogenous 
factors.  Tdp1 has been regarded as a potential therapeutic co-target of Top1 in that it seemingly 
counteracts the effects of Top1 inhibitors, such as camptothecin and indenoisoquinolines and its 
clinically used derivatives.  Thus, by reducing the repair of Top1-DNA lesions, Tdp1 inhibitors 
have the potential to augment the anticancer activity of Top1 inhibitors.  There are no known 
specific pharmacological inhibitors of Tdp1.  In our attempts to design new chemical scaffolds 
for anti-cancer activity against various protein targets, we have recently synthesized a host of 
piperidinyl-based sulfamides.  Some of these compounds have shown activity in screening for 
Tdp 1 inhibition activity in biochemical assays against recombinant Tdp1.  Using molecular 
modeling and homology studies, a small library of compounds has been synthesized and tested 
further.   
 
2.2. Introduction 
Most people and living organisms on planet earth are exposed to substances that are 
known to damage DNA, which is caused by UV light, radiation (including x-rays and gamma 
rays), plastics, cigarette smoke, pesticides, micronutrient deficiency, hydrolysis or thermal 
disruption, etc.  While rare, mistakes also occur during DNA replication, namely, when a cell 
copies its DNA in preparation for cell division.  Ultimately, damaged DNA can be prompted to a 
tumor cell by proliferating through continuous cell division.  Many anticancer drugs used for 
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chemotherapy generate their anti-cancer activity by damaging DNA in rapidly replicating tumor 
cells, and this poses a significant risk of generating a new cancer, such as leukemia.  Therefore, 
there is a high demand to develop new inhibitors that may help to repair DNA or oppose the 
unwanted action of these anticancer agents.  Topoisomerase I (Top1) inhibitors, such as 
Camptothecins,2 are chemotherapeutic agents which prevent the replication of single strand DNA 
molecules, ultimately leading to cell death (Figure 2.1).  The natural product camptothecin (2.1) 
was first isolated from the bark of the Chinese tree, Camptotheca acuminata, by the National 
Cancer Institute (NCI).3  The water-soluble derivatives of Camptothecin–Topotecan (2.2) and 
Irinotecan (2.3) were developed successfully and approved by the US Food and Drug 
Administration (FDA): Topotecan for ovarian and lung cancers and Irinotecan for colorectal 
cancer.4 
 
Figure 2.1. Structures of Top1 inhibitors.  
2.3. Topoisomerase I (Top1) and Tyrosyl-DNA phosphodiesterase 1 (Tdp1) 
Nuclear DNA (nDNA) is approximately a 2 meter-long polymer that is located in a cell 
nuclear volume of 10-17 m3.  Because it is highly compacted, cellular DNA must have many 
curved DNA domains/loops and points of contact between these domains (Figure 2.2). 5 
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Furthermore, DNA metabolism needs the two strands of the double helix to be separated to serve 
as templates for transcription, replication, recombination and repair and this fundamental 
processes commences during the cell cycle to maintain its own integrity and generate genetic 
diversity.  Due to the size and mass of replication and transcription complexes, the rigid 
complexes do not rotate easily around the DNA helix.  This limitation of free rotation of the 
flanking DNA domain generates supercoiled DNA, which needs to be relaxed by topoisomerases. 
TOP1 relieves DNA torsional stress and relaxes supercoiled DNA by nicking the DNA and 
rotating the broken strand around the TOP1-bound DNA strand.  The yellow circle in Figure 2.2 
A shows the covalently linked catalytic tyrosine of TOP1.  Figure 2.2 B is an expanded version 
of DNA-relaxation by a TOP1 cleavage complex (TOP1cc).  The first step is a trans-
esterification reaction catalyzed by the TOP1 whereby the catalytic tyrosine (Y) is linked to the 
3’-DNA end (nicking step) (Figure 2.2 B, left).  A nucleophilic attack by the tyrosine residue of 
TOP1 on the phosphate moiety of the substrate releases tyrosine and forms a new covalent 
enzyme-DNA complex, TOP1cc (Figure 2.3).6  In the second step, the torsion strain from DNA 
supercoiling allows the controlled rotation of the 5’ end of the nicked DNA strand around the 
intact strand (Figure 2.2 B, middle).  Once the DNA is relaxed, the nucleophilic attack of the 
tyrosyl-DNA-phosphodiester bond by the free 5’-hydroxyl end of the nicked DNA is required to 
religate (bind back) with the corresponding 3’ end of DNA, which is called the closing step of 
the nicking-closing reaction (DNA religation, Figure 2.2 B, right and Figure 2.3).  TOP1ccs are 
generally ephemeral that they are not detectable because the closing step is much faster than the 
nicking step.  It is crucial that any misalignment of the 5’-hydroxyl-DNA end with the scissile 
tyrosyl-DNA-phosphodiester bond leads to an accumulation of TOP1cc, and it will end up as 
DNA modification7 or result in apoptosis.8  
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A
B
 
Figure 2.2. Relaxation of DNA supercoiling by TOP1-mediated DNAcleavage complexes.5 (This 
figure was copied from ‘Pommier, Y., Topoisomerase I inhibitors: camptothecins and beyond. 
Nature Reviews Cancer 2006, 6, 789–802) 
 
Figure 2.3. Trans-esterification catalyzed by Top1. 
O
H
O
Base
O
P OO
O
O
Base
5'
3'
+1
-1
DNA cleavage
DNA religation
Top1
O
Base
O
P O
HO
O
Base
O
5'
3'
+1
-1
Top1
O
Tyrosine residue
DNA
TOP1cc
 
 
62
Camptothecin, a Top1 inhibitor, targets Top1 and novel Top1 inhibitors are in 
development as anticancer agents that prevent the religation of DNA after cleavage during 
replication (Figure 2.4).9  Mechanistically and undesirably, Top1 inhibitors selectively bind to 
the TOP1-DNA interface and damage DNA by trapping covalent complexes between the Top1 
catalytic tyrosine and the 3′-end of the broken DNA.10 
 
Figure 2.4. Mechanism for each of Top1 and inhibitor with DNA (This figure was copied from 
“Pommier, Y. et al., Progress in Nucleic Acid Research and Molecular Biology, Vol 81, Moldave, 
K., Ed. 2006; pp 179–229.”) 
Tyrosyl-DNA phosphodiesterase 1 (Tdp1) is a recently discovered DNA repair enzyme 
that catalyzes the cleavage (hydrolysis) of phosphodiester bond between the Top1 catalytic 
tyrosine residue and a DNA 3'-phosphate as shown Figure 2.5.1, 11, 12, 13  When the 5’-hydroxyl 
end of the broken DNA is too far to carry out the nucleophilic addition resulting in DNA 
religation, then Tdp1 hydrolyzes the intermediate tyrosyl-phosphodiester bond using a water 
molecule.7c, 14   Tdp1 repairs topoisomerase I (Top1)-DNA covalent complexes by this 
mechanism and Tdp1 has the potential to enhance the negative activity of Top 1 inhibitors in 
cancer cell as mentioned before.15  The PNKP (Polynucleotide kinase 3’-phosphatase) enzyme 
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can then hydrolyze the damaged DNA by either removing 3’-phosphates from, or by 
phosphorylating 5’-hydroxyl groups on the broken DNA backbone.  This is now a substrate for 
DNA polymerase, which is an enzyme that assists in DNA replication, by adding free 
nucleotides to the 3’ end of a newly forming strand, and ligase which helps the combining of 
DNA strands together by catalyzing the formation of a phosphodiester bond.  As discussed above, 
Tdp1 counteracts the action of Top1 inhibitors and possibly decrease their effectiveness in 
reducing cancer cells.  Tdp1 repairs DNA lesions and chemotherapeutic-mediated DNA damage, 
such as the DNA breaks prompted by top1 inhibitors.  Thus, Tdp1 is a potentially rational 
anticancer target whose inhibition should improve the activity of cancer chemotherapeutics. 
 
Figure 2.5. Action of Tdp1 and PNKP. 
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Tdp1 inhibitors have become a major area of drug research for anti-cancer treatment.5,16 
A recent study on a steroid-linked benzenesulfonate (NSC 88915) and other derivatives reported 
that both the steroid and phenylsulfonyl ester moieties of NSC 88915 are required for Tdp1 
inhibition (Figure 2.6). 17   In particular, the p-Br-substituted benzenesulfonate NSC 88915 
showed the best result among the derivatives, its IC50 value was 7.7 ± 0.8 µM. 
 
Figure 2.6. Structure of NSC88915 and other derivatives. 
 
Since only a limited number of weak Tdp1 inhibitors have been reported, 18  we 
commenced the investigation by designing and developing new desired compounds from a 
sulfamide moiety.  The structural features considered for initial scaffold design were based on 
various literature reports on compounds tested as inhibitor of Aggrecanase-1, 19 TACE 20 or KSP 
(Kinesin Spindle Protein). 21   Herein, we report the study of a small library of sulfamide 
compounds, designed, synthesized and tested for Tdp1 inhibitory activity 
 
2.4. Chemistry 
The initial study was the synthesis of the sulfonamide compound 2.7, which has a p-
bromo phenyl ring similar to NSC88915 (Scheme 2.1).  The synthesis route for the sulfonamide 
2.7 was started from the reaction of p-bromo benzenesulfonyl chloride with m-fluoroaniline 
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under basic conditions.  After the generation of sulfonamide intermediate 2.4, a Mitsunobu 
reaction was carried out to generate the piperidine-containing secondary amine 2.5. Reductive 
amination after deprotection of Boc group, using HCl, was successfully accomplished to 
generate sulfonamide compound 2.7. 
Scheme 2.1. Preparation of sulfonamide 2.7. 
 
In order to observe the effect of an amino ester moiety on DNA binding or H-bonding, 
we changed the phenyl ring to an amino ester.  The new scaffold design is composed of three 
fragments as outlined in Figure 2.7, namely, a western subunit (hydrophilic amino ester), central 
subunit (sulfamide with phenyl ring), and eastern subunit (benzyl piperidine).  Modification of 
the structure of the inhibitor was mainly focused on these three fragments. 
 
Figure 2.7. Scaffold design for Tdp 1 analogues. 
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Piperidinyl sulfamides derivatives 2.21–2.25 were prepared starting from the reductive 
amination reaction of p-fluoroaniline 2.10 or n-butylamine 2.11 and N-Boc-4-piperidinone 2.12 
to give 2.13 and 2.14 (Scheme 2.2).22  The secondary amines 2.13 and 2.14 were coupled with 
chlorosulfonyl isocyanate (CSI) and t-BuOH in the presence of Et3N as a base to the 
corresponding Boc-protected sulfamide moieties 2.15 and 2.16.23  The subsequent Mitsunobu 
reaction was carried out with the α-hydroxyl amino ester 2.9 to generate the amino ester-linked 
sulfamides 2.17 and 2.18.24  In this regard, L-valine was converted to the α-hydroxyl carboxylic 
acid 2.8 using the Van Slyke25 reaction which maintains the chiral integrity using H2SO4 and 
NaNO2 in water at 0 °C overnight with vigorous generation of nitrogen gas being observed.
26  
Amino ester 2.9 was obtained from amino acid 2.8 via esterification using MeOH/acid.27,28  
Deprotection of the Boc group furnished the secondary amines 2.19 and 2.20, and reductive 
amination afforded the piperidinyl sulfamides 2.21–2.25.29  
 
Scheme 2.2. Preparation of compounds 2.21–2.25. 
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2.4.1. Initial Gel Study 
Results of the initial gel study of sulfamide compounds 2.21, 2.25, and other 
intermediates are shown in Figure 2.8. Key points of Figure 2.8, include: (A) Sulfamide 
intermediates and final sulfamide compounds; (B) Tdp1 biochemical assays. Single-stranded 
14Y (14-mer strand) was used as substrates and 32P-Radiolabeling (*) was at the 5’ terminus of 
the strand. Tdp1 catalyzes the hydrolysis of the 3’-phosphotyrosine bond using water molecule 
and converts 14Y to an oligonucleotide with 3’-phosphate 14P; (C) Gel illustrates Tdp1 
inhibition by sulfamides with single strand 14Y. 3’-Phosphate oligonucleotide product (14P) was 
developed faster than the corresponding tyrosyl oligonucleotide substrate (14Y). Reactions were 
performed with sulfamides in concentration 0.01, 0.1, 1.0, 10, and 100 µM, and (D) Cleavage 
inhibition analysis of the gel shown in panel C was calculated as percentage.  Gel study for 
compounds LSC-JHJ-I-55-1 and LSC-JHJ-I-64-1 was carried out together but they are 
intermediates for other projects.  Compound 2.21 showed the best result among the tested 
compounds with a measured IC50 value of 23.7 μM.  
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Figure 2.8. Inhibition of Tdp1 activity by sulfamides and intermediates (Initial Gel Study). 
 
2.4.2. Protein Docking Study 
Dr. Iwona Weidlich carried out molecular modeling of piperidinyl sulfamide derivatives 
(Figure 2.9).  The arrow indicates the direction to the Tdp1 active site.  Hydrophobic and 
hydrophilic surface areas of the protein are colored in grey and orange, respectively.  The 
coloring of atoms is as follows: carbon – yellow (A), green (B); nitrogen – blue; oxygen – red; 
sulfur - orange.  Ligands are displayed in stick representations, while all hydrogen atoms have 
been shown.  Hydrogen bonds are represented by green dotted lines.  Both inhibitors bind in the 
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2.4.3. Synthesis of Piperidinyl Sulfamides 
Since we obtained the promising results of the gel study and protein docking study, we 
continued to make an analogue of the piperidinyl sulfamide.  The same synthetic route was 
utilized for the synthesis of sulfamide compound 2.30 where L-leucine was used as the starting 
substrate as outlined in Scheme 2.3.  After the conversion of L-leucine to α-hydroxy ester 2.27 
through 2.26 via esterification, it was used for the Mitsunobu reaction with 2.15 to furnish 
intermediate 2.28.  In an analogous manner to the aforementioned L-valine-derived analogues 
2.21–2.25, de-protection and reductive amination with p-substituted benzaldehyde generated 
compound 2.30. 
 
 
Scheme 2.3. Preparation of compound 2.30. 
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sulfamoyl chlorides 2.32 and 2.33 at a low temperature.31  The sulfamoyl chloride 2.32 and 2.33 
then reacted with p-F-phenyl piperidinyl amine 2.31 to furnish sulfamides 2.34 and 2.35.  The 
secondary piperidinyl amine 2.36 and 2.37 were prepared using HCl (4N in 1,4-dioxane), and 
reductive amination afforded sulfamides 2.38, 2.39, 2.40 and 2.41.  Acylation also proceeded 
from compound 2.36 and 2.37 to generate compound 2.42, 32  and compound 2.43 was 
synthesized from D-valine. 
 
Scheme 2.4. Synthetic route for the preparation of compounds 2.38–2.43. 
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which was reacted with benzaldehyde under reductive amination conditions to afford compound 
2.45 in 80% yield. Reductive amination reaction with m-fluoroaniline at 0 °C to room 
temperature, generated amine 2.46 which was coupled with 2.32 under basic condition to 
complete the synthesis of sulfamide compound 2.47 in 51%.  
 
Scheme 2.5. Synthesis of sulfamide compound 2.47 derived from L-valine. 
 
Secondary amine 2.48 was prepared by the reductive amination of 3,5-bis-trifluoromethyl 
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Scheme 2.6. Preparation of compound 2.53. 
 
An alternative route to the modified amino ester part is through the use of chlorosulfonyl 
isocyanate (CSI) chemistry (Scheme 2.7).  A solution of CSI and α-hydroxyl ester 2.9, generated 
from L-valine via diazotization and esterification, was cannulated to a solution of secondary 
amine 2.31 in CH2Cl2 at 0 °C to obtain a carbamate compound 2.54 in moderate yield.  
Generation of secondary amine 2.55 via Boc-deprotection of 2.54 and reductive amination with 
benzaldehyde, afforded the sulfur-containing carbamate compound 2.56.  The coupling reaction 
with 2.55 and p-fluorobenzoyl chloride generated compound 2.57 containing a carbonyl group. 
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Scheme 2.7. Preparation of compound 2.56 and 2.57. 
 
2.5. Biology 
2.5.1. Expression and Purification of Tdp1.  
Wild-type and mutant (H493R) human Tdp1 enzymes were expressed in E. coli BL21 
(DE3) cells and purified as described earlier,33 following the described method in reference 
(Nucleic Acids Res. 2007, 35, 4474–4484).  Human Tdp1 expressing plasmid pHN1910 (a gift 
from Dr. Howard Nash, Laboratory of Molecular Biology, National Institute of Mental Health, 
National Institutes of Health) was constructed using vector pET-15b (Novagen, Madison, WI, 
USA) with full-length human Tdp1 and an additional His-tag sequence of 
MGSSHHHHHHSSGLVPRGSHMLEDP in its N terminus.  The His-tagged human Tdp1 was 
purified from Novagen BL21 cells using chelating sepharoseTM fast flow column (Amersham 
Biosciences, Piscataway, NJ, USA) according to the company’s protocol.  The collected 
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fractions were assayed immediately for Tdp1 activity.  Fractions that showed Tdp1 activity were 
pooled and dialyzed in 20 % glycerol, 50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 10 mM β-
mercaptoethanol and 2 mM EDTA.  Dialyzed samples were aliquoted and stored at -80 °C. Tdp1 
concentration was determined using the Bradford protein assay (Bio-Rad Laboratories, Hercules, 
CA, USA). Tdp1 purity was determined as a single ~70kDa band representing over 95% of the 
detectable proteins stained by Coomassie after SDS–polyacrylamide gel electrophoresis (SDS-
PAGE). 
 
2.5.2. Tdp1 Gel-Based Assay 
A 1 nM 5’-32P-labeled DNA substrate was incubated with 0.1 nM recombinant Tdp1 in 
the absence or presence of inhibitor for 20 min at 25 °C in a reaction buffer containing 50 µM 
Tris-HCl (pH 7.5), 80 mM KCl, 2 mM EDTA, and 40 μg/mL bovine serum albumin (BSA). 
Reactions were terminated by the addition of two volumes of gel loading buffer (96% (v/v) 
formamide, 10 µM EDTA, 1% (w/v) xylene cyanol, and 1% (w/v) bromphenol blue). The 
samples were subsequently heated to 95 °C for 5 min and subjected to 18% sequencing gel 
electrophoresis. A concentration of 100 nM was used when employing the SCAN1 mutant 
H493R. In addition, H493R reactions were divided in half.  One-half of the reaction was run on a 
sequencing gel, while the other half was analyzed by 4-20% SDS-PAGE electrophoresis. 
Imaging and quantification were performed using the Typhoon 8600 and ImageQuant software 
(Molecular Dynamics), respectively. 
The results of the final gel study with 17 compounds including compound 2.21 are shown 
in Figure 2.10.  While the compound 2.21 is showing Tdp1 inhibition identical to our previous 
observations, the compound 2.47 is inactive against Tdp1. This experiment is showing very 
 
interestin
compoun
chirality 
enzyme. 
  
Figure 2
 
2.6. Mole
2.6.1. Pr
T
ChemBio
were per
g result. Co
d 2.47 has 
of the comp
.10. Gel stud
cular Mod
eparation o
he piperidin
Draw Ultra
formed usi
mpound 2.
(S)-configu
ound contri
y with final
eling of Pip
f ligand str
yl sulfamid
 12.0.34  Ad
ng the buil
21 has (R)-
ration. From
butes to the
 compounds
eridinyl Su
uctures 
e derivatives
ditional mo
ding tools 
 76
configuratio
 this obse
 affinity of 
. 
lfamide Der
 described 
lecular cons
available in
n on the a
rvation, it c
inhibitor fo
ivatives 
in this paper
truction and
 MACROM
mino ester 
ould be co
r the active
 were draw
 modeling o
ODEL 20
moiety, wh
ncluded tha
 site of the 
 
n in the pro
f the deriva
11 (Schröd
ereas 
t the 
Tdp1 
gram 
tives 
inger 
 
 
77
Inc.). 35   The ligands were minimized using the OPLS-2005 force field.  The preparation 
procedure in GLIDE requires the preparation of the structures in the appropriate ionization state. 
We used 2D to 3D conversion program LigPrep 36  to generate accurate energy minimized 
molecular structures, expands tautomeric and ionization states, ring conformations, and 
stereoisomers to produce broad chemical and structural diversity of ligand libraries for further 
computational analyses. 
 
2.6.2. Molecular Docking  
To investigate the binding mode of the piperidinyl sulfamide derivatives to Tdp1 at the 
molecular level, we performed docking analysis using the high-resolution structure of Tdp1, co-
crystallized with a peptide-vanadate-DNA substrate mimic (PDB accession code 1NOP).  After 
construction of a molecular model from 1NOP (published earlier)30 the prepared ligands were 
docked into the substrate binding pocket of Tdp1 using the program GLIDE (Schrödinger)37 with 
the Extra Precision mode.  A set of Grid files was generated with residues H263, K265, H493 
and K495 at the center of the binding box defining the space through which the center of the 
docked ligand is allowed to move.  The size of the cube box was set to 16 Å edge in length in 
order to explore a large region of the protein.  To conduct a more precise analysis of docked 
poses of the ligands, we mapped the output docking poses to the pharmacophores of the lead 
compounds30 using absolute positioning in program MOE.38  
 
2.7. Conclusion 
Overall, the routes described in this chapter are applicable to the synthesis of sulfamides 
related to a promising Tdp1 inhibitor.  We identified piperidinyl sulfamide derivative 2.21, 
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which has exhibited inhibitory activity against Tdp1 at low µM concentrations.  The inhibitory 
activity was confirmed using a gel-based assay.  Through the analysis of concentration versus 
percentage inhibition curves, we estimated the IC50 value for 2.21 as 23.7 μM (Figure 2.7).  To 
investigate the binding mode of piperidinyl sulfamide derivatives to Tdp1 at the molecular level, 
we studied docking analysis.  From a stereoview representation of 2.21 (Figure 2.10), we found 
that the benzyl piperidine moiety is oriented towards the Tdp1 active site and hydrophobic amino 
ester moiety forms a hydrogen bond with Tyrosine 204.  We are currently investigating more 
compounds with varying pharmacophores that might be active against Tdp1. 
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CHAPTER 3 
 
Study of Anticancer Activity of Piperidinyl Sulfamides Derivatives  
Using the USA National Cancer Institute 60 Human Cancer Cell Line (NCI 60) Screen  
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3.1. Introduction 
Cancer is not one disease, but rather many diseases in which abnormal cells divide 
without control and are able to occupy other tissues.  Cancer cells can spread to other parts of the 
human body through the blood and lymph systems.1  Damaged or mutated DNA affects normal 
cell growth and division, while the immortal cells become a mass of tissue called tumor.  In spite 
of enormous developments in the field of medical research area, which have resulted in higher 
cure rates for a number of malignancies, cancer is the second ranked leading cause of death after 
heart disorders in developing, as well as, advanced countries.2  Although major advances have 
been made in the chemotherapeutic treatment of some patients, high obligation to the demanding 
task of discovering new anti-cancer drugs remains crucially important.  As a major pioneering 
cancer research center, the US National Cancer Institute (NCI) has played a significant role in 
leading the discovery and development of cancer treatment.  Since 1955, NCI has provided 
screening support to cancer researchers globally.  In the late 1980s, 60 anticancer drug screens 
were developed with the aim of changing the emphasis of drug discovery from murine 
neoplasms (household rats and mice tumors) to human solid tumors as an in vitro drug-discovery 
tool.3  Since then, it was available to identify the clinical activity of the compounds for the 
human adult tumor, such as lung, colon, breast, and prostate cancers.  
The compounds shown in Figure 3.1 are examples identified by the NCI 60 cell line 
screen.  The first boronic acid compound (NSC 681239, Bortezomib, 3.1) is the first therapeutic 
proteasome inhibitor, which was synthesized in 1995 at Myogenics Topotecan (NSC 609699, 
3.2),4 and is a TOP1 inhibitor to treat ovarian cancer and lung cancer, as well as other types of 
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cancers.5 Doxoruicin (NSC 123127, 3.3) is microbial product for breast cancer, bladder cancer, 
and stomach cancer.6 
 
Figure 3.1. Examples of compounds identified by NCI 60 cell line. 
 
The discovery and development of potential anticancer drugs by NCI are based on a 
series of sequential screening and detailed testing steps to identify new, effective lead 
compounds and to eliminate inactive and/or highly toxic materials from further consideration. 
With this concern, Tdp1 related compounds were submitted and screened against the NCI-60 cell 
line, and the results will be discussed. 
 
3.2. NCI 60 Cell Line Screening 
Pharmacological evaluation of anticancer activity was carried out on selected compounds 
by the developmental therapeutic program of Frederick National Laboratory for Cancer 
Research, Frederick, Maryland.  All selected compounds for in vitro cancer screening have been 
given a unique NSC (National Service Center) number.  Compounds in Table 3.1 were submitted 
to the NCI-60 cell line screen and evaluated for their in vitro anticancer activity at a single dose 
(1 × 10-5M or 10 μM) against the full NCI-60 cell line panels (Table 3.1).  Some sulfamide 
intermediates were also submitted to compare the NCI-60 cell line results with final compound 
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results.  Details of the methodologies for the NCI-60 cell line screening are described at 
http://dtp.nci.nih.gov/branches/btb/ivclsp.html.3, 7   Briefly, the panel is organized into nine 
subpanels representing diverse histologies: leukemia, melanoma, and cancers of lung, colon, 
kidney, ovary, breast, prostate, and central nervous system.  The human tumor cells are grown in 
supplemented RPMI 1640 medium containing 5% fetal bovine serum and 2 mL glutamine for 24 
h.  The cells are inoculated into 96-well microtiter plates in 100 μL at plating densities ranging 
from 5,000 to 40,000 cells/well depending on the doubling time of individual cell lines. After 
cell inoculation, the microtiter plates are incubated at 37 °C, 5 % CO2, 95 % air and 100 % 
relative humidity for 24 h prior to addition of experimental drugs.  The submitted compounds 
2.7-2.57 in Table 3.1 were dissolved in DMSO and incubated with cells at five concentrations 
with 10-fold dilutions, the highest being 10-4 M and the others being 10-5, 10–6, 10-7, and 10-8 M.  
The assay is terminated by the addition of cold trichloroacetic acid, and the cells are fixed and 
stained with sulforhodamine B.  Bound stain is solubilized, and the absorbance is read on an 
automated plate reader.  The cytostatic parameter that is 50% growth inhibition (GI50, 
concentrations required to inhibit the growth by 50%) was calculated from time zero, control 
growth, and the five concentration level absorbance.  The cytotoxic parameter that is inhibitory 
concentrations (LC50, lethal concentration, standard measure of the toxicity of the medium that 
kills half of the sample population in a specified period, lower number means more toxic) 
represents the average of two independent experiments.  In vitro screening is a two-stage process 
starting with the evaluation of all compounds against the NCI-60 human tumor cell lines with a 
single dose of 10.0 μM, which is done by following the same protocol as for five-dose screening.  
The output from the single dose screen was reported as a mean graph (given in the 
Supplementary data section with general interpretation) of the percentage growth of the treated 
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cells.  Results of each test agents are reported as percentage growth of the treated cell when 
compared with untreated control cells.  The value numbers from the single dose screen were 
analyzed by the COMPARE program with only the compounds that showed more than 60% of 
growth inhibition in at least 8 tumor cell lines selected for further testing, while the others were 
assumed as inactive.  
 
Table 3.1. List of compounds screened for NCI 60 cell lines. 
NSC 
No. 
Structure 
NSC 
No. 
Structure 
750772 
(2.7) 
 
750710 
(2.15) 
 
750711 
(2.16) 
 
750706 
(2.21) 
 
747166 
(2.22) 
 
767523 
(2.23) 
 
767524 
(2.24) 
750707 
(2.25) 
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749205 
(2.30) 
 
749201 
(2.34) 
 
750715 
(2.38) 
 
750713 
(2.40) 
 
750714 
(2.42) 
 
750712 
(2.43) 
 
764209 
(2.47) 
 
749204 
(2.53) 
 
749203 
(2.56) 
 
749202 
(2.57) 
 
 
3.2.1. In vitro anticancer activity 
The one-dose data for the aforementioned screen is reported as a mean graph of the 
percent growth of treated cells and will be similar in appearance to the mean graphs from the 5-
dose assay.  The number reported for the one-dose assay is growth relative to the no-drug control, 
and relative to the time zero number of cells.  This allows detection of both growth inhibition 
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(values between 0 and 100) and lethality (values less than 0).  This is the same as for the 5-dose 
assay, described on http://dtp.nci.nih.gov/branches/btb/ivclsp.html.  For example, a value of 100 
means no growth inhibition.  A value of 40 would mean 60% growth inhibition.  A value of 0 
means no net growth over the course of the experiment.  A value of -40 would mean 40% 
lethality.  A value of -100 means all cells are dead.  Information from the one-dose mean graph is 
available for COMPARE analysis (http://dtp.nci.nih.gov/docs/compare/compare.html).  The 
primary, one-dose screening data showed that NSC 749204 (2.53) was active, while other 
compounds were determined as inactive.  Table 3.2 is the summary of one-dose experiments for 
each compound.  Even if it was not selectively considered using a 60% of growth inhibition as 
criterion, many compounds were moderately sensitive on the non-small cell lung cancer (HOP-
92) and leukemia (HL-60(TB) cell lines.  Compound 2.7 (NSC 750772) showed 35.19% growth 
inhibition against the RPMI-8226 cell line (Leukemia), compound 2.15 (NSC 750710), 67.08% 
against the HOP-92 cell line (Non-small cell lung cancer), compound 2.16 (NSC 750711), 78.38% 
against the HL-60(TB) cell line (Leukemia), compound 2.21 (NSC 750706), 43.68% against the 
HL-60(TB) cell line (Leukemia), compound 2.22 (NSC 747166), 12.34% against the HOP-62 
cell line (Non-small cell lung cancer), compound 2.23 (NSC 767523), 67.24% against the UO-31 
cell line (Renal cancer), compound 2.24 (NSC 767524), 33.30% against the CCRF-CEM cell 
line (Leukemia), compound 2.25 (NSC 750707), 69.67% against the UO-31 cell line (Renal 
cancer), compound 2.30 (NSC 749205), 39.58% against the HOP-92 cell line (Non-small cell 
lung cancer), compound 2.34 (NSC 749201), 71.49% against  the HOP-92 cell line (Non-small 
cell lung cancer), compound 2.38 (NSC 750715), 76.86% against the CCRF-CEM cell line 
(Leukemia), compound 2.40 (NSC 750713), 39.99% against the HL-60(TB) cell line (Leukemia), 
compound 2.42 (NSC 750714), 43.07% against the HL-60(TB) cell line (Leukemia), compound 
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2.43 (NSC 750712), 62.35% against the A498 cell line (Renal cancer), compound 2.47 (NSC 
764209), 87.42% against the SNB-75 cell line (CNS cancer), compound 2.53 (NSC 749204), 
19.49% against the HT29 cell line (Colon cancer), compound 2.56 (NSC 749203), 41.46% 
against the MOLT-4 cell line (Leukemia), and compound 2.57 (NSC 749202), 83.92% against 
the NCI-H322M cell line (Non-small cell lung cancer).  A compound that reduced the growth of 
a cell line to 32% or less (negative number indicate kills), is considered in vitro active.8,9  The 
output from the NCI 60-cell lines single dose screen of NSC 749204 was reported as a mean 
graph (Figure 3.2).  
 
Table 3.2. Anti-cancer screening data of compounds. 
Comp. No. 
(NSC No.) 
60 cell line assay in one dose at 10‒5 concentration 
Range of growth 
percentage 
Most sensitive  
cell line 
Growth % 
of  most 
sensitive 
cell line  
Mean  Delta range activitya 
2.7 
(750772) 
 
35.19 to 112.96 Leukemia (RPMI-8226) 35.19 82.41 47.22 77.77 inactive 
2.15 
(750710) 
67.08 to 134.43 Non-small cell lung cancer 
(HOP-92) 
67.08 100.62 33.54 67.35 inactive 
2.16 
(750711) 
78.38 to 132.86 Leukemia (HL-60(TB)) 78.38 103.06 24.68 54.48 inactive 
2.21 
(750706) 
43.68 to 115.29 Leukemia (HL-60(TB)) 43.68 81.90 38.22 71.61 inactive 
2.22 
(747166) 
12.34 to 208.78 Non-small cell lung cancer 
(HOP-62) 
12.34 100.63 88.29 196.44 active 
2.23 
(767523) 
67.24 to 117.68 Renal Cancer (UO-31) 67.24 97.34 30.10 50.44 inactive 
2.24 
(767524) 
33.20 to 109.93 Leukemia (CCRF-CEM) 33.20 84.99 51.79 76.73 inactive 
2.25 
(750707) 
69.67 to 118.35 Renal cancer (UO-31) 69.67 98.62 28.95 48.68 inactive 
2.30 
(749205) 
39.58 to 107.51 Non-small cell lung cancer 
(HOP-92) 
39.58 78.32 38.74 67.93 inactive 
2.34 71.49 to 130.53 Non-small cell lung cancer 71.49 97.81 26.32 59.04 inactive 
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(749201) (HOP-92) 
2.38 
(750715) 
76.86 to 124.74 Leukemia (CCRF-CEM) 76.86 98.79 21.93 47.88 inactive 
2.40 
(750713) 
39.99 to 131.35 Leukemia (HL-60(TB)) 39.99 96.65 56.66 91.36 inactive 
2.42 
(750714) 
43.07 to 131.06  Leukemia (HL-60(TB)) 43.07 99.49 56.42 87.99 inactive 
2.43 
(750712) 
62.35 to 131.82 Renal cancer (A498) 62.35 100.64 38.29 69.47 inactive 
2.47 
(764209) 
87.42 to 126.22 CNS (SNB-75) 87.42 105.30 17.88 38.80 inactive 
2.53 
(749204) 
19.49 to 92.88 Colon cancer (HT29) 19.49 56.65 121.91 158.14 active 
2.56 
(749203) 
41.46 to 116.72 Leukemia (MOLT-4) 41.46 98.11 56.65 84.64 inactive 
2.57 
(749202) 
83.92 to 127.35 Non-small cell lung cancer  
(NCI-H322M) 
83.92 99.52 15.60 43.43 inactive 
a Compounds active of that particular cell lines, which shown growth inhibition ≤ 32% cell growth reduction 
following 48 h incubation with test compounds. 
 
 
Figure 3.2. Selected NCI60-cell lines screen
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ing data for one dose study of 2.53 (NSC 749204). 
 
 
 
94
3.2.2. Five-dose assay 
When the result of growth inhibition is satisfied to more than 60% over 8 cell lines, the 
compound is selected for the five-dose assay.  To explain the data, the activity of a one-test 
compound on three non-small-cell lung cancer cell lines is shown in Figure 3.3.3  The response 
parameters GI50 (50% growth inhibition) and LC50 (50% lethal concentration) are extracted from 
concentration-response curves by linear interpolation.  TGI (total growth inhibition, 
concentration at which the total growth inhibition is 100%) is indicated as the x-axis intercept.  
Five-dose assays are carried out with 10-fold dilutions at five different concentrations (0.01, 0.1, 
1, 10 and 100 μM).  Thus, for EKVX cell line, GI50 = 0.12, the TGI = 0.84 and the LC50 of effect 
is not reached. 
 
Figure 3.3. Activity of a one-test compound on three non-small-cell lung cancer cell lines. This 
graph was depicted with a hypothetical number to explain GI50, TGI, and LC50 value. (This 
Figure was copied from ‘Shoemaker, R. H., The NCI60 human tumor cell line anticancer drug 
screen. Nat. Rev. Cancer 2006, 6, 813–823’). 
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The complete in-vitro anti-cancer data collected on the 60 subpanel cell lines for the most 
active compound, 2.53 (NSC 749204), is highlighted in Tables 3.3 and 3.4.  Secondary screening 
was carried out on this active compound in order to determine its cytostatic and cytotoxic 
activities.  Compound 2.53 (NSC 749204) satisfied 60% of growth inhibition as a criterion over 
8 cell lines and was further selected for the NCI full panel five-dose assay at 10-fold dilutions 
using five different concentrations (0.01, 0.1, 1, 10 and 100 μM).  The result of compound 2.53 
for five-dose screening is given with three response parameters (GI50, TGI and LC50) for each 
cell line from log10 of sample concentration (molar) vs. percentage growth inhibition curves of 
nine cancer diseases (Figures 3.4 and 3.5).  NCI renamed the IC50 value, the concentration that 
causes 50% growth inhibition, the GI50 value (growth inhibitory activity) to emphasize the 
correction for the cell count at time zero.  Namely, GI50 is the concentration of test compound 
where 100 × (T-T0) / (C-T0) = 50.  T is the optical density of the test well after a 48-h period of 
exposure to test drug, T0 is the optical density at time zero, and C is the controlled optical density.   
The GI50 value (growth inhibitory activity) corresponds to the concentration of the compound 
causing 50% decrease in net cell growth, namely it is the growth inhibitory power of the testing 
compound.  The TGI value (cytostatic activity, the inhibition of cell growth and multiplication) 
is the concentration of the compound resulting in total growth inhibition.  The LC50 value, 
signifies cytotoxic activity (the quality of being toxic to cells), and is the concentration of the 
compound causing a net 50% loss of initial cells at the end of the incubation period of 48 h.  
Furthermore, a mean graph midpoint (MID) is calculated giving an averaged activity parameter 
over all cell lines. 
Compound 2.53 (NSC 749204) shows moderate to good anticancer activity against many 
tested cell lines responding nine different panels with GI50 values between 1.88 and 21.0 μM.  
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Regarding sensitivity against some individual cell lines, the compound showed good activity 
against colon cancer COLO 205 and HCC-2998 cell lines with GI50 value 1.88 and 3.01 μM, 
respectively.  Generally, obtained data shows a good sensitivity profile towards colon cancer 
(least for COLO 205 cell line, GI50 = 1.88 μM and maximum for SW-620 cell line, GI50 = 11.1 
μM).  The compound also shows the sensitivity toward leukemia (least for SR cell line, GI50 = 
3.18 μM and maximum for CCRF-CEM cell line, GI50 = 12.8 μM) and the breast cancer 
subpanel (least for MDA-MB-468 cell line, GI50 = 3.25 μM and maximum for MDA-MB-
231/ATCC cell line, GI50 = 12.7 μM).  Compound 2.53 also exhibited sensitivity toward some of 
cell lines of the melanoma cancer cell panel such as LOX IMVI (GI50 = 8.10 μM), MALME-3M 
(GI50 = 6.89 μM), M14 (GI50 = 3.75 μM), and SK-MEL-5 (GI50 = 3.19 μM).  All remaining 
subpanel cell lines showed maximum sensitive toward tested compounds with not more than 21 
μM of GI50 concentrations.  
 
 
 
 
 
 
 
  
 
Figure 3
 
.4. Nine panel dose response curves
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 of compound 2.53 (NSC 749204).  
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Table 3.4. Anti-tumor activity (GI50/μM)
a, TGIb and toxicity (LC50/μM)
c data of 2.53 (NSC 
749204) selected for 5 dose studies for the NCI60-cell lines screen. 
NSC 749204 
Panel/cell line  GI50 TGI LC50 Panel/cell line GI50 TGI LC50
       
Leukemia    Melanoma    
CCRF-CEM 12.8 30.7 73.6 LOX IMVI  8.10 25.0 68.4 
HL-60(TB) 4.69 18.2 52.5 MALME-3M  6.89 22.3 59.0 
K-562 4.63 16.0 47.8 M14 3.75 15.0 42.8 
MOLT-4 11.5 27.4 65.4 MDA-MB-435  10.2 24.8 60.4 
RPMI-8226 7.57 25.6 77.2 SK-MEL-2  21.0 41.0 79.8 
SR 3.81 9.22 >100 SK-MEL-28  14.0 27.8 55.3 
      SK-MEL-5 3.19 12.0 36.1 
Non-small cell lung cancer    UACC-257  16.4 30.8 58.1 
A549/ATCC 14.0 31.0 69.1 UACC-62 11.0 24.6 55.1 
EKVX 12.2 28.9 68.4      
HOP-62 15.0 29.0 56.2 Ovarian cancer    
HOP-92 5.76 20.0 46.2 IGROV1 18.8 44.9 >100 
NCI-H226 13.2 30.2 69.1 OVCAR-3  10.4 23.0 51.1 
NCI-H23 12.2 25.9 55.3 OVCAR-4  11.9 24.7 51.0 
NCI-H322M 13.9 29.4 62.1 OVCAR-5  15.8 29.7 55.8 
NCI-H460 7.13 22.1 57.7 OVCAR-8  14.6 33.4 76.7 
NCI-H522 14.9 37.0 91.8 NCI/ADR-RES 10.7 23.4 50.9 
        SK-OV-3  15.5 29.0 54.3 
Colon cancer        
COLO 205  1.88 3.59 6.85 Renal cancer    
HCC-2998  3.01 11.7 36.2 786-0  11.2 24.0 51.1 
HCT-116  4.41 16.4 43.7 A498 12.9 26.2 53.4 
HCT-15  4.42 17.9 50.8 ACHN  14.0 30.0 64.5 
HT29  3.78 14.6 42.5 CAKI-1  7.23 22.3 53.6 
KM12  4.92 17.6 46.8 RXF 393  10.6 23.7 53.2 
SW-620  11.1 24.9 55.8 SN12C  4.69 18.5 52.3 
        TK-10  17.2 32.7 62.1 
CNS cancer   UO-31  11.7 26.0 57.6 
SF-268  11.5 26.3 60.2      
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a GI50: 50% growth inhibition, concentration of drug resulting in a 50% reduction in net protein 
increase compared with control cells. 
b TGI: total cell growth inhibition 
c LC50: lethal concentration, concentration of drug lethal to 50% of cells. 
 
 
The criterion for selectivity of a compound depends on the ratio obtained by dividing the 
full panel MID (the average sensitivity of all cell lines towards the test agent) by their individual 
subpanel MID (the average sensitivity of all cell lines of a particular subpanel towards the test 
agent).  Ratios between 3 and 6 refer to moderate selectivity; ratios greater than 6 indicate high 
selectivity towards the corresponding cell line, while compounds not meeting either of these 
criteria were rated non-selective.10  Following this criterion, compound 2.53 (NSC 749204) was 
found to be mildly selective toward the colon cancer panel.  In addition, compound 2.53 was also 
found to demonstrate mild to no-selectivity in both the leukemia and breast cancer subpanels.  
 
SF-295  10.5 24.5 57.2 Prostate cancer    
SF-539  13.2 26.4 52.9 PC-3  7.61 20.8 47.5 
SNB-19  13.0 25.8 51.3 DU-145  13.4 27.4 56.0 
SNB-75  6.24 20.4 45.8      
U251  11.1 27.9 76.5 Breast cancer    
        MCF7  6.91 21.9 56.2 
      
MDA-MB-
231/ATCC 
12.7 29.3 67.7 
    HS 578T 11.3 27.1 65.1 
    BT-549 8.34 22.9 56.7 
    T-47D 5.34 19.6 50.4 
    MDA-MB-468 3.25 15.3 43.4 
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Table 3.5. Calculated value of GI50 of the cell lines: full cell line panel, MG-MID and 
selectivity ratio of the compound 2.53 (NSC 749204).   
Panel Cell line GI50 (10
-6 M) 
Concentration 
per cell line 
Subpanel 
concentration 
Subpanel MID Selectivity ratio 
Leukemia CCRF-CEM 12.8 
45 7.500 1.340 
 HL-60(TB) 4.69 
 K-562 4.63 
 MOLT-4 11.5 
 RPMI-8226 7.57 
 SR 3.81 
Non-small cell  A549/ATCC 14.0 
108.29 12.032 0.835 
lung cancer EKVX 12.2 
 HOP-62 15.0 
 HOP-92 5.76 
 NCI-H226 13.2 
 NCI-H23 12.2 
 NCI-H322M 13.9 
 NCI-H460 7.13 
 NCI-H522 14.9 
Colon cancer COLO 205  1.88 
33.52 4.789 2.098 
 HCC-2998  3.01 
 HCT-116  4.41 
 HCT-15  4.42 
 HT29  3.78 
 KM12  4.92 
 SW-620  11.1 
CNS cancer SF-268  11.5 
65.54 10.923 0.920 
 SF-295  10.5 
 SF-539  13.2 
 SNB-19  13.0 
 SNB-75  6.24 
 U251  11.1 
Melanoma LOX IMVI  8.10 
94.53 10.503 0.957  MALME-3M  6.89 
 M14 3.75 
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 MDA-MB-435  10.2 
 SK-MEL-2  21.0 
 SK-MEL-28  14.0 
 SK-MEL-5 3.19 
 UACC-257  16.4 
 UACC-62 11.0 
Ovarian cancer IGROV1 18.8 
97.7 13.957 0.720 
 OVCAR-3  10.4 
 OVCAR-4  11.9 
 OVCAR-5  15.8 
 OVCAR-8  14.6 
 NCI/ADR-RES 10.7 
 SK-OV-3  15.5 
Renal cancer 786-0  11.2 
89.52 11.190 0.898 
 A498 12.9 
 ACHN  14.0 
 CAKI-1  7.23 
 RXF 393  10.6 
 SN12C  4.69 
 TK-10  17.2 
 UO-31  11.7 
Prostate cancer PC-3  7.61 
21.01 10.505 0.957 
 DU-145  13.4 
Breast cancer MCF7  6.91 
47.84 7.973 1.260 
 MDA-MB-
231/ATCC 
12.7 
 HS 578T 11.3 
 BT-549 8.34 
 T-47D 5.34 
 MDA-MB-468 3.25 
 
The log molar concentration of the resulted screening of compound 2.53 (NSC 749204) 
shown for each of the parameters; for log GI50 ranged from -5.73 to -4.68, for log TGI ranged 
from -5.45 to -4.39, for log LC50 ranged from -5.16 to -4.00 (Table 3.6). A mean graph midpoint 
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(MG-MID) calculated for each of the parameters; log GI50 (-5.05), log TGI (-4.64), and log LC50 
(-4.26). 
 
Table 3.6. Values of the log molar concentration of response parameter (log10GI50, log10TGI and 
log10LC50) of the compound 2.53 (NSC 749204).  
Cancer disease Used cell lines log10GI50 log10TGI log10LC50 
Leukemia CCRF-CEM -4.89 -4.51 -4.13 
 HL-60(TB) -5.33 -4.74 -4.28 
 K-562 -5.33 -4.80 -4.32 
 MOLT-4 -4.94 -4.56 -4.18 
 RPMI-8226 -5.12 -4.59 -4.11 
  SR -5.42 -5.04 -4.00 
Non-small cell lung cancer A549/ATCC -4.86 -4.51 -4.16 
 EKVX -4.91 -4.54 -4.16 
 HOP-62 -4.83 -4.54 -4.25 
 HOP-92 -5.24 -4.70 -4.33 
 NCI-H226 -4.88 -4.52 -4.16 
 NCI-H23 -4.92 -4.59 -4.26 
 NCI-H322M -4.86 -4.53 -4.21 
 NCI-H460 -5.15 -4.65 -4.24 
 NCI-H522 -4.83 -4.43 -4.04 
Colon cancer COLO 205 -5.73 -5.45 -5.16 
 HCC-2998 -5.52 -4.93 -4.44 
 HCT-116 -5.36 -4.78 -4.36 
 HCT-15 -5.35 -4.75 -4.29 
 HT29 -5.42 -4.84 -4.37 
 KM12 -5.31 -4.75 -4.33 
 SW-620 -4.95 -4.60 -4.25 
CNS cancer SF-268 -4.94 -4.58 -4.22 
 SF-295 -4.98 -4.61 -4.24 
 SF-539 -4.88 -4.58 -4.28 
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 SNB-19 -4.89 -4.59 -4.29 
 SNB-75 -5.20 -4.69 -4.34 
 U251 -4.99 -4.55 -4.12 
Melanoma LOX IMVI -5.09 -4.60 -4.16 
 MALME-3M -5.16 -4.65 -4.23 
 M14 -5.43 -4.82 -4.37 
 MDA-MB-435 -4.99 -4.61 -4.22 
 SK-MEL-2 -4.68 -4.39 -4.10 
 SK-MEL-28 -4.85 -4.56 -4.26 
 SK-MEL-5 -5.50 -4.92 -4.44 
 UACC-257 -4.79 -4.51 -4.24 
 UACC-62 -4.96 -4.61 -4.26 
Ovarian cancer IGROV1 -4.73 -4.35 -4.00 
 OVCAR-3 -4.98 -4.64 -4.29 
 OVCAR-4 -4.92 -4.61 -4.29 
 OVCAR-5 -4.80 -4.53 -4.25 
 OVCAR-8 -4.84 -4.48 -4.12 
 NCI/ADR-RES -4.97 -4.63 -4.29 
 SK-OV-3 -4.81 -4.54 -4.27 
Renal cancer 786-0 -4.95 -4.62 -4.29 
 A498 -4.89 -4.58 -4.27 
 ACHN -4.85 -4.52 -4.19 
 CAKI-1 -5.14 -4.65 -4.27 
 RXF 393 -4.98 -4.62 -4.27 
 SN12C -5.33 -4.73 -4.28 
 TK-10 -4.76 -4.49 -4.21 
 UO-31 -4.93 -4.59 -4.24 
Prostate cancer PC-3 -5.12 -4.68 -4.32 
 DU-145 -4.87 -4.56 -4.25 
Breast cancer MCF7 -5.16 -4.66 -4.25 
 MDA-MB-231/ATCC -4.90 -4.53 -4.17 
 HS 578T -4.95 -4.57 -4.19 
 BT-549 -5.08 -4.64 -4.25 
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3.3. Conclusion 
Compounds synthesized for the study of Tdp1 inhibition were screened in the NCI-60 
cancer cell line assay to identify their anti-cancer activity.  Among the selected compounds for 
screening, compound 2.53 (NSC 749204) was selected for five-dose experiments and showed 
moderate-to-good anticancer activity against many tested cell lines responding nine different  
panels with GI50 values between 1.88 and 21.0 μM.  Compound 2.53 (NSC 749204) was found 
to be mildly selective in the colon cancer panel, as well as mildly-to-non-selective in the 
leukemia and breast cancer subpanel.  
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4.1. Introduction 
Among the various human diseases, cancer, human immunodeficiency virus infection / 
acquired immunodeficiency syndrome (HIV/AIDS), and hepatitis C virus (HCV) are among the 
most devastating diseases in contemporary human history.  Accordingly, development and 
discovery of novel potent, significantly selective, and less toxic antitumor, antiviral drugs is one 
of the main hurdles to overcome health problems.  Manytimes, AIDS patients have accompany 
cancers and other lethal diseases because the immune system is so weakened by the HIV in a 
human body.  
Drug repositioning (drug repurposing, reprofiling and indication switch) has gained 
attention from drug discovery.1  Development of a new pharmaceutical product requires at least 
10 to 15 years and costs between $500 million and $2 billion.2  Thus, the identification and 
characterization of new pharmacological activities through screening from existing therapeutic 
drugs is an effective method to accelerate the translation of discoveries in short time and to save 
the development cost.  It also opens new applications of the subsequent target identification and 
validation.  
There are several examples of newly rescued drugs from old drugs 4.1–4.7 shown in 
Table 4.1.3  These drugs are newly indicated for cancers that affect blood, bone marrow, and 
lymph nodes.  With successful results from old drugs to new treatments, scientists are becoming 
more and more interested in drug repositioning.4 
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Table 4.1. Developed treatments for hematological malignancies from old drugs.  
Drugs Original indications New indications Notes 
 
Ciclopirox (4.1) 
Fungal infection Leukemia Preclinical5 
  
Clioquinol (4.2) 
Fungal and protozoal 
infection 
Leukemia and 
Myeloma 
Phase I6 
Cyproheptadine (4.3) 
Antihistamine 
Leukemia, Mantle 
cell lymphoma, and 
myeloma 
Preclinical7 
O
HO
H
O
OH
OH
HF
 
Dexamethasone (4.4) 
Inflammatory and 
autoimmune 
conditions 
Multiple myeloma 
Clinical, FDA 
approved8 
 
Fluphenazine (4.5) 
Mental and 
emotional disorders 
Multiple myeloma 
and other plasma 
cell neoplasm 
Phase II9 
Flubendazole (4.6) 
Antihelmintics Leukemia, myeloma Preclinical10 
 
Thalidomide (4.7) 
Morning sickness Multiple myeloma 
Clinical, FDA 
approved11 
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Recently, focused studies of the effective inhibitions of selective cancer cells by HIV 
protease inhibitors have surfaced in the literature (Figure 4.1).12  Nelfinavir (4.8) is an HIV 
protease inhibitor that is recently being evaluated in an oncology clinical trial as a potential 
candidate of cancer therapeutic treatment.13  Liu reported that Nelfinavir (4.8) selectively inhibits 
the growth of HER2-positive breast cancer cells in vitro.12a  Although breast cancer is one of the 
leading causes of cancer death, only few treatment options are available, and development of 
new drug targets is still in need.  In 2012, Dennis and coworkers reported that Nelfinavir (4.8) 
and bortezomib (4.9) are able to induce endoplasmic reticulum (ER) stress, whereas the 
combination enhances ATF3 and CHOP expression to cause cell death.12b   Betulinic acid (4.10) 
is a natural product possessing biological activities such as including anti-cancer, anti-malarial, 
anti-inflammatory and anti-HIV properties.12c,d  Cobicistat (4.11), a potential inhibitor of 
cytochrome P450 3A enzymes, has been developed as a pharmacoenhancer (booster) for 
coformulation with HIV drugs.12e  Tenofovir alafenamide fumarate (TAF), or GS 7340, (4.12) is 
under development by Gilead Sciences for use in the treatment of HIV infection.  Cobicistat 
(4.11) is a substrate of breast cancer resistance protein (BCRP), and experimental data shown 
that Cobicistat (4.11) has a competitive mode of inhibition with coadministrated agent 4.12 
during intestinal absorption to inhibit breast cancer resistance protein (BCRP). 
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Figure 4.1. Active compounds possessing biological activity on cancer cell.  
 
In this regard, we previously synthesized and reported an array of sulfur-based potential 
HIV-PR inhibitors (DMP 323 analogs in Jung Ho Jun Master Thesis) that we now have 
submitted to the NCI-60 cancer cell line screen and herein report the summarized results in order 
to discuss possible opportunities in an oncology study.  
 
4.2. Summary of the synthesis of cyclic sulfamide compounds 
Cyclic urea-based compounds have demonstrated antiviral activity and there are 
prominent examples of highly potent HIV protease inhibitors developed by pharmaceutical 
industry.14,15,16  Previous studies have elucidated the effect of substituents, absolute and relative 
stereochemistry, hydrophobicity etc., on the hydrogen bonding and catalytic aspartate 
interactions with enzyme, and thereby, overall inhibitor potency. 17   It is well known that 
modification with sulfamide functional group provides an attractive and versatile opportunity for 
the selective and potent modulation of protein function.18  These observations inspired us to 
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explore the potential of cyclic sulfamide analogs of ureas, for anti-cancer activity.  Since it is 
already published in my Master thesis and paper,19 the methodologies in synthesizing cyclic 
sulfamide compounds utilizing ring-closing metathesis (RCM) are only summarized in this 
section.  Synthesis of cyclic sulfamide 4.15, which has alkyl substituents at the P1/P1' positions, 
was accomplished from 4.13 (Scheme 4.1).  Alkylation of C2-cymmetric sulfamide 4.13, 
followed by the conversion of the ester groups to terminal olefins, RCM, and subsequent 
dihydroxylation generated cyclic sulfamide 4.15.  
 
 Scheme 4.1. Symmetric Sulfamides from SO2Cl2: Ester as Latent Olefin. 
 
The initial synthesis of amino ester derived C2-symmetric sulfamides 4.22 and further 
synthesis is described in Scheme 4.2.  Condensation of a slight excess of phenylalanine•HCl with 
SO2Cl2 in CH2Cl2 at 0 ºC furnished sulfamides 4.17 in 93% yield.  Benzylation using benzyl 
bromide and reduction by the addition of LiAlH4 cautiously into a reaction mixture in THF at 
low temperature (0 ºC) allowed primary alcohol 4.18 in 91%.  Swern oxidation and following 
Wittig reaction20 using n-butyl lithium provided terminal olefin 4.20 in moderate yield.  Addition 
of the G-II catalyst in 3–6 mol% in refluxing benzene was found to be highly efficient for the 
metathesis of these substrates to provide cyclic C2-symmetric sulfamides 4.21 in quantitative 
yield.  This pathway represents the first important example of a C2-symmetric sulfamide that has 
functionality occupying the P1/P1’ and P2/P2’ positions.  Each reaction of dihydroxylation and 
epoxidation from 4.21 yielded diol 4.22 and the 7-membered epoxy sulfamide 4.23. 
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Scheme 4.2 
 
With the desire for a more effective route to C2-symmetric sulfamides with bulky 
endocyclic substituents occupying the P1/P1' positions, an improved synthetic pathway was 
explored.  This route employed a two-directional chain synthesis21 on the leucine-derived, C2-
symmetric sulfamide 4.24 (Scheme 4.3).  Dialkylation of 4.24 with benzyl bromide under 
standard conditions (K2CO3, CH3CN, 70 ºC) and LiAlH4 reduction gave the corresponding bis-
benzylated sulfamide 4.25 in 99% yield.  Next, a two-step protocol was used to convert the diol 
moieties to sulfamide diene 4.26.  Swern oxidation in 99% followed by bis-Wittig olefination 
(PPh3CH2Br, n-BuLi, THF) yielded 4.26 in 89%.  With use of 5 mol% of the G-II catalyst, C2-
symmetric sulfamide 4.27 was furnished in moderate yield.  Dihydroxylation proceeded 
smoothly to produce sulfamide diol 4.28 in 99% yield.  Alternatively, treatment with m-CPBA 
yielded epoxy sulfamide 4.29 in an un-optimized yield of 52%. 
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Scheme 4.3 
 
 
Attempt at the installation of an α-hydroxyl amine at the P2/P2’ positions is shown in 
Scheme 4.4.  Several efforts were studied to open the epoxide ring using sodium azide with 
various conditions (Table 4.2).22  The first reaction condition using sodium azide and epoxide 
4.29 in DMF and H2O (7:1) did not afford the ring-opened product.  The second reaction 
condition utilized cerium chloride and NaN3 in CH3CN and H2O (9:1), yet also failed to yield the 
desired products.  Finally, the reaction condition using NH4Cl with NaN3 in DMF and H2O (7:1) 
furnished desired product 4.30 and 4.31 in less than 30% yield (ratio 1.3:1) 23.  These two α-
hydroxyl azides, 4.30 and 4.31, could be distinguished by NOE analysis (Figure 4.2).  The 
relationship between H1 and H3 of 4.30 is cis, since no NOE was seen between H2 and either H1 
or H3. 
Investigations using the Staudinger reaction will be explored in the future.  Under the 
simple reaction condition (PPh3 and H2O), sulfamides 4.30 and 4.31 should be able to be 
converted to α-hydroxyl amines 4.32 and 4.33.  Since the α-hydroxyl amines have a higher 
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probability to engage in hydrogen bonds, the degree of coordination between these α-hydroxyl 
amines and aspartate residues present in the active site of HIV-PR could potentially be enhanced 
in comparison with the corresponding diol compound.  These efforts will be reported in due 
course. 
 
Scheme 4.4. Ring opening reaction using NaN3. 
 
 
Table 4.2. Result of ring opening reaction using various conditions. 
 
Figure 4.2 
 
An attractive route to diol 4.37 is outlined in Scheme 4.5 and utilizes the pinacol coupling 
reaction that converts internal or external aldehydes to cis or trans diols using various catalysts.  
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The first trial to generate a trans-diol using titanium cyclopentadiene catalyst was performed.24  
The reaction of aldehyde 4.19b, titanium catalyst 4.34, and TMSCl in the presence of catalytic 
amount of Zn powder in THF did not furnish the desired trans-diol, 4.35.  Secondly, a widely 
known method to furnish cis-diol using SmI2 was applied to the pinacol coupling reaction, but 
the desired product cis-diol 4.38 was not generated.25  Fortunately, by using a protocol reported 
by Pederson and coworkers,26 pinacol coupling reaction of the aldehyde 4.19b with a vanadium 
(lI) reagent, [V2Cl3(THF)6]2[Zn2Cl6] generated diol 4.37 as a single diastereomer in 56% yield.  
We next embarked upon studies to elucidate the stereochemistry of diol 4.37.   
Scheme 4.5 
 
 There are three possible stereochemical outcomes of the pinacol coupling, namely two 
trans-diastereomers 4.37a, 4.37b, and the cis-diol 4.37c (Figure 4.3).  1H NMR NOE studies 
allowed us to assign the product as the cis-diol 4.37c.   
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Figure 4.3 
 
An approach to synthesize meso compound 4.44 utilizing CSI and chiral amino acid was 
developed (Scheme 4.6).  Mitsunobu reaction of α-hydroxy ester 4.39, which was generated by 
the reaction of α-hydroxy amino acid and amberlyst-15 ion exchange resin in MeOH, and the 
unsymmetric sulfamide 4.38, 27  provided the N-Boc protected sulfamide 4.40 in 72% yield.  
Benzylation and deprotection of Boc group furnished 4.41, and further benzylation and LiAlH4 
reduction produced meso sulfamide 4.42.  Swern oxidation followed by Wittig reaction 
generated terminal olefin 4.43, and RCM using the G-II catalyst (5 mol%) furnished cyclized 
meso sulfamide 4.44 in good yields. 
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Scheme 4.6 
 
 
The newest route to unsymmetric sulfamides is represented in Scheme 4.6.  This 
approach involves the use of the Mitsunobu reaction of sulfamoyl carbamates to apply a 
stereogenic center occupying the P1 position in a tri-differentiated sulfamide.19  Mitsunobu 
reaction of sulfamide 4.45 with readily prepared chiral nonracemic secondary allylic alcohol 4.46 
provided sulfamide 4.47 in 67% yield.  Allylation afforded sulfamide diene 4.48 in 92%.  RCM 
(96%), Boc-deprotection (96%) and benzylation (89%) gave the desired cyclic sulfamide 4.50 in 
excellent yield.  Finally, dihydroxylation gave sulfamide diol 4.51 in good yield (70%) and with 
high diastereoselectivity (dr=16:1). 
Scheme 4.7 
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Another new approach to unsymmetric sulfamides is represented in Scheme 4.8.19  This 
strategy involves mono benzylation followed by p-methoxy benzylation on the nitrogen to 
generate diverse substituents occupying the P2 and P2’ positions in a tri-differentiated sulfamide.  
Mono benzylation of sulfamide 4.24 with benzyl bromide allowed sulfamide 4.52 in 53% yield 
with dibenzylated sulfamide as a byproduct. p-Methoxy benzylation of 4.52 on the rest of 
nitrogen and reduction of ester gave diol 4.53.  Dess-Martin oxidation of 4.53 in wet CH2Cl2 
organic solvent generated unstable dialdehyde 4.54.28  Wittig reaction using KHMDS to produce 
terminal olefin 4.55, and RCM in refluxing benzene generated desired cyclic sulfamide 4.56. 
 
Scheme 4.8 
 
 
The methods outlined below were exploited further in the synthesis of an unsymmetric 
sulfamide bearing tetra-differentiated P1/P1'/P2/P2' regions (Scheme 4.9).19  Mitsunobu reaction 
of sulfamide 4.57 29  and L-ethyl lactate, and benzylation of sulfamoyl carbamate furnished 
unsymmetric sulfamide 4.58 in 94% yield.  Boc-deprotection and protection of the remaining 
sulfamide nitrogen with p-methoxybenzyl chloride gave 77% of sulfamide 4.59.  LiAlH4 
reduction (38%), Swern oxidation (99%), and Wittig olefination (69%) gave the metathesis 
precursor 4.60.  Ring-closing metathesis with 5 mol % of the G-II catalyst afforded 69% of 
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unsymmetric sulfamide 4.61.  Conversion of the cyclic internal olefin to the corresponding diol 
via cis-dihydroxylation was the final step toward analogues of DMP 323.  Dihydroxylation 
furnished the sulfamide diol 4.62 in 91% yield, albeit with modest diastereoselectivity (dr=3.9:1).   
 
Scheme 4.9  
 
 
4.3. Anticancer drug discovery NCI-60 cell line screening at National Cancer Institute 
(NCI) 
4.3.1. One-dose assay 
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given a unique NSC (National Service Center) number.  The compounds 4.21–4.78 in Table 4.3 
were submitted to NCI-60 cell line screening.  Compounds 4.63–4.78 were prepared by our 
group members and synthetic methods and supplemental data can be found in cited 
references.30,19b  Cyclic sulfamide, urea, and phosphorus containing compounds 4.63–4.78 were 
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screened to obtain structure activity relationships (SAR).  Details of the methodologies for NCI-
60 cell line screening are described at http://dtp.nci.nih.gov/branches/btb/ivclsp.html.31  Briefly, 
the panel is organized into nine subpanels representing diverse histologies: leukemia, melanoma, 
and cancers of lung, colon, kidney, ovary, breast, prostate, and central nervous system.  The 
human tumor cells are grown in supplemented RPMI 1640 medium containing 5% fetal bovine 
serum and 2 mL glutamine for 24 h.  The cells are inoculated into 96-well microtiter plates in 
100 μL at plating densities ranging from 5,000 to 40,000 cells/well depending on the doubling 
time of individual cell lines.  After cell inoculation, the micro-titer plates are incubated at 37° C, 
5 % CO2, 95 % air and 100 % relative humidity for 24 h prior to addition of experimental drugs.  
The selected compounds 4.21–4.78 were dissolved in DMSO and incubated with cells at five 
concentrations with 10-fold dilutions, the highest being 10-4 M and the others being 10-5, 10–6, 
10-7, and 10-8 M.  The assay is terminated by addition of cold trichloroacetic acid, and the cells 
are fixed and stained with sulforhodamine B.  Bound stain was solubilized, and the absorbance 
read on an automated plate reader.  The cytostatic parameter that is 50% growth inhibition (GI50, 
concentrations required to inhibit growth by 50%) was calculated from time zero, control growth, 
and the five concentration level absorbance.  The cytotoxic parameter that is, inhibitory 
concentrations (LC50, lethal concentration, standard measure of the toxicity of the medium that 
kills half of the sample population in a specified period, lower number means more toxic) 
represent the average of two independent experiments.  The in vitro screening is a two-stage 
process started with the evaluation of all the compounds against the NCI-60 human tumor cell 
lines with a single dose of 10.0 μM, which is done by following same protocol as for five-dose 
screening.  The output from the single dose screen was reported as a mean graph (given in the 
Supplementary data with general interpretation).  Only the compounds, which showed more than 
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60% of growth inhibition in at least 8 tumor cell lines, were selected for further testing and the 
others were assumed as inactive.  
 
Table 4.3. List of compounds screened for NCI 60-cell lines. 
Compd No. 
NSC No. 
Structure Activity 
Compd  No. 
NSC No. 
Structure Activity 
4.21 
NSC 764190 
 
Active 
4.22 
NSC 751486 
 
Active 
4.23 
NSC 751478 
N
S
N
OO
BnBn
Ph Ph
O  
Active 
4.27 
NSC 751468 
 
 
 
4.28 
NSC 751469 
 
 
4.29 
NSC 751470 
 
 
 
4.37C 
NSC 764189 
 
Active 
4.44 
NSC 751477 
 
 
4.56 
NSC 751472 
 
 
4.61 
NSC 751473 
 
 
4.62a 
NSC 751479 
 
 
4.62b 
NSC 751483 
 
 
4.63 
NSC 751467 
 
 
 
4.64 
NSC 764191 
 
 125
4.65 
NSC 764192 
 
 
4.66 
NSC 764193 
 
4.67 
NSC 764194 
 
 
4.68 
NSC 764195 
 
 
4.69 
NSC 764196 
 
 
4.70 
NSC 764197 
 
 
4.71 
NSC 767525 
 
 
4.72 
NSC 767526 
 
 
4.73 
NSC 767527 
 
 
4.74 
NSC 767528 
 
 
4.75 
NSC 767529 
 
4.76 
NSC 767530 
 
4.77 
NSC 767531 
 
 
4.78 
NSC 767532 
 
 
 
The one-dose data is reported as a mean graph of the percent growth of treated cells and 
is similar in appearance to mean graphs from the 5-dose assay.  The number reported for the one-
dose assay is growth relative to the no-drug control, and relative to the time zero number of cells. 
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This allows detection of both growth inhibition (values between 0 and 100) and lethality (values 
less than 0).  This is the same as for the 5-dose assay, described on 
http://dtp.nci.nih.gov/branches/btb/ivclsp.html.  For example, a value of 100 means no growth 
inhibition.  A value of 40 would mean 60% growth inhibition.  A value of 0 means no net growth 
over the course of the experiment.  A value of -40 would mean 40% lethality.  A value of -100 
means all cells are dead.  Information from the One-dose mean graph is available for COMPARE 
analysis (http://dtp.nci.nih.gov/docs/compare/compare.html).  This primary one-dose screening 
showed that compounds (4.21, 4.22, 4.23, and 4.37c) were active, while other compounds are 
determined as inactive.  Table 4.4 is the summary of one-dose experiment for each compound. 
Even if it was not selectively considered 60% of growth inhibition as criterion, many compounds 
are moderately sensitive on the breast cancer (MDA-MB-468), renal cancer (UO-31 and CAKI-1) 
and leukemia (MOLT-4 and SR). 
Compound 4.21 (NSC 764190) showed 11.87% growth inhibition against the SR cell line 
(Leukemia), compound 4.22 (NSC 751486), 0% against the UO-31 cell line (Renal cancer), 
compound 4.23 (NSC 751478), 6.52% against MDA-MB-468 the cell line (Breast cancer), 
compound 4.27 (NSC 751468), 39.65% against MDA-MB-468 the cell line (Breast cancer), 
compound 4.28 (NSC 751469), 46.61% against HCT-116 the cell line (Colon cancer), compound 
4.29 (NSC 751470), 35.50% against MDA-MB-468 the cell line (Breast cancer), 4.37c (NSC 
751489), 18.03% against MDA-MB-468 the cell line (Breast cancer), compound 4.44 (NSC 
751477), 41.68% against the MDA-MB-468 cell line (Breast cancer), compound 4.56 (NSC 
751472), 44.15% against the MDA-MB-468 cell line (Breast cancer), compound 4.61 (NSC 
751473), 81.62% against the HT29 cell line (Colon cancer), compound 4.62a (NSC 751479), 
67.93% against the SNB-75 cell line (CNS cancer), compound 4.62b (NSC 751483), 75.56% 
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against the UO-31 cell line (Renal cancer), Compound 4.63 (NSC 751467), 69.49% against the 
SNB-19 cell line (CNS cancer), compound 4.64 (NSC 751491), 71.87% against the Leukemia 
MOLT-4 cell line (Leukemia), compound 4.65 (NSC 764192), 78.05% against the SNB-75 cell 
line (CNS cancer), compound 4.66 (NSC 764193), 87.73% against the UO-31 cell line (Renal 
cancer), compound 4.67 (NSC 764194), 43.31% against the CAKI-1 cell line (Renal cancer), 
compound 4.68 (NSC 764195), 57.52% against the HCT-116 cell line (Colon cancer), compound 
4.69 (NSC 764196), 73.57% against the CAKI-1 cell line (Renal cancer), compound 4.70 (NSC 
764197), 82.35% against the UO-31 cell line (Renal cancer), compound 4.71 (NSC 767525), 
79.70% against the NCI-H522 cell line (Non-small cell lung cancer), compound 4.72 (NSC 
767526), 34.17% against the MOLT-4 cell line (Leukemia), compound 4.73 (NSC 767527), 
39.80% against the MOLT-4 cell line (Leukemia), compound 4.74 (NSC 767528), 82.41% 
against the SR cell line (Leukemia), compound 4.75 (NSC 767529), 76.18% against the SNB-75 
cell line (CNS cancer), compound 4.76 (NSC 767530), 80.47% against the SR cell line 
(Leukemia), compound 4.77 (NSC 767531), 64.25% against the UO-31 cell line (Renal cancer), 
and compound 4.78 (NSC 767532), 64.80% against the UO-31 cell line (Renal cancer) (Table 
4.4).  The compounds which reduced the growth of the cell lines to 32% or less (negative 
number indicate kills) are considered in vitro active.32,33  The output from the NCI-60 cell lines 
single dose screen of NSC 764190 was reported as a mean graph (Figure 4.4). 
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Table 4.4. Anti-cancer screening data of compounds. 
NSC No. 
60-cell line assay in one-dose at 10‒5 concentration 
Range of growth 
percentage 
Most sensitive  
cell line 
Growth % of  
most sensitive 
cell line  
Mean  Delta range 
751467 69.49 to 127.06 CNS cancer (SNB-19) 69.49 100.68 31.19 57.57 
751468 39.65 to 140.80 Breast cancer (MDA-MB-468) 39.65 85.77 46.12 101.15 
751469 46.61 to 113.74 Colon cancer (HCT-116) 46.61 81.18 34.57 67.13 
751470 35.50 to 123.55 Breast cancer (MDA-MB-468) 35.50 79.44 43.94 88.05 
751472 44.15 to 132.68 Breast cancer (MDA-MB-468) 44.15 81.64 37.49 88.53 
751473 81.62 to 126.01 Colon cancer (HT29) 81.62 102.22 20.60 44.39 
751477 41.68 to 110.24 Breast cancer (MDA-MB-468) 41.68 76.40 35.15 68.99 
751478 6.52 to 114.43 Breast cancer (MDA-MB-468) 6.52 46.84 40.32 107.91 
751479 67.93 to 150.32 CNS cancer (SNB-75) 67.93 100.64 32.71 82.39 
751483 75.56 to 125.47 Renal cancer (UO-31) 75.56 99.69 24.13 49.91 
751486 -45.75 to 60.35 Renal cancer (UO-31) 0 -0.81a 44.94 106.10 
751489 18.03 to 102.81 Breast cancer (MDA-MB-468) 18.03 65.12 47.09 91.32 
764190 11.87 to 99.65 Leukemia (SR) 11.87 55.00 43.13 87.78 
764191 71.87 to 116.41 Leukemia (MOLT-4) 71.87 96.44 24.57 44.54 
764192 78.05 to 120.37 CNS cancer (SNB-75) 78.05 103.32 25.27 42.32 
764193 87.73 to 125.96 Renal cancer (UO-31) 87.73 104.45 16.72 38.23 
764194 43.31 to 107.76 Renal cancer (CAKI-1) 43.31 82.97 39.66 64.45 
764195 57.52 to 122.20 Colon cancer (HCT-116) 57.52 85.01 38.72 75.91 
764196 73.57 to 127.74 Renal cancer (CAKI-1) 73.57 101.26 27.69 54.17 
764197 82.35 to 129.96 Renal cancer (UO-31) 82.35 99.55 17.20 47.61 
767525 79.70 to 119.76 
Non-small cell lung cancer (NCI-
H522) 
79.70 101.95 22.25 40.06 
767526 34.17 to 115.22 Leukemia (MOLT-4) 34.17 80.46 46.29 81.05 
767527 39.80 to 110.48 Leukemia (MOLT-4) 39.80 85.89 46.09 70.68 
767528 82.41 to 119.28 Leukemia (SR) 82.41 102.75 20.34 36.87 
767529 76.18 to 122.73 CNS cancer (SNB-75) 76.18 101.04 30.17 51.86 
767530 80.47 to 187.29 Leukemia (SR) 80.47 104.72 24.25 106.82 
767531 64.25 to 119.03 Renal cancer (UO-31) 64.25 100.51 36.26 55.75 
767532 64.80 to 119.30 Renal cancer (UO-31) 64.80 99.27 34.47 54.50 
a Negative indicates the cell kill 
 
 
Figure 4.4. Selected NCI60-cell lines screen
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ing data for one-dose study of 4.21 (NSC 764190). 
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Table 4.5 represents the growth percent inhibition (100 - growth percent) of compounds 
that inhibited more than 50% of growth inhibition for one-dose studies from the NCI60-cell lines 
screen.  Generally, compounds were selectively sensitive on the leukemia, colon cancer, prostate 
cancer and breast cancer cell.  Especially, almost every compound in Table 4.5 showed strong 
inhibition of the breast cancer cell line (MDA-MB-468). 
 
Table 4.5. Growth percent inhibition of compounds inhibited more than 50% for one-dose 
studies for the NCI 60-cell lines screen. 
Panel/cell 
line 
NSC 
751468 
NSC 
751470 
NSC 
751472 
NSC 
751477 
NSC 
751478 
NSC 
751486 
NSC 
764189 
NSC 
764190 
NSC 
767527 
          
Leukemia  
CCRF-CEM     70.51 92.67  51.40  
HL-60(TB)     54.91   64.27  
K-562     76.65 96.88 58.11 77.03  
MOLT-4     64.56 94.35 73.65 76.28 61.20 
RPMI-8226     72.12  62.31 62.52  
SR     70.44 95.55 58.23 88.13  
          
Colon cancer  
HCT-116  51.37 50.59  82.98  68.99 73.22  
HCT-15     73.92 96.84  74.64  
HT29 55.97    53.32 93.05    
KM12     59.78   50.04  
SW-620      90.78    
          
Prostate cancer  
PC-3    52.03 57.96 95.11 60.25 59.13  
 V66666DU-
145 
    65.74    
 
          
Breast cancer  
MCF7       66.13 52.57  
MDA-MB-
231/ATCC 
    75.79  58.41  
 
HS 578T      80.33    
BT-549      84.33    
T-47D     67.51 92.13  50.55  
MDA-MB-
468 
60.35 64.5 55.85 58.32 93.48  81.97 82.62 
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4.3.2. Five-dose assay 
The log mean values for GI50 and LC50 in NCI-60 cell lines for compounds 4.21, 4.22, 
4.23, and 4.37c are provided in Table 4.6 along with the log delta value (the maximum 
sensitivity in excess of the mean) and the log range (the maximum difference between the least 
sensitive and the most sensitive cell lines).  These parameters provided insights into selectivity 
and potency of anti-tumor agents.  Large values of the delta and range indicate high selectivity 
for some histological cancers over others.  The lower median log GI50 values of compounds 4.22, 
4.23 and 4.37c show that these three compounds are active, followed by 4.21.  The high median 
log LC50 value of 4.21, along with the low delta and range value, indicates the complete absence 
of cytotoxicity against all cell lines. 
 
Table 4.6. Cytostatic (GI50) and cytotoxic (LC50) parameters for 4.21 (NSC 764190), 4.22 (NSC 
751486),4.23 (NSC 751478), and 4.37c (NSC 764189). 
Compound 
GI50  LC50 
Median Delta Range  Median Delta Range 
4.21  (NSC 764190) -4.94 1.63 2.57  -4.0 0 0.0 
4.22  (NSC 751486) -5.49 0.58 0.85  -4.8 0.18 0.28 
4.23  (NSC 751478) -5.31 1.25 1.44  -5.12 0 0.0 
4.37c  (NSC 764189) -5.30 0 0.0  -5.3 0 0.0 
 
The complete in-vitro anti-cancer data collected on NCI-60 subpanel cell lines for the 
four most active compounds informed are shown in Table 4.7.  Secondary screening was carried 
out on these active compounds (4.21, 4.22, 4.23, and 4.37c) in order to determine their cytostatic 
and cytotoxic activities.  Generally, cyclic sulfamides possessing benzyl group substituted at the  
3- and 6-positions have antitumor activities in several cancer cells.  Cyclic sulfamides 4.27, 4.28, 
4.29, 4.44, 4.56, 4.61, 4.62a and 4.62b which have alkyl substituents at the 3- and 6-positions do 
not have noticeable sensitivities toward the 60 tumor cell screening line.  To compare as in vitro 
SAR data, unsymmetric phosphorus-containing analogues of DMD 232 4.64–4.66, 4.69, cyclic 
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ureas 4.67, 4.68, 4.70, and di- or tri-substituted unsymmetric cyclic sulfamides 4.71–4.78 were 
submitted to 60-cell lines additionally.  One-dose experimental results show that these 
compounds did not possess enough biological availability to warrant additional five-dose 
screening.  The result of compound 4.21 for five-dose screening is given by three response 
parameters (GI50, TGI and LC50) for each cell line from log10 of sample concentration (molar) vs 
percentage growth inhibition curves in nine cancer diseases (Figure 4.5). 
 
Table 4.7. Anti-tumor activity (GI50/μM)
a, TGIb and toxicity (LC50/μM)
c data of compounds 
selected for 5 dose studies for the NCI60-cell lines screen. 
Panel/cell line 
4.21 (NSC 764190) 4.22 (NSC 751486) 4.23 (NSC 751478) 4.37c (NSC 764189) 
GI50 TGI LC50 GI50 TGI LC50 GI50 TGI LC50 GI50 TGI LC50 
             
Leukemia 
CCRF-CEM 3.85 >100 >100 5.96 >20 >20 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
HL-60(TB) 3.43 >100 >100 2.97 8.72 >20 4.75 >7.5 >7.5 >5.0 >5.0 >5.0 
K-562 2.00 >100 >100 3.05 9.38 >20 3.34 >7.5 >7.5 >5.0 >5.0 >5.0 
MOLT-4 2.15 >100 >100 2.86 1.02 >20 4.12 >7.5 >7.5 >5.0 >5.0 >5.0 
RPMI-8226 0.859 >100 >100 4.49 >20 >20 4.92 >7.5 >7.5 >5.0 >5.0 >5.0 
SR 1.66 >100 >100 nd nd nd nd nd nd nd nd nd 
             
Non-small cell lung cancer 
A549/ATCC 7.67 >100 >100 2.99 7.62 19.4 3.78 >7.5 >7.5 >5.0 >5.0 >5.0 
EKVX nd >100 >100 3.43 9.86 >20 6.55 >7.5 >7.5 >5.0 >5.0 >5.0 
HOP-62 >100 >100 >100 3.71 7.34 14.5 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
HOP-92 4.40 >100 >100 3.15 6.68 14.1 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
NCI-H226 4.35 >100 >100 3.04 6.17 12.5 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
NCI-H23 1.66 >100 >100 3.11 6.71 14.5 3.47 >7.5 >7.5 >5.0 >5.0 >5.0 
NCI-H322M >100 >100 >100 4.48 11.8 >20 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
NCI-H460 2.75 >100 >100 3.41 7.91 18.3 2.53 >7.5 >7.5 >5.0 >5.0 >5.0 
NCI-H522 5.46 >100 >100 0.847 4.79 14.5 1.83 >7.5 >7.5 >5.0 >5.0 >5.0 
             
Colon cancer 
COLO 205  >100 >100 >100 4.26 10.5 >20 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
HCC-2998  >100 >100 >100 3.41 6.20 11.3 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
HCT-116  0.535 >100 >100 2.43 5.05 10.5 0.844 >7.5 >7.5 >5.0 >5.0 >5.0 
HCT-15  3.51 >100 >100 4.37 1.82 >20 3.92 >7.5 >7.5 >5.0 >5.0 >5.0 
HT29  42.6 >100 >100 2.63 5.64 12.1 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
KM12  9.92 >100 >100 2.94 5.84 11.6 7.19 >7.5 >7.5 >5.0 >5.0 >5.0 
SW-620  nd >100 >100 3.18 7.12 15.9 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
             
CNS cancer 
SF-268  7.85 >100 >100 3.44 8.03 18.8 6.08 >7.5 >7.5 >5.0 >5.0 >5.0 
SF-295  0.667 >100 >100 2.62 5.68 12.3 1.80 >7.5 >7.5 >5.0 >5.0 >5.0 
SF-539  >100 >100 >100 3.37 6.76 13.6 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
SNB-19  >100 >100 >100 4.69 >20 >20 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
SNB-75  >100 >100 >100 2.31 7.28 >20 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
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nd: not determined. 
a GI50: 50% growth inhibition, concentration of drug resulting in a 50% reduction in net protein 
increase compared with control cells. 
b TGI: total cell growth inhibition 
c LC50: lethal concentration, concentration of drug lethal to 50% of cells. 
U251  1.11 >100 >100 3.07 6.47 13.6 1.84 >7.5 >7.5 >5.0 >5.0 >5.0 
             
Melanoma 
LOX IMVI  1.40 >100 >100 3.28 7.09 15.3 5.38 >7.5 >7.5 >5.0 >5.0 >5.0 
MALME-3M  >100 >100 >100 2.75 6.37 14.7 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
M14 nd >100 >100 3.04 6.07 12.1 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
MDA-MB-435  >100 >100 >100 3.33 7.10 15.1 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
SK-MEL-2  >100 >100 >100 2.80 5.76 11.8 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
SK-MEL-28  >100 >100 >100 3.35 6.90 14.2 1.79 >7.5 >7.5 >5.0 >5.0 >5.0 
SK-MEL-5 1.14 >100 >100 3.05 5.80 11.1 2.89 >7.5 >7.5 >5.0 >5.0 >5.0 
UACC-257  2.23 >100 >100 2.89 5.93 12.2 6.75 >7.5 >7.5 >5.0 >5.0 >5.0 
UACC-62 2.66 >100 >100 2.86 6.40 14.3 nd nd nd >5.0 >5.0 >5.0 
             
Ovarian cancer 
IGROV1 >100 >100 >100 3.57 7.24 14.7 5.06 >7.5 >7.5 >5.0 >5.0 >5.0 
OVCAR-3  2.34 >100 >100 2.90 6.07 12.7 4.03 >7.5 >7.5 >5.0 >5.0 >5.0 
OVCAR-4  0.483 >100 >100 2.72 7.26 19.4 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
OVCAR-5  >100 >100 >100 3.57 9.10 >20 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
OVCAR-8  >100 >100 >100 4.20 11.2 >20 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
NCI/ADR-RES 7.03 >100 >100 3.40 8.58 >20 5.23 >7.5 >7.5 >5.0 >5.0 >5.0 
SK-OV-3  >100 >100 >100 4.15 10.6 >20 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
             
Renal cancer 
786-0  >100 >100 >100 3.24 6.86 14.5 5.12 >7.5 >7.5 >5.0 >5.0 >5.0 
A498 1.77 >100 >100 2.45 5.18 10.9 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
ACHN  2.10 >100 >100 6.01 >20 >20 5.88 >7.5 >7.5 >5.0 >5.0 >5.0 
CAKI-1  2.83 >100 >100 3.65 7.33 14.7 0.949 >7.5 >7.5 >5.0 >5.0 >5.0 
RXF 393  28.0 >100 >100 2.60 5.24 10.5 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
SN12C  9.42 >100 >100 3.26 7.68 18.1 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
TK-10  8.26 >100 >100 3.77 8.38 18.6 3.90 >7.5 >7.5 >5.0 >5.0 >5.0 
UO-31  >100 >100 >100 2.73 5.96 13.1 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
             
Prostate cancer 
PC-3  0.580 >100 >100 3.48 10.4 >20 3.06 >7.5 >7.5 >5.0 >5.0 >5.0 
DU-145  >100 >100 >100 3.21 7.55 17.8 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
             
Breast cancer 
MCF7  >100 >100 >100 4.77 13.6 >20 4.27 >7.5 >7.5 >5.0 >5.0 >5.0 
MDA-MB-231/ATCC >100 >100 >100 2.82 6.39 14.5 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
HS 578T >100 >100 >100 3.27 8.38 >20 >7.5 >7.5 >7.5 >5.0 >5.0 >5.0 
BT-549 >100 >100 >100 2.65 5.53 11.6 4.09 >7.5 >7.5 >5.0 >5.0 >5.0 
T-47D >100 >100 >100 3.95 10.2 >20 6.81 >7.5 >7.5 >5.0 >5.0 >5.0 
MDA-MB-468 0.267 60.1 >100 2.98 7.17 17.3 0.274 >7.5 >7.5 >5.0 >5.0 >5.0 
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Figure 4.5. Dose response curves (% growth verses samples concentration at NCI fixed protocol, 
μM) obtained from the NCI in vitro disease-oriented human cancer cell line of compounds 4.21 
(NSC 764190) in nine cancer diseases. 
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Figure 4.5. Dose response curves (% growth verses samples concentration at NCI fixed protocol, 
μM) obtained from the NCI in vitro disease-oriented human cancer cell line of compounds 4.21 
(NSC 764190) in nine cancer diseases (continued). 
 
 
The criterion for selectivity of a compound depends on the ratio obtained by dividing the 
full panel MID (the average sensitivity of all cell lines towards the test agent) by their individual 
subpanel MID (the average sensitivity of all cell lines of a particular subpanel towards the test 
agent).  The ratios between 3 and 6 refer to moderate selectivity; ratios greater than 6 indicate 
high selectivity towards the corresponding cell line, while compounds not meeting either of there 
criteria are rated non-selective.34  Since it is difficult for the calculation of GI50 in cases which 
have values of >7.5 μM, they are excluded from the calculation.  Following this criterion, 
compound 4.23 (NSC 751478) was found to be mildly selective toward every cancer panel.  
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Table 4.8. Calculated value of GI50 of the cell lines: full cell line panel, MG-MID and 
selectivity ratio of compound 4.23 (NSC 751478).   
 
Panel Cell line GI50 (10
-6 M) 
Concentration 
per cell line 
Subpanel 
concentration 
Subpanel MID Selectivity ratio 
Leukemia CCRF-CEM >7.5 
17.13 4.282 0.922 
 HL-60(TB) 4.75 
 K-562 3.34 
 MOLT-4 4.12 
 RPMI-8226 4.92 
 SR nd 
Non-small cell  A549/ATCC 3.78 
18.16 3.632 1.088 
lung cancer EKVX 6.55 
 HOP-62 >7.5 
 HOP-92 >7.5 
 NCI-H226 >7.5 
 NCI-H23 3.47 
 NCI-H322M >7.5 
 NCI-H460 2.53 
 NCI-H522 1.83 
Colon cancer COLO 205  >7.5 
11.954 3.984 0.991 
 HCC-2998  >7.5 
 HCT-116  0.844 
 HCT-15  3.92 
 HT29  >7.5 
 KM12  7.19 
 SW-620  >7.5 
CNS cancer SF-268  6.08 
9.72 3.24 1.219 
 SF-295  1.80 
 SF-539  >7.5 
 SNB-19  >7.5 
 SNB-75  >7.5 
 U251  1.84 
Melanoma LOX IMVI  5.38 
16.81 4.203 0.940 
 MALME-3M  >7.5 
 M14 >7.5 
 MDA-MB-435  >7.5 
 SK-MEL-2  >7.5 
 SK-MEL-28  1.79 
 SK-MEL-5 2.89 
 UACC-257  6.75 
 UACC-62 nd 
Ovarian cancer IGROV1 5.06 
14.32 4.773 0.828 
 OVCAR-3  4.03 
 OVCAR-4  >7.5 
 OVCAR-5  >7.5 
 OVCAR-8  >7.5 
 NCI/ADR-RES 5.23 
 SK-OV-3  >7.5 
Renal cancer 786-0  5.12 
15.849 3.962 0.997 
 A498 >7.5 
 ACHN  5.88 
 CAKI-1  0.949 
 RXF 393  >7.5 
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 SN12C  >7.5 
 TK-10  3.90 
 UO-31  >7.5 
Prostate cancer PC-3  3.06 
3.06 3.06 1.291 
 DU-145  >7.5 
Breast cancer MCF7  4.27 
15.444 3.861 1.023 
 MDA-MB-
231/ATCC 
>7.5 
 HS 578T >7.5 
 BT-549 4.09 
 T-47D 6.81 
 MDA-MB-468 0.274 
nd: not determined 
 
 
Based on the discussion on the criterion of selectivity, compound 4.22 (NSC 751486) 
was found to be mild selective in the colon cancer panel.  It was also found to be mildly selective 
in every cancer panel.  
 
Table 4.9. Calculated value of GI50 of the cell lines: full cell line panel, MG-MID and 
selectivity ratio of compound 4.22 (NSC 751486).   
 
Panel Cell line GI50 (10
-6 M) 
Concentration 
per cell line 
Subpanel 
concentration 
Subpanel MID Selectivity ratio 
Leukemia CCRF-CEM 5.96 
19.33 3.866 0.863 
 HL-60(TB) 2.97 
 K-562 3.05 
 MOLT-4 2.86 
 RPMI-8226 4.49 
 SR nd 
Non-small cell  A549/ATCC 2.99 
28.167 3.130 1.066 
lung cancer EKVX 3.43 
 HOP-62 3.71 
 HOP-92 3.15 
 NCI-H226 3.04 
 NCI-H23 3.11 
 NCI-H322M 4.48 
 NCI-H460 3.41 
 NCI-H522 0.847 
Colon cancer COLO 205  4.26 
23.22 3.317 1.006 
 HCC-2998  3.41 
 HCT-116  2.43 
 HCT-15  4.37 
 HT29  2.63 
 KM12  2.94 
 SW-620  3.18 
CNS cancer SF-268  3.44 
19.50 3.25 1.027 
 SF-295  2.62 
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 SF-539  3.37 
 SNB-19  4.69 
 SNB-75  2.31 
 U251  3.07 
Melanoma LOX IMVI  3.28 
27.35 3.039 1.098 
 MALME-3M  2.75 
 M14 3.04 
 MDA-MB-435  3.33 
 SK-MEL-2  2.80 
 SK-MEL-28  3.35 
 SK-MEL-5 3.05 
 UACC-257  2.89 
 UACC-62 2.86 
Ovarian cancer IGROV1 3.57 
24.51 3.501 0.953 
 OVCAR-3  2.90 
 OVCAR-4  2.72 
 OVCAR-5  3.57 
 OVCAR-8  4.20 
 NCI/ADR-RES 3.40 
 SK-OV-3  4.15 
Renal cancer 786-0  3.24 
27.71 3.464 0.964 
 A498 2.45 
 ACHN  6.01 
 CAKI-1  3.65 
 RXF 393  2.60 
 SN12C  3.26 
 TK-10  3.77 
 UO-31  2.73 
Prostate cancer PC-3  3.48 
6.69 3.345 0.998 
 DU-145  3.21 
Breast cancer MCF7  4.77 
20.44 3.407 0.980 
 MDA-MB-
231/ATCC 
2.82 
 HS 578T 3.27 
 BT-549 2.65 
 T-47D 3.95 
 MDA-MB-468 2.98 
nd: not determined 
 
The next table, Table 4.10, contains the calculated values of the selectivity ratio of 
compound 4.21 (NSC 764190).  Cases with values over 100 of the GI50 value were excluded 
from the calculation.  Following the selectivity criterion, compound 4.21 (NSC 764190) was 
found to be mildly selective toward the leukemia (selectivity ratio = 2.238) and melanoma 
(selectivity ratio = 2.801) cancer panels.  Even though it was chosen in only one cell line from 
each of the prostate cancer and breast cancer panels for the calculation of the selectivity ratio, 
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compound 4.21  (NSC 764190) was indicated to be highly selective toward these two cancer 
panels.  
 
 
Table 4.10. Calculated value of GI50 of the cell lines: full cell line panel, MG-MID and 
selectivity ratio of the compound 4.21 (NSC 764190).   
 
Panel Cell line GI50 (10
-6 M) 
Concentration 
per cell line 
Subpanel 
concentration 
Subpanel MID Selectivity ratio 
Leukemia CCRF-CEM 3.85 
13.949 2.325 2.238 
 HL-60(TB) 3.43 
 K-562 2.00 
 MOLT-4 2.15 
 RPMI-8226 0.859 
 SR 1.66 
Non-small cell  A549/ATCC 7.67 
26.29 4.382 1.188 
lung cancer EKVX nd 
 HOP-62 >100 
 HOP-92 4.40 
 NCI-H226 4.35 
 NCI-H23 1.66 
 NCI-H322M >100 
 NCI-H460 2.75 
 NCI-H522 5.46 
Colon cancer COLO 205  >100 
56.565 14.141 0.368 
 HCC-2998  >100 
 HCT-116  0.535 
 HCT-15  3.51 
 HT29  42.6 
 KM12  9.92 
 SW-620  nd 
CNS cancer SF-268  7.85 
9.627 3.209 1.622 
 SF-295  0.667 
 SF-539  >100 
 SNB-19  >100 
 SNB-75  >100 
 U251  1.11 
Melanoma LOX IMVI  1.40 
7.43 1.858 2.801 
 MALME-3M  >100 
 M14 nd 
 MDA-MB-435  >100 
 SK-MEL-2  >100 
 SK-MEL-28  >100 
 SK-MEL-5 1.14 
 UACC-257  2.23 
 UACC-62 2.66 
Ovarian cancer IGROV1 >100 
9.853 3.284 1.585 
 OVCAR-3  2.34 
 OVCAR-4  0.483 
 OVCAR-5  >100 
 OVCAR-8  >100 
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 NCI/ADR-RES 7.03 
 SK-OV-3  >100 
Renal cancer 786-0  >100 
52.38 8.73 0.596 
 A498 1.77 
 ACHN  2.10 
 CAKI-1  2.83 
 RXF 393  28.0 
 SN12C  9.42 
 TK-10  8.26 
 UO-31  >100 
Prostate cancer PC-3  0.580 
0.58 0.58 8.972 
 DU-145  >100 
Breast cancer MCF7  >100 
0.267 0.267 19.491 
 MDA-MB-
231/ATCC 
>100 
 HS 578T >100 
 BT-549 >100 
 T-47D >100 
 MDA-MB-468 0.267 
nd: not determined 
 
The log molar concentration of the resulted screening of compound 4.23 (NSC 751478) 
shown for each of the parameters; for log GI50 ranged from -6.56 to -5.12, for log TGI ranged  
-5.12 only, for log LC50 ranged -5.12 only (Table 4.11).  A mean graph midpoint (MG-MID) 
calculated for each of the parameters; log GI50 (-5.31), log TGI (-5.12), and log LC50 (-5.12). 
 
Table 4.11. Values of the log molar concentration of response parameter (log10GI50, log10TGI 
and log10LC50) of the 4.23 (NSC 751478).  
Cancer disease Used cell lines log10GI50 log10TGI log10LC50 
Leukemia CCRF-CEM > -5.12 > -5.12 > -5.12 
 HL-60(TB) -5.32 > -5.12 > -5.12 
 K-562 -5.48 > -5.12 > -5.12 
 MOLT-4 -5.38 > -5.12 > -5.12 
 RPMI-8226 -5.31 > -5.12 > -5.12 
Non-small cell lung cancer A549/ATCC -5.42 > -5.12 > -5.12 
 EKVX -5.18 > -5.12 > -5.12 
 HOP-62 > -5.12 > -5.12 > -5.12 
 HOP-92 > -5.12 > -5.12 > -5.12 
 NCI-H226 > -5.12 > -5.12 > -5.12 
 NCI-H23 -5.46 > -5.12 > -5.12 
 NCI-H322M > -5.12 > -5.12 > -5.12 
 NCI-H460 -5.60 > -5.12 > -5.12 
 NCI-H522 -5.74 > -5.12 > -5.12 
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Colon cancer COLO 205 > -5.12 > -5.12 > -5.12 
 HCC-2998 > -5.12 > -5.12 > -5.12 
 HCT-116 -6.07 > -5.12 > -5.12 
 HCT-15 -5.41 > -5.12 > -5.12 
 HT29 > -5.12 > -5.12 > -5.12 
 KM12 -5.14 > -5.12 > -5.12 
 SW-620 > -5.12 > -5.12 > -5.12 
CNS cancer SF-268 -5.22 > -5.12 > -5.12 
 SF-295 -5.75 > -5.12 > -5.12 
 SF-539 > -5.12 > -5.12 > -5.12 
 SNB-19 > -5.12 > -5.12 > -5.12 
 SNB-75 > -5.12 > -5.12 > -5.12 
 U251 -5.73 > -5.12 > -5.12 
Melanoma LOX IMVI -5.27 > -5.12 > -5.12 
 MALME-3M > -5.12 > -5.12 > -5.12 
 M14 > -5.12 > -5.12 > -5.12 
 MDA-MB-435 > -5.12 > -5.12 > -5.12 
 SK-MEL-2 > -5.12 > -5.12 > -5.12 
 SK-MEL-28 > -5.12 > -5.12 > -5.12 
 SK-MEL-5 -5.75 > -5.12 > -5.12 
 UACC-257 -5.54 > -5.12 > -5.12 
 UACC-62 -5.17 > -5.12 > -5.12 
Ovarian cancer IGROV1 -5.30 > -5.12 > -5.12 
 OVCAR-3 -5.39 > -5.12 > -5.12 
 OVCAR-4 > -5.12 > -5.12 > -5.12 
 OVCAR-5 > -5.12 > -5.12 > -5.12 
 OVCAR-8 > -5.12 > -5.12 > -5.12 
 NCI/ADR-RES -5.28 > -5.12 > -5.12 
 SK-OV-3 > -5.12 > -5.12 > -5.12 
Renal cancer 786-0 -5.29 > -5.12 > -5.12 
 A498 > -5.12 > -5.12 > -5.12 
 ACHN -5.23 > -5.12 > -5.12 
 CAKI-1 -6.02 > -5.12 > -5.12 
 RXF 393 > -5.12 > -5.12 > -5.12 
 SN12C > -5.12 > -5.12 > -5.12 
 TK-10 -5.41 > -5.12 > -5.12 
 UO-31 > -5.12 > -5.12 > -5.12 
Prostate cancer PC-3 -5.51 > -5.12 > -5.12 
 DU-145 > -5.12 > -5.12 > -5.12 
Breast cancer MCF7 -5.37 > -5.12 > -5.12 
 MDA-MB-231/ATCC > -5.12 > -5.12 > -5.12 
 HS 578T > -5.12 > -5.12 > -5.12 
 BT-549 -5.39 > -5.12 > -5.12 
 T-47D -5.17 > -5.12 > -5.12 
 MDA-MB-468 -6.56 > -5.12 > -5.12 
MID  -5.31 -5.12 -5.12 
Delta  1.25 0 0 
Range  1.44 0 0 
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The log molar concentration of the resulted screening of compound 4.22 (NSC 751486) 
shown for each of the parameters; for log GI50 ranged from -6.07 to -5.22, for log TGI ranged 
from -5.32 to -4.70, for log LC50 ranged from -4.98 to -4.70 (Table 4.12).  A mean graph 
midpoint (MG-MID) calculated for each of the parameters; log GI50 (-5.49), log TGI (-5.10), and 
log LC50 (-4.80). 
 
Table 4.12. Values of the log molar concentration of response parameter (log10GI50, log10TGI 
and log10LC50) of the 4.22 (NSC 751486).  
Cancer disease Used cell lines log10GI50 log10TGI log10LC50 
Leukemia CCRF-CEM -5.22 > -4.70 > -4.70 
 HL-60(TB) -5.53 -5.06 > -4.70 
 K-562 -5.52 -5.03 > -4.70 
 MOLT-4 -5.54 -4.99 > -4.70 
 RPMI-8226 -5.35 > -4.70 > -4.70 
Non-small cell lung cancer A549/ATCC -5.52 -5.12 -4.71 
 EKVX -5.47 -5.01 > -4.70 
 HOP-62 -5.43 -5.13 -4.84 
 HOP-92 -5.50 -5.18 -4.85 
 NCI-H226 -5.52 -5.21 -4.90 
 NCI-H23 -5.51 -5.17 -4.84 
 NCI-H322M -5.35 -4.93 > -4.70 
 NCI-H460 -5.47 -5.10 -4.74 
 NCI-H522 -6.07 -5.32 -4.84 
Colon cancer COLO 205 -5.37 -4.98 > -4.70 
 HCC-2998 -5.47 -5.21 -4.95 
 HCT-116 -5.61 -5.30 -4.98 
 HCT-15 -5.36 -4.74 > -4.70 
 HT29 -5.58 -5.25 -4.92 
 KM12 -5.53 -5.23 -4.94 
 SW-620 -5.50 -5.15 -4.80 
CNS cancer SF-268 -5.46 -5.10 -4.73 
 SF-295 -5.58 -5.25 -4.91 
 SF-539 -5.47 -5.17 -4.87 
 SNB-19 -5.33 > -4.7 > -4.70 
 SNB-75 -5.64 -5.14 > -4.70 
 U251 -5.51 -5.19 -4.87 
Melanoma LOX IMVI -5.48 -5.15 -4.81 
 MALME-3M -5.56 -5.20 -4.83 
 M14 -5.52 -5.22 -4.92 
 MDA-MB-435 -5.48 -5.15 -4.82 
 SK-MEL-2 -5.55 -5.24 -4.93 
 SK-MEL-28 -5.47 -5.16 -4.85 
 SK-MEL-5 -5.52 -5.24 -4.96 
 UACC-257 -5.54 -5.23 -4.91 
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The log molar concentration of the resulted screening of compound 4.37c (NSC 764189) 
shown for each of the parameters; for log GI50 ranged - 5.30 only, for log TGI ranged - 5.30 only, 
for log LC50 ranged - 5.30 only.  A mean graph midpoint (MG-MID) calculated for each of the 
parameters; log GI50 (-5.30), log TGI (-5.30), and log LC50 (-5.30) (refer to the Supplementary 
data in chapter 5). 
The log molar concentration of the resulted screening of compound 4.21 (NSC 764190) 
shown for each of the parameters; for log GI50 ranged from -6.57 to -4.00, for log TGI ranged 
from -4.22 to -4.00, for log LC50 ranged -4.00 only (Table 4.13).  A mean graph midpoint (MG-
MID) calculated for each of the parameters; log GI50 (-4.94), log TGI (-4.0), and log LC50 (-4.0). 
 
 UACC-62 -5.54 -5.19 -4.84 
Ovarian cancer IGROV1 -5.45 -5.14 -4.83 
 OVCAR-3 -5.54 -5.22 -4.90 
 OVCAR-4 -5.57 -5.14 -4.71 
 OVCAR-5 -5.45 -5.04 > -4.70 
 OVCAR-8 -5.38 -4.95 > -4.70 
 NCI/ADR-RES -5.47 -5.07 > -4.70 
 SK-OV-3 -5.38 -4.98 > -4.70 
Renal cancer 786-0 -5.49 -5.16 -4.84 
 A498 -5.61 -5.29 -4.96 
 ACHN -5.22 > -4.70 > -4.70 
 CAKI-1 -5.44 -5.13 -4.83 
 RXF 393 -5.58 -5.28 -4.98 
 SN12C -5.49 -5.11 -4.74 
 TK-10 -5.42 -5.08 -4.73 
 UO-31 -5.56 -5.22 -4.88 
Prostate cancer PC-3 -5.46 -4.98 > -4.70 
 DU-145 -5.49 -5.12 -4.75 
Breast cancer MCF7 -5.32 -4.87 > -4.70 
 MDA-MB-231/ATCC -5.55 -5.19 -4.84 
 HS 578T -5.49 -5.08 > -4.70 
 BT-549 -5.58 -5.26 -4.94 
 T-47D -5.40 -4.99 > -4.70 
 MDA-MB-468 -5.53 -5.14 -4.76 
MID  -5.49 -5.10 -4.80 
Delta  0.58 0.22 0.18 
Range  0.85 0.22 0.28 
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Table 4.13. Values of the log molar concentration of response parameter (log10GI50, log10TGI 
and log10LC50) of the 4.21 (NSC 764190).  
Cancer disease Used cell lines log10GI50 log10TGI log10LC50 
Leukemia CCRF-CEM -5.41 > -4.00 > -4.00 
 HL-60(TB) -5.46 > -4.00 > -4.00 
 K-562 -5.70 > -4.00 > -4.00 
 MOLT-4 -5.67 > -4.00 > -4.00 
 RPMI-8226 -6.07 > -4.00 > -4.00 
 SR -5.78 > -4.00 > -4.00 
Non-small cell lung cancer A549/ATCC -5.12 > -4.00 > -4.00 
 HOP-62 > -4.00 > -4.00 > -4.00 
 HOP-92 -5.36 > -4.00 > -4.00 
 NCI-H226 -5.36 > -4.00 > -4.00 
 NCI-H23 -5.78 > -4.00 > -4.00 
 NCI-H322M > -4.00 > -4.00 > -4.00 
 NCI-H460 -5.56 > -4.00 > -4.00 
 NCI-H522 -5.26 > -4.00 > -4.00 
Colon cancer COLO 205 > -4.00 > -4.00 > -4.00 
 HCC-2998 > -4.00 > -4.00 > -4.00 
 HCT-116 -6.27 > -4.00 > -4.00 
 HCT-15 -5.45 > -4.00 > -4.00 
 HT29 -4.37 > -4.00 > -4.00 
 KM12 -5.00 > -4.00 > -4.00 
 SW-620 nd > -4.00 > -4.00 
CNS cancer SF-268 -5.11 > -4.00 > -4.00 
 SF-295 -6.18 > -4.00 > -4.00 
 SF-539 > -4.00 > -4.00 > -4.00 
 SNB-19 > -4.00 > -4.00 > -4.00 
 SNB-75 > -4.00 > -4.00 > -4.00 
 U251 -5.96 > -4.00 > -4.00 
Melanoma LOX IMVI -5.85 > -4.00 > -4.00 
 MALME-3M > -4.00 > -4.00 > -4.00 
 M14 nd > -4.00 > -4.00 
 MDA-MB-435 > -4.00 > -4.00 > -4.00 
 SK-MEL-2 > -4.00 > -4.00 > -4.00 
 SK-MEL-28 > -4.00 > -4.00 > -4.00 
 SK-MEL-5 -5.94 > -4.00 > -4.00 
 UACC-257 -5.65 > -4.00 > -4.00 
 UACC-62 -5.57 > -4.00 > -4.00 
Ovarian cancer IGROV1 > -4.00 > -4.00 > -4.00 
 OVCAR-3 -5.63 > -4.00 > -4.00 
 OVCAR-4 -6.32 > -4.00 > -4.00 
 OVCAR-5 > -4.00 > -4.00 > -4.00 
 OVCAR-8 > -4.00 > -4.00 > -4.00 
 NCI/ADR-RES -5.15 > -4.00 > -4.00 
 SK-OV-3 > -4.00 > -4.00 > -4.00 
Renal cancer 786-0 > -4.00 > -4.00 > -4.00 
 A498 -5.75 > -4.00 > -4.00 
 ACHN -5.68 > -4.00 > -4.00 
 CAKI-1 -5.55 > -4.00 > -4.00 
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4.4. Conclusion 
In conclusion, an analog of DMP 323 from a variety of synthesized symmetric, and 
unsymmetric cyclic sulfamides and additional urea and phosphorus-containing compounds were 
screened in NCI 60 cancer cell line to identify biologically active compounds.  With the concept 
of drug repositioning, we studied a new opportunity of application of these compounds which are 
known HIV protease inhibitors to potential agents for the treatment of cancer.  The two-stage 
process of in vitro screening was carried out: wherein 29 compounds were selected for one-dose 
study and 4 compounds selected for a five-dose study for in vitro cytotoxicity evaluation. 
Generally, compounds were selectively sensitive on the leukemia, colon cancer, prostate cancer 
and breast cancer cell.  Notably, almost every compound demonstrated strong inhibition against 
breast cancer (MDA-MB-468).  The primary one-dose study revealed that compounds 4.21, 4.22, 
4.23, and 4.37c possessed high activity against different cancer types.  Four such compounds 
were further tested in the five-dose experiment.  To understand the mechanism of the observed 
cytotoxicity, investigations with a representative compound are underway to learn about the 
effect for apoptosis, migration, anchorage independent growth and cellular senescence. 
 
 RXF 393 -4.55 > -4.00 > -4.00 
 SN12C -5.03 > -4.00 > -4.00 
 TK-10 -5.08 > -4.00 > -4.00 
 UO-31 > -4.00 > -4.00 > -4.00 
Prostate cancer PC-3 -6.24 > -4.00 > -4.00 
 DU-145 > -4.00 > -4.00 > -4.00 
Breast cancer MCF7 > -4.00 > -4.00 > -4.00 
 MDA-MB-231/ATCC > -4.00 > -4.00 > -4.00 
 HS 578T > -4.00 > -4.00 > -4.00 
 BT-549 > -4.00 > -4.00 > -4.00 
 T-47D > -4.00 > -4.00 > -4.00 
 MDA-MB-468 -6.57 > -4.22 > -4.00 
MID  -4.94  -4.0  -4.0 
Delta  1.63 0.22 0 
Range  2.57 0.22 0.0 
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5.1. General Methods 
All air and moisture sensitive reactions were carried out in flame- or oven dried 
glassware under argon or nitrogen using standard gas tight syringes, cannulas, and septa.  
Methylene chloride (CH2Cl2), tetrahydrofuran (THF), diethyl ether (Et2O), and toluene were 
purified by passage through a Solv-Tek solvent purification system employing activated Al2O3, 
or used them immediately after purchasing from Sigma-Aldrich as anhydrous solvent grade. 
Triethylamine (Et3N) was stored over KOH.  Sodium triacetoxyborohydride (97%) was 
purchased from Sigma-Aldrich and was not further purified.  All amino acids and amines were 
purchased from Sigma-Aldrich.  Thin layer chromatography was performed on silica gel 60F254 
plates (EM-5717, Merck).  Visualization of TLC spots were effected using KMnO4 stain or UV 
lamp (254 nm).  Flash column chromatography was performed with Teledyne ISCO CombiFlash 
companion using various sizes of Teledyne columns or Grace® Flash Cartridges.  
Deuterochloroform (CDCl3) with and without TMS (0.03% (v/v)) was purchased from Sigma-
Aldrich and stored in desiccator at room temperature.  1H and 13C NMR spectra were recorded in 
CDCl3 (unless otherwise noted) on either Varian-400 MHz spectrometer operating at 400MHz 
and 100 MHz, respectively.  
 
 
 
 
 
 
 
155 
 
 
5.2. Experimental Procedure and data: Chapter 2  
4-Bromo-N-(3-fluorophenyl)benzenesulfonamide (2.4) 
 
To a solution of 3-fluoroaniline (1.0 mL, 10.39 mmol) and pyridine (1.3 mL, 16.07 mmol) 
in CH2Cl2 (20 mL) was added a solution of 4-bromobenzene sulfonyl chloride (2.65 g, 10.44 
mmol) in CH2Cl2 (30 mL) at room temperature.  The color of solution was changed to light 
orange. The reaction mixture was stirred overnight.  The reaction mixture was evaporated, and 
purified by the ISCO-Flash column chromatography in 0% to 40% of EtOAc in hexane to get 
white solid as a product 2.4 (3.31 g, 97 %).  
 
Analytical data for 2.4: Rf = 0.83 (Sol. EtOAc:Hexane = 1/1); FTIR (neat) 3240, 2383, 2368, 
1612, 1601, 1573, 1483, 1468, 1399, 1389, 1334, 1265, 1154, 1130, 1088, 1067, 1009, 962, 913, 
823, 762, 742, 682, 630 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.70–7.65 (m, 2H), 7.62–7.57 (m, 
2H), 7.25 (s, 1H), 7.20 (ddd, J = 8.2, 8.2, 6.3 Hz, 1H), 6.91 (ddd, J = 10.0, 2.3, 2.3 Hz, 1H), 
6.85–6.80 (m, 2H); 13C NMR (101 MHz, Chloroform-d) δ 163.18 (d, J = 247.2 Hz), 137.81, 
137.74 (d, J = 6.4 Hz), 132.68, 130.88 (d, J = 9.3 Hz), 128.84, 128.67,  116.69 (d, J = 3.1 Hz), 
112.61 (d, J = 21.2 Hz), 108.64 (d, J = 25.3 Hz); HRMS (M+Na)
+ 
calcd for C12H9BrFNNaO2S
+ 
(M+Na) required 351.9419, found 351.9410.  
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tert-Butyl 4-(4-bromo-N-(3-fluorophenyl)phenylsulfonamido)piperidine-1-carboxylate  
(2.5) 
 
To a solution of 2.4 (0.52 g, 1.56 mmol) and DIAD (0.92 mL, 4.67 mmol) in THF (10 
mL) was added a solution of tert-butyl-4-hydroxy-1-piperidinecarboxylate (0.38 g, 1.88 mmol) 
and PPh3 (1.23 g, 4.70 mmol) in THF (10 mL) at room temperature and heated to 60 ºC for 
overnight.  The reaction mixture was evaporated, and purified by the ISCO-Flash column 
chromatography in 0% to 40% of EtOAc in hexane to get white solid as a product 2.5 (0.63 g, 
78 %). 
 
Analytical data for 2.5: Rf = 0.68 (Sol. EtOAc:Hexane = 1/1); 
1H NMR (400 MHz, 
CDCl3) δ 7.66–6.55 (m, 4H), 7.31 (ddd, J = 8.1, 6.4, 6.4 Hz, 1H), 7.11 (dddd, J = 8.3, 8.3, 2.5, 
0.8 Hz, 1H), 6.83–6.72 (m, 2H), 4.29 (tt, J = 12.1, 3.8 Hz, 1H), 4.12 (m, 2H), 2.74 (t, J = 12.9 Hz, 
2H), 1.76 (d, J = 12.2 Hz, 2H), 1.37 (s, 9H), 1.27–1.26 (m, 2H).  
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4-Bromo-N-(3-fluorophenyl)-N-(piperidin-4-yl)benzenesulfonamide hydrochloride (2.6) 
 
To a solution of 2.5 (0.63g, 1.22 mmol) in CH2Cl2 (20 mL) was added 4N HCl in 1,4-
dioxane (20 mL,) at 0 °C and stirred overnight.  A reaction mixture was evaporated to remove 
solvent, and then the mixture was dried under reduced vacuum to furnish a white solid as a 
product 2.6.  It used without further purification.   
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4-Bromo-N-(1-(4-fluorobenzyl)piperidin-4-yl)-N-(3-fluorophenyl)benzenesulfonamide 
(2.7) 
 
To a solution of 2.6 (0.34 g, 0.76 mmol), 4-fluorobenzaldehyde (0.09 mL, 0.84 mmol) 
and Et3N (0.1 mL, 0.72 mmol) in CH2Cl2 (10 mL) was added NaBH(OAc)3 (0.52 g, 2.44 mmol) 
at 0 °C and stirred for overnight.  The reaction mixture was extracted with CH2Cl2 (100 mL X 3) 
and then the combined organic layer was dried over MgSO4, filtered, evaporated, and purified by 
the ISCO-Flash column chromatography in 0% to 40% of EtOAc in hexane to get white oil as a 
product 2.7 (0.10 g, 24 %).  
 
Analytical data for 2.7: Rf = 0.81 (Sol. EtOAc:Hexane = 1/1); FTIR (neat) 3241, 3098, 
2986, 2383, 2309, 1796, 1770, 1733, 1611, 1600, 1573, 1482, 1467, 1400, 1389, 1334, 1264, 
1154, 1129, 1087, 1067, 1009, 962, 912, 823, 762, 741, 682, 621 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.64–7.55 (m, 2H), 7.57 (d, J = 8.6 Hz, 2H), 7.29 (m, 1H), 7.23–7.13 (m, 2H), 7.09 
(ddd, J = 8.2, 2.4, 2.4 Hz, 1H), 6.95 (dd, J = 8.5, 8.5 Hz, 2H), 6.79–6.73 (m, 2H), 4.22–4.08 (m, 
1H), 3.39 (s, 2H), 2.92–2.74 (m, 2H), 2.14–1.94 (m, 2H), 1.78-1.65 (m, 2H), 1.52–1.33 (m, 2H); 
13C NMR (101 MHz, Chloroform) δ 162.58 (d, J = 248.9 Hz), 162.58 (d, J = 248.9 Hz), 140.20, 
136.63 (d, J = 8.9 Hz), 132.43, 130.08 (d, J = 9.2 Hz), 128.94, 128.84, 128.34 (d, J = 2.7 Hz), 
127.76, 119.82 (d, J = 21.4 Hz), 116.47 (d, J = 20.5 Hz), 115.52 (d, J = 21.4 Hz), 115.21 (d, J = 
21.1 Hz), 62.00, 57.99, 52.89, 31.77; HRMS (M+H)
+ 
calcd for C24H24BrF2N2O2S
+ (M+H) 
required 521.0710, found 521.0846.  
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(S)-2-hydroxy-3-methylbutanoic acid (2.8) 
 
To a solution of L-valine (5.00 g, 42.72 mmol) in 1N H2SO4 (100 mL) was added slowly 
a solution of NaNO2 (6.02 g, 87.25 mmol) at 0 °C and stirred overnight.  The reaction mixture 
was extracted with diethyl ether (100 mL X 4) and concentrated by azeotropic distillation with 
toluene to provide yellow oil.  A yellow oil was dried under reduced vacuum to furnish a crystal 
as white needles 2.8 (3.50 g, 70%).  
 
Analytical data for 2.8: FTIR (neat) 3428, 2968, 2936, 2879, 1716, 1645, 1211, 1136, 
1027, 727, 616 cm-1; 
1
H NMR (CD3CN, 400 MHz) δ 4.03 (d, 1H), 2.06 (m, 1H), 0.99 (d, J = 8.0 
Hz, 3H), 0.87 (d, J = 8.0 Hz, 3H); 
13
C NMR (CDCl
3
, 101 MHz) δ 175.6, 117.7, 74.7, 31.9, 18.4.  
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(S)-methyl 2-hydroxy-3-methylbutanoate (2.9) 
 
To a solution of 2.8 (3.49 g, 29.54 mmol) in methanol (50 mL) was added amberlyst-15 
ion exchange resin at room temperature and stirred for overnight.  The reaction mixture was 
filtered and evaporated to remove solvent to give yellow oil.  The yellow oil was purified by the 
ISCO-Flash column chromatography in 0% to 40% of EtOAc in hexane to get yellow oil as a 
product 2.9 (2.03 g, 52%).  
 
Analytical data for 2.9: Rf = 0.71 (Sol. EtOAc:Hexane = 1/1, checked by KMnO4 stain 
solution); FTIR (neat) 2958, 2922, 2851, 1743, 1672, 1428, 1621, 1428, 1276, 1175, 1147, 936, 
860, 756 cm-1; 1H NMR (400 MHz, CDCl
3
) δ 4.02 (dd, J = 6.0, 3.6 Hz, 1H), 3.76 (s, 3H), 2.80 (d, 
J = 6.0 Hz, 1H), 2.04 (dqq, J = 6.9, 6.9, 3.4 Hz, 1H), 0.99 (d, J = 6.9 Hz, 3H), 0.84 (d, J = 6.9 Hz, 
3H); 
13
C NMR (CDCl
3
, 101 MHz) δ 175.5, 75.3, 52.4, 32.3, 18.7, 16.2.  
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tert-Butyl 4-(3-fluorophenylamino)piperidine-1-carboxylate (2.13) 
 
To a solution of 1-Boc-4-piperidone (7.92 g, 39.77 mmol) and 3-fluoroaniline (4.0 mL, 
41.61 mmol) in CH2Cl2 (100 mL) was added NaBH(OAc)3 (26.05 g, 122.90 mmol) at 0 °C and 
stirred for 2 hrs.  To a reaction mixture was added glacial acetic acid (5.0 mL, 87.34 mmol) at 
0 °C and stirred at ambient temperature overnight.  The reaction mixture was washed with 
saturated aqueous NaHCO3 solution.  The mixture was extracted with CH2Cl2 (200 mL X 3) and 
then the combined organic layer was dried over MgSO4, filtered, evaporated, and purified by the 
ISCO-Flash column chromatography in 0% to 40% of EtOAc in hexane to get white solid as a 
product 2.13 (11.21 g, 99%).  
 
Analytical data for 2.13: Rf = 0.88 (Sol. EtOAc:Hexane = 1/1);  FTIR (neat) 3353, 3010, 
2168, 2141, 1666, 1621, 1494, 1421, 1236, 1160, 936, 756, 687, 609 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.08 (ddd, J = 8.1, 6.8, 6.8 Hz, 1H), 6.40–6.38 (m, 1H), 6.36–6.32 (m, 1H), 6.28 (ddd, 
J = 4.45, 2.3, 2.3 Hz, 1H), 4.18-3.93 (m, 2H), 3.66 (s, 1H), 3.43-3.32 (m, 1H), 2.92 (t, J = 12.0 
Hz, 2H), 2.09–1.94 (td, J = 7.4, 2.7 Hz, 2H), 1.47 (s, 9H), 1.39–1.26 (m, 2H); 13C NMR (101 
MHz, Chloroform-d) δ 164.29 (d, J = 242.7 Hz), 154.87, 148.69 (d, J = 11.0 Hz), 130.53 (d, J = 
10.2 Hz), 109.18 (d, J = 2.2 Hz), 103.90 (d, J = 21.6 Hz), 99.84 (d, J = 25.4 Hz), 79.79, 76.82, 
50.25, 32.35, 28.56; HRMS (M+Na)
+ 
calcd for C16H23FN2NaO2
+ (M+Na) required 317.1636, 
found 317.1635.  
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tert-Butyl 4-((N-(tert-butoxycarbonyl)sulfamoyl)(3-fluorophenyl)amino)piperidine-1- 
carboxylate (2.15) 
 
To a solution of chlorosulfonyl isocyanate (1.5 mL, 17.23 mmol) in CH2Cl2 (20 mL) was 
added to a solution of tert-butyl alcohol (1.65 mL, 17.25 mmol) in CH2Cl2 (20 mL) at 0 °C.  This 
solution was cannulated to a solution of 2.13 (3.46 g, 11.75 mmol) and Et3N (3.0 mL, 21.52 
mmol) in CH2Cl2 (30 mL) at 0 °C.  After that, the reaction mixture was stirred at ambient 
temperature for overnight.  The reaction mixture was extracted with CH2Cl2 (100 mL X 4) and 
dried over MgSO4, filtered, evaporated, and purified by the ISCO-Flash column chromatography 
in 0% to 40% of EtOAc in hexane to get white solid as a product 2.15 (6.20 g, 91%). 
 
Analytical data for 2.15: Rf = 0.80 (Sol. EtOAc:Hexane = 1/1); FTIR (neat) 3745, 3712, 
3067, 2977, 2944, 2863, 2357, 2325, 1735, 1659, 1436, 1366, 1353, 1243, 1168, 1135, 1056, 979, 
827, 725, 694, 616 cm-1; 1H NMR (400 MHz, Chloroform-d) δ 7.38 (ddd, J = 8.2, 6.4, 6.4 Hz, 
1H), 7.15 (dddd, J = 8.3, 8.3, 2.5, 0.9 Hz, 1H), 7.07–7.01 (m, 2H), 6.95 (ddd, J = 4.4, 2.4, 2.4 Hz, 
1H), 4.41 (tt, J = 12.1, 3.8 Hz, 1H), 4.20–4.05 (m, 2H), 2.78 (t, J = 11.9 Hz, 2H), 2.03–1.94 (m, 
2H), 1.52 (s, 9H), 1.38 (s, 9H), 1.27 (dtd, J = 15.5, 4.0 Hz, 2H); 13C NMR (101 MHz, cdcl3) δ 
162.70 (d, J = 249.0 Hz), 154.56, 149.52, 135.99 (d, J = 9.7 Hz), 130.38 (d, J = 9.1 Hz), 128.11 
(d, J = 3.5 Hz), 119.48 (d, J = 21.7 Hz), 116.89 (d, J = 20.9 Hz). 83.87, 79.91, 59.35, 59.35, 
31.81, 28.49, 28.17. 
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(R)-tert-Butyl 4-((N-(tert-butoxycarbonyl)-N-(1-methoxy-3-methyl-1-oxobutan-2-yl) 
sulfamoyl)(3-fluorophenyl)amino)piperidine-1-carboxylate (2.17) 
 
To a solution of 2.13 (1.01 g, 2.14 mmol) and DIAD (3.0 mL, 6.59 mmol) in THF (20 
mL) was added a solution of 2.9 (0.34 g, 2.60 mmol) and PPh3 (1.69 g, 6.44 mmol) in THF (20 
mL) at room temperature and then the reaction mixture was heated at 65 °C for overnight.  The 
reaction mixture was extracted with CH2Cl2 (150 mL X 3) and the combined organic layer was 
dried over MgSO4, filtered, evaporated, and purified by the ISCO-Flash column chromatography 
in 0% to 40% of EtOAc in hexane to get white oil as a product 2.17 (1.22 g, 97%).  
 
Analytical data for 2.17: Rf = 0.86 (Sol. EtOAc:Hexane = 1/1);
 []25D = + 1.188 (c = 
1.094, CHCl3); FTIR (neat) 3333, 2991, 2978, 2924, 2853, 1666, 1611, 1588, 1524, 1476, 1430, 
1366, 1342, 1311, 1233, 1187, 1167, 1139, 998, 980, 936, 862, 821, 756, 627 cm-1; 1H NMR 
(400 MHz, Chloroform-d) δ 7.36 (ddd, J = 8.2, 6.5, 6.5 Hz, 1H), 7.14 (ddd, J = 10.8, 10.8, 2.5 
Hz, 1H), 7.11–7.07 (m, 1H), 6.99 (ddd, J = 9.6, 2.2, 2.2 Hz, 1H), 4.47 (tt, J = 12.0, 3.7 Hz, 1H), 
4.30 (d, J = 8.8 Hz, 1H), 4.12 (q, J = 7.2 Hz, 2H), 3.59 (s, 3H), 2.80 (t, J = 12.2 Hz, 2H), 2.42 
(ddt, J = 13.5, 8.7, 6.8 Hz, 1H), 2.03–1.94 (m, 2H), 1.50 (s, 9H), 1.38 (s, 9H), 1.26 (ddd, J = 8.7, 
3.9, 2.2 Hz, 2H), 1.07 (d, J = 6.4 Hz, 3H), 0.92 (d, J = 7.0 Hz, 3H); 13C NMR (101 MHz, cdcl3) δ 
170.18, 162.34 (d, J = 247.6 Hz), 154.59, 150.64, 135.87 (d, J = 10.1 Hz), 129.73 (d, J = 9.1 Hz), 
129.01 (d, J = 3.2 Hz), 120.27 (d, J = 21.8 Hz), 116.50 (d, J = 21.0 Hz), 84.59, 79.83, 60.60, 
59.43, 59.27, 52.07, 28.49, 28.30, 28.09, 22.28, 19.50. 
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(R)-Methyl 2-(N-(3-fluorophenyl)-N-(piperidin-4-yl)sulfamoylamino)-3-methylbutanoate  
dihydrochloride (2.19) 
 
To a solution of 2.17 (0.39 g, 0.66 mmol) in CH2Cl2 (20 mL) was added 4N HCl in 1,4-dioxane 
(5 mL) at 0 °C and stirred overnight.  A reaction mixture was evaporated to remove solvent, and 
then the mixture was dried under reduced vacuum to furnish a white solid as a product 2.19. It 
used without further purification.   
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(R)-Methyl 2-(N-(1-(4-fluorobenzyl)piperidin-4-yl)-N-(3-fluorophenyl)sulfamoylamino)-3- 
methyl butanoate (2.21) 
 
To a solution of 2.19 (0.13 g, 0.34 mmol) and 4-fluorobenzaldehyde (0.045 mL, 0.42 
mmol) in CH2Cl2 (20 mL) was added NaBH(OAc)3 (0.22 g, 1.03 mmol) at 0 °C and stirred for 2 
hrs.  To a solution was added glacial acetic acid (0.04 mL, 0.70 mmol) at 0 °C and stirred 
overnight.  The reaction mixture was extracted with CH2Cl2 (150 mL X 3) and EtOAc (200 mL) 
and then the combined organic layer was dried over MgSO4, filtered, evaporated, and purified by 
the ISCO-Flash column chromatography in 0% to 60% of EtOAc in hexane to get white oil as a 
product 2.21 (0.0742 g, 45%). 
 
Analytical data for 2.21: Rf = 0.89 (Sol. EtOAc:Hexane = 1/1); []25D = + 23.661 (c = 
0.224, CH2Cl2);  FTIR (neat) 3316, 2925, 2854, 2383, 23236, 1589, 1512, 1495, 1338, 1226, 
1151, 938, 828, 760, 685 cm-1; 1H NMR (400 MHz, Chloroform-d) δ 7.32 (ddd, J = 16.3, 16.3, 
8.2 Hz, 1H), 7.21–7.15 (m, 2H), 7.10–7.02 (m, 2H), 6.99–6.95 (m, 2H), 6.94–6.93 (m, 1H), 5.02 
(d, J = 9.4 Hz, 1H), 3.89 (tt, J = 12.1, 3.8 Hz, 1H), 3.77 (dd, J = 9.4, 5.0 Hz, 1H), 3.73 (s, 3H), 
3.42 (s, 2H), 2.90–2.87 (m, 2H), 2.11–2.02 (m, 2H), 2.02–1.98 (m, 1H), 1.97–1.90 (m, 1H), 1.83 
(dt, J = 12.3, 3.1 Hz, 1H), 1.47 (dddd, J = 19.6, 12.2, 7.6, 4.0 Hz, 2H), 0.94 (d, J = 6.8 Hz, 3H), 
0.88 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 174.47, 164.6 (d, J = 248.5 Hz), 164.2 
(d, J = 247.5 Hz), 140.0 (d, J = 11.1 Hz), 135.34, 132.86, 132.44 (d, J = 84.8 Hz), 129.65, 
121.08 (d, J = 21.2), 117.91 (d, J = 21.2), 117.20 (d, J = 22.2 Hz), 63.88, 63.62, 60.26, 54.84, 
54.78, 54.52, 34.07, 33.42, 33.15, 20.89, 19.83; HRMS (M+H)
+ 
calcd for C24H32F2N3O4S
+ (M+H) 
required 496.2081, found 496.2090.  
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(R)-Methyl 2-(N-(3-fluorophenyl)-N-(1-(4-hydroxybenzyl)piperidin-4-yl)sulfamoyl-amino)-
3-methylbutanoate (2.22) 
 
A solution of 2.19 (0.38 g, 0.98 mmol), 4-hydroxybenzaldehyde (0.15 g, 1.11 mmol) in 
CH2Cl2 (20 mL) was treated with NaBH(OAc)3 (0.65 g, 3.05 mmol) at room temperature and 
stirred for 2 hrs.  To a reaction mixture was added glacial acetic acid (0.11 mL, 1.92 mmol) at 0 
ºC and stirred overnight.  A reaction mixture was quenched with aqueous NaHCO3 solution and 
extracted with CH2Cl2 (150 mL X 2) and then the combined organic layer was dried over MgSO4, 
filtered, evaporated, and purified by the ISCO-Flash column chromatography in 0% to 40% of 
EtOAc in hexane to get white solid as a product 2.22 (0.08 g, 17%).  
 
Analytical data for 2.22: Rf = 0.29 (Sol. EtOAc:Hexane = 1/1); []25D = + 27.471 (c = 0.597, 
CH2Cl2); FTIR (neat) 3711, 2925, 2855, 2369, 1731, 1610, 1593, 1516, 1366, 1248, 1144, 1131, 
1059, 1033, 1010, 831, 777, 692 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.26 (ddd, J = 14.7, 8.0, 0 
Hz, 1H), 7.05 (d, J = 8.3 Hz, 2H), 7.02(m, 2H), 6.89 (m, 1H), 6.62 (d, J = 8.3 Hz, 2H), 4.97 (d, J 
= 9.4 Hz, 1H), 3.87 (t, J = 11.9 Hz, 1H), 3.74 (dd, J = 9.3, 5.0 Hz, 1H), 3.71 (s, 3H), 3.36 (s, 2H), 
2.90 (d, J = 10.9 Hz, 2H), 2.10–1.96 (m, 3H), 1.87 (ddd, J = 43.9, 12.2, 0 Hz, 2H), 1.47 (m, 2H), 
0.92 (d, J = 6.8 Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 172.33, 162.37 
(d, J = 249.5 Hz), 155.14, 137.62, 130.69, 130.28 (d, J = 83.8 Hz), 129.82 (d, J = 9.1 Hz), 
127.42 (d, J = 3.0 Hz), 118.85 (d, J = 22.2 Hz), 115.52 (d, J = 48.5 Hz), 115.17, 62.03, 61.41, 
58.04, 52.67, 52.61, 52.42, 31.92, 31.09, 30.82, 18.74, 17.66; HRMS (M+H)
+ 
calcd for 
C24H33FN3O5S 
+ (M+H) required 494.2125, found 494.2160.   
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(R)-Methyl 2-(N-(3-fluorophenyl)-N-(1-(3-hydroxybenzyl)piperidin-4-yl)sulfamoyl-amino)-
3-methylbutanoate (2.23) 
 
A solution of 2.19 (0.18 g, 0.45 mmol), 3-hydroxybenzaldehyde (0.06 g, 0.45 mmol) in 
CH2Cl2 (10 mL) was treated with NaBH(OAc)3 (0.29 g, 1.36 mmol) at room temperature and 
stirred for 2 hrs.  To a reaction mixture was added glacial acetic acid (0.05 mL, 0.87 mmol) at 0 
ºC and stirred overnight.  A reaction mixture was quenched with aqueous NaHCO3 solution and 
extracted with CH2Cl2 (100 mL X 2) and then the combined organic layer was dried over MgSO4, 
filtered, evaporated, and purified by the ISCO-Flash column chromatography in 0% to 40% of 
EtOAc in hexane to get white solid as a product 2.23 (38.1 mg, 17%).  
 
Analytical data for 2.23: Rf = 0.42 (Sol. EtOAc:Hexane = 1/1); []25D = + 1.538 (c = 0.130, 
CH2Cl2); FTIR (neat) 3274, 2964, 2874, 2845, 2299, 2256, 1738, 1591, 1486, 1455, 1339, 1264, 
1207, 1161, 1140, 1054, 982, 911, 888, 858, 777, 730, 692, 649, 605 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.28 (ddd, J = 14.7, 8.0, 0 Hz, 1H) 7.11 (dd, J = 7.8, 7.8 Hz, 1H), 7.03 (m, 2H), 6.91 (d, 
J = 9.5 Hz, 1H), 6.76–6.63 (m, 3H), 5.00 (d, J = 9.4 Hz, 1H), 3.87 (t, J = 12.0 Hz, 1H), 3.76 (dd, 
J = 8.2, 3.3 Hz, 1H), 3.71 (s, 3H), 3.38 (s, 2H), 2.90 (d, J = 11.0 Hz, 2H), 2.06 (t, J = 12.2 Hz, 
2H), 1.99 (m, 1H), 1.85 (ddd, J = 44.2, 12.4, 0 Hz, 2H), 1.49 (ddd, J = 20.8, 11.6, 8.8 Hz, 2H), 
0.92 (d, J = 6.8 Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 172.33, 161.15, 
155.89, 137.42, 129.86 (d, J = 9.1 Hz), 129.39, 127.42 (d, J = 3.0 Hz), 121.31, 118.85 (d, J = 
22.2 Hz), 116.01, 115.96 (d, J = 11.1 Hz), 115.69, 114.48, 62.34, 61.43, 57.97, 52.84, 52.78, 
52.43, 31.92, 31.11, 30.84, 18.75, 17.67; HRMS (M+H)
+ 
calcd for C24H33FN3O5S 
+ (M+H) 
required 494.2125, found 494.3777.   
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(R)-Methyl 2-((N-(1-(3,4-dihydroxybenzyl)piperidin-4-yl)-N-(3-fluorophenyl)sulfamoyl)- 
amino)-3-methylbutanoate (2.24) 
 
A solution of 2.19 (0.16 g, 0.41 mmol), 3,4-dihydroxybenzaldehyde (0.06 g, 0.45 mmol) 
in CH2Cl2 (10 mL) was treated with NaBH(OAc)3 (0.29 g, 1.36 mmol) at room temperature and 
stirred for 2 hrs.  To a reaction mixture was added glacial acetic acid (0.05 mL, 0.87 mmol) at 0 
ºC and stirred overnight.  A reaction mixture was quenched with aqueous NaHCO3 solution and 
extracted with CH2Cl2 (100 mL X 2) and then the combined organic layer was dried over MgSO4, 
filtered, evaporated, and purified by the ISCO-Flash column chromatography in 0% to 40% of 
EtOAc in hexane to get white solid as a product 2.24 (0.06 g, 28.5%).  
 
Analytical data for 2.24: Rf = 0.07 (Sol. EtOAc:Hexane = 1/1); []25D = + 2.033 (c = 0.246, 
CH2Cl2); FTIR (neat) 3283, 2964, 2875, 2360, 2257, 1737, 1667, 1607, 1592, 1486, 1445, 1339, 
1266, 1206, 1161, 1139, 1055, 982, 912, 787, 731, 693, 650, 604 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.23 (ddd, J = 15.5, 7.9, 0 Hz, 1H), 6.98 (t, J = 7.5 Hz, 1H), 6.91 (d, J = 7.8 Hz, 1H), 
6.84 (d, J = 9.3 Hz, 1H), 6.62–6.47 (m, 3H), 5.50 (bs, 3H), 3.87 (t, J = 11.5 Hz, 1H), 3.71 (s, 1H), 
3.69 (s, 3H), 3.37 (s, 2H), 2.95 (d, J = 10.2 Hz, 2H), 2.13 (t, J = 11.5 Hz, 2H), 1.98 (dq, J = 11.6, 
6.8 Hz, 1H), 1.84 (ddd, J = 47.1, 11.4, 0 Hz, 2H), 1.53–1.43 (m, 2H), 0.89 (d, J = 6.8 Hz, 3H), 
0.84 (d, J = 6.8 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 172.45, 162.29 (d, J = 249.5 Hz), 
144.70, 144.27, 137.49 (d, J = 9.1 Hz), 129.94 (d, J = 9.1 Hz), 127.12, 122.11, 118.67, 118.45, 
116.91,115.89 (d, J = 20.2 Hz), 114.93, 61.63, 61.52, 57.04, 52.44, 52.12, 51.99, 31.83, 30.04, 
29.72, 18.76, 17.69; HRMS (M+H)+
 
calcd for C24H33FN3O6S 
+ (M+H) required 510.2074, found 
510.2185.   
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tert-Butyl 4-(butylamino)piperidine-1-carboxylate (2.14) 
 
To a solution of 1-Boc-4-piperidone (6.28 g, 31.50 mmol) and butylamine (3.10 mL, 
31.24 mmol) in CH2Cl2 (200 mL) was added NaBH(OAc)3 at 0 °C and stirred for 2 hrs. To a 
reaction mixture was added glacial acetic acid (3.6 mL, 62.89 mmol) at 0 °C and stirred at 
ambient temperature overnight.  The reaction mixture was washed with saturated aqueous 
NaHCO3 solution.  The mixture was extracted with CH2Cl2 (150 mL X 3) and then the combined 
organic layer was dried over MgSO4, filtered, and evaporated to a product 2.14 as a colorless oil 
with spectral data identical to those previously reported.1  It used without further purification.  
 
Analytical data for 2.14: FTIR (neat) 3711, 2960, 2933, 2862, 2383, 2368, 1683, 1422, 
1365, 1274, 1239, 1159, 865, 732, 649 cm-1; HRMS (M+H)+
 
calcd for C14H29N2O2 
+ (M+H) 
required 257.2224, found 257.2230.   
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tert-Butyl 4-((N-(tert-butoxycarbonyl)sulfamoyl)(butyl)amino)piperidine-1-carboxylate 
(2.16) 
 
A solution of the tert-butyl alcohol (1.8 mL, 18.82 mmol) in CH2Cl2 (20 mL) was treated 
with a solution of CSI (1.65 mL, 18.96 mmol) in CH2Cl2 (20 mL) at 0 °C.  This mixture was 
cannulated to a solution of 2.14 and Et3N (3.3 mL, 23.68 mmol) in CH2Cl2 (20 mL). The reaction 
mixture was stirred at ambient temperature for overnight.  The reaction mixture was extracted 
with CH2Cl2 (150 mL X 3) and the combined organic layer was dried over MgSO4, filtered, 
evaporated, and purified by the ISCO-Flash column chromatography in 0% to 40% of EtOAc in 
hexane to get white oil as a product 2.16 (4.66 g, 68%).  
 
Analytical data for 2.16: Rf = 0.69 (Sol. EtOAc:Hexane = 1/1); FTIR (neat) 3259, 2974, 
2935, 2873, 1734, 1668, 1436, 1366, 1244, 1136, 1022, 916, 869, 829, 771, 729, 604 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.49 (s, 1H), 4.27–4.24 (m, 1H), 4.13 (ddd, J = 14.3, 7.1, 2.9 Hz, 2H), 
3.91–3.83 (m, 1H), 3.27 (t, J = 8.0 Hz, 2H), 2.76 (t, J = 11.6 Hz, 2H), 1.81 (d, J = 11.5 Hz, 2H), 
1.64–1.53 (m, 2H), 1.48 (d, J = 2.6 Hz, 9H), 1.47 (d, J = 2.7 Hz, 9H), 1.31 (dd, J = 8.9, 6.2 Hz, 
2H), 1.26 (m, 2H), 0.91 (td, J = 7.2, 2.6 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 171.43, 154.81, 
150.21, 149.40, 84.57, 83.48, 80.08, 57.17, 45.20, 33.44, 28.63, 28.27, 28.09, 20.29, 13.98; 
HRMS (M+H)+
 
calcd for C19H37N3NaO6S 
+ (M+H) required 458.2295, found 458.2294.   
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(R)-tert-Butyl 4-((N-(tert-butoxycarbonyl)-N-(1-methoxy-3-methyl-1-oxobutan-2-yl)- 
sulfamoyl) (butyl)amino)piperidine-1-carboxylate (2.18) 
 
To a solution of 2.16 (0.10 g, 0.73 mmol), 2.9 (0.29 g, 0.66 mmol), and PPh3 (1.96 g, 
7.45 mmol) in THF (5 mL) was added DEAD (40% wt. in toluene, 32 mL, 1.28 mmol) at 0 ºC 
and stirred 10 min.  The reaction mixture was heated at 60 ºC.  The reaction mixture was 
quenched with 1M aqueous HCl solution and extracted with CH2Cl2 (100 mL X 3) and then the 
combined organic layer was dried over MgSO4, filtered, evaporated, and purified by the ISCO-
Flash column chromatography in 0% to 20% of EtOAc in hexane to get white oil as a product 
2.18 (0.19 g, 53%).  
 
Analytical data for 2.18: Rf = 0.8 (Sol. EtOAc:Hexane = 1/1); 
1H NMR (400 MHz, 
CDCl3) δ 4.46 (dd, J = 8.9, 2.6 Hz, 1H), 4.26–4.15 (m, 2H), 3.87 (td, J = 12.0, 3.1 Hz, 1H), 3.67 
(s, 3H), 3.51–3.43 (m, 1H), 3.21–3.05 (m, 1H), 2.70 (m, 2H), 2.43 (m, 1H), 1.81 (d, J = 11.9 Hz, 
1H), 1.67 (d, J = 12.7 Hz, 1H), 1.62–1.48 (m, 2H), 1.40 (d, J = 3.2 Hz, 9H), 1.38 (d, J = 2.7 Hz, 
9H), 1.29–1.16 (m, 4H), 1.14–1.06 (m, 6H), 0.93 (dd, J = 7.0, 2.5 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 170.61, 154.63, 150.73, 83.96, 79.73, 66.84, 56.12, 52.14, 45.59, 33.70, 31.87, 29.11, 
28.42, 28.18, 27.97, 22.37, 20.38, 20.12, 19.59, 14.48, 13.80.  
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(R)-Methyl 2-(N-butyl-N-(piperidin-4-yl)sulfamoylamino)-3-methylbutanoate 2HCl (2.20) 
 
To a solution of 2.18 (0.19 g, 0.35 mmol) in CH2Cl2 (10 mL) was added 4N HCl in 1,4-
dioxane (2.4 mL) at 0 °C and stirred overnight.  A reaction mixture was evaporated to remove 
solvent, and then the mixture was dried under reduced vacuum to furnish a white solid as a 
product 2.20. It used without further purification.   
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(R)-Methyl 2-(N-butyl-N-(1-(4-fluorobenzyl)piperidin-4-yl)sulfamoylamino)-3-methyl- 
butanoate (2.25)    
 
A solution of 2.20 (0.1481 g, 0.3507 mmol) and p-fluorobenzaldehyde (0.04 mL, 0.38 
mmol) in CH2Cl2 (20 mL) was treated with Et3N (0.15 mL, 1.08 mmol) at 0 ºC and stirred for 10 
minutes. NaBH(OAc)3 (0.23 g, 1.07 mmol) was added to a reaction mixture at 0 ºC and stirred at 
ambient temperature overnight.  The reaction mixture was extracted with CH2Cl2 (100 mL X 3) 
and then the combined organic layer was dried over MgSO4, filtered, evaporated, and purified by 
the ISCO-Flash column chromatography in 0% to 40% of EtOAc in hexane to get colorless oil as 
a product 2.25 (0.08 g, 51%).  
 
Analytical data for 2.25: Rf = 0.28 (Sol. EtOAc:Hexane = 1/1); []25D = + 7.209 (c = 
0.652, CH2Cl2); FTIR (neat) 3295, 2958, 2874, 2801, 2342, 2296, 1740, 1508, 1468, 1325, 1276, 
1166, 1153, 1133, 1015, 995, 924, 861, 828, 770, 629 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.30–
7.24 (m, 2H), 7.01 (m, 2H), 4.84, (d, J = 9.9 Hz, 1H), 3.77 (s, 3H), 3.70 (dd, J = 10.0, 5.2 Hz, 
1H), 3.53–3.47 (m, 1H), 3.46 (s, 2H), 3.10 (dd, J = 10.3, 5.0 Hz, 2H), 2.92 (d, J = 9.8 Hz, 2H), 
2.10–1.95 (m, 3H), 1.78 (dt, J = 13.5, 3.0 Hz, 2H), 1.72 (dt, J = 8.1, 4.0 Hz, 2H), 1.58 (dddd, J = 
15.8, 11.2, 7.8, 5.2 Hz, 2H), 1.37–1.20 (m, 2H), 1.01 (d, J = 6.7 Hz, 3H), 0.93 (m, 6H); 13C 
NMR (101 MHz, CDCl3) δ 173.12, 162.23 (d, J = 246.4 Hz), 134.13, 130.78 (d, J = 8.1 Hz), 
115.25 (d, J = 22.2 Hz), 77.61, 77.29, 76.97, 62.28, 61.22, 56.80, 53.36, 53.31, 52.56, 44.36, 
33.95, 31.89, 31.09, 30.77, 20.40, 19.23, 18.02, 14.04; HRMS (M+H)
+ 
calcd for C22H37FN3O4S
+ 
(M+H) required 458.2489, found 458.2465. 
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(S)-2-Hydroxy-4-methylpentanoic acid (2.26) 
 
To a solution of L-leucine (10.10 g, 77.02 mmol) in 1N H2SO4 (100 mL) was added 
dropwise a solution of NaNO2 (12.41 g, 179.86 mmol) at 0 °C and stirred overnight.  The 
reaction mixture was extracted with diethyl ether (200 mL X 3) and concentrated by azeotropic 
distillation with toluene to provide yellow solid.  A yellow solid was dried under reduced 
vacuum to furnish a crystal as white needles 2.26 (9.92 g, 97%).  
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(S)-Methyl 2-hydroxy-4-methylpentanoate (2.27) 
 
To a solution of 2.26 (9.20 g, 69.61 mmol) in methanol (100 mL) was added amberlyst-
15 ion exchange resin at room temperature and stirred for overnight.  The reaction mixture was 
filtered and evaporated to remove solvent to give yellow oil.  The yellow oil was purified by the 
ISCO-Flash column chromatography in 0% to 40% of EtOAc in hexane to get yellow oil as a 
product 2.27 (6.56 g, 64%) Rf = 0.71 (Sol. EtOAc:Hexane = 1/1, checked by KMnO4 stain 
solution). 
 
Analytical data for 2.27:  
1
H NMR (CD3CN, 400 MHz) δ 
1H NMR (400 MHz, CDCl3) δ 
4.21–4.12 (m, 1H), 3.72 (s, 3H), 2.86 (s, 1H), 1.83 (dt, J = 13.5, 6.8 Hz, 1H), 1.56–1.46 (m, 2H), 
0.89 (dd, J = 6.7, 4.1 Hz, 6H); 
13
C NMR (CDCl
3
, 101 MHz) δ 175.5, 75.3, 52.4, 32.3, 18.7, 16.2.   
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(R)-tert-Butyl 4-((N-(tert-butoxycarbonyl)-N-(1-methoxy-4-methyl-1-oxopentan-2-yl)- 
sulfamoyl)(3-fluorophenyl)amino)piperidine-1-carboxylate (2.28)  
 
To a solution of 2.15 (1.04 g, 2.20 mmol) and DIAD (2.9 mL, 6.66 mmol) in THF (20 
mL) was added a solution of 2.27 (0.36 g, 2.45 mmol) and PPh3 (1.73 g, 6.583 mmol) in THF 
(20 mL) at 0 ºC and then the reaction mixture was heated at 60 °C for overnight.  The reaction 
mixture was extracted with CH2Cl2 (150 mL X 3) and the combined organic layer was dried over 
MgSO4, filtered, evaporated, and purified by the ISCO-Flash column chromatography in 0% to 
20% of EtOAc in hexane to get white oil as a product 2.28 (1.12 g, 85%).  
 
Analytical data for 2.28:  Rf = 0.81 (Sol. EtOAc:Hexane = 1/1); []25D = + 25.000 (c = 
0.168, CH2Cl2); FTIR (neat) 2957, 2870, 1732, 1693, 1592, 1486, 1425, 1365, 1275, 1238, 1146, 
979, 884, 865, 845, 772, 718, 694, 615 cm-1;  1H NMR (400 MHz, CDCl3) δ 7.37 (ddd, J = 16.2, 
16.2, 8.2 Hz, 1H), 7.14 (dddd, J = 8.3, 8.3, 2.5, 0.8 Hz, 1H), 7.06 (dd, J = 7.9, 0.8 Hz, 1H), 6.97 
(ddd, J = 9.5, 2.3, 2.3 Hz, 1H), 4.66 (t, J = 6.6 Hz, 1H), 4.54–4.40 (m, 1H), 4.14–4.10 (m, 2H), 
3.63 (s, 2H), 2.82–2.76 (m, 2H), 2.17 (s, 2H), 2.00 (d, J = 11.4 Hz, 3H), 1.51 (s, 9H), 1.39 (s, 
9H), 1.31–1.19 (m, 3H), 0.81 (d, J = 6.3 Hz, 3H), 0.76 (d, J = 6.3 Hz, 3H); 13C NMR (101 MHz, 
CDCl3) δ 170.97, 162.54 (d, J = 248.5 Hz), 154.66, 150.69, 135.85 (d, J = 10.1 Hz), 129.98 (d, J 
= 9.1 Hz), 128.95, 120.22 (d, J = 22.2 Hz), 116.69 (d, J = 21.2 Hz), 84.64, 79.90, 59.59, 52.45, 
40.44, 31.80, 31.15, 28.56, 28.24, 25.02, 23.05, 22.87, 22.13, 14.34; HRMS (M+Na)
+ 
calcd for 
C28H44FN3NaO8S
 + (M+Na) required Exact Mass: 624.2725, found 624.2726.  
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(R)-Methyl 2-(N-(3-fluorophenyl)-N-(piperidin-4-yl)sulfamoylamino)-4-methylpentanoate 
 2HCl (2.29) 
N
F
NH
S
N
H
O O
MeO
O 2HCl
 
To a solution of 2.28 (1.12 g, 1.87 mmol) in CH2Cl2 (40 mL) was added 4N HCl in 1,4-
dioxane (4 mL) at 0 °C and stirred overnight.  A reaction mixture was evaporated to remove 
solvent, and then the mixture was dried under reduced vacuum to furnish a white solid as a 
product 2.29. It used without further purification.   
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(R)-Methyl 2-(N-(3-fluorophenyl)-N-(1-(4-(trifluoromethyl)benzyl)piperidin-4- 
yl)sulfamoyl-amino)-4-methylpentanoate (2.30) 
 
A solution of 2.29 (0.07 g, 0.15 mmol), 4-trifluoromethylbenzaldehyde (0.03 g, 0.17 
mmol) in CH2Cl2 (3 mL) was treated with Et3N (0.06 mL, 0.43 mmol) and NaBH(OAc)3 (0.10 g, 
0.47 mmol) at room temperature and stirred for overnight.  A reaction mixture was quenched 
with aqueous NaHCO3 solution and extracted with CH2Cl2 (50 mL X 3) and then the combined 
organic layer was dried over MgSO4, filtered, evaporated, and purified by the ISCO-Flash 
column chromatography in 0% to 30% of EtOAc in hexane to get colorless syrup as a product 
2.30 (0.04 g, 44%). 
 
Analytical data for 2.30:  Rf = 0.61 (Sol. EtOAc:Hexane = 1/1); []25D = + 6.320 (c = 
0.269, CH2Cl2); FTIR (neat) 3280, 2956, 2872, 2383, 2368, 2342, 1744, 1606, 1592, 1485, 1435, 
1324, 1160, 1120, 1064, 1018, 981, 822, 787, 692, 644 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.49 
(d, J = 8.1 Hz, 2H), 7.32 (d, J = 7.5 Hz, 2H), 7.30–7.21 (m, 1H), 7.09–7.01 (m, 2H), 6.94 (dt, J = 
9.6, 2.3 Hz, 1H), 4.92 (d, J = 9.5 Hz, 1H), 3.98–3.82 (m, 2H), 3.78–3.64 (m, 3H), 3.61 (ddd, J = 
9.3, 6.6, 4.3 Hz, 1H), 3.45 (s, 2H), 2.88–2.80 (m, 2H), 2.06 (td, J = 11.8, 2.6 Hz, 2H), 1.94–1.78 
(m, 2H), 1.66 (dq, J = 13.3, 6.6 Hz, 1H), 1.53–1.36 (m, 2H), 1.27–1.18 (m, 1H), 0.87 (d, J = 6.5 
Hz, 6H); 13C NMR (101 MHz, CDCl3) δ 173.53, 162.66 (d, J = 249.5 Hz), 142.39, 138.06 (d, J = 
10.1 Hz), 130.07 (d, J = 9.1 Hz), 129.42, 129.35 (d, J = 5.0 Hz), 127.68 (d, J = 3.0 Hz), 125.39 
(d, J = 3.0 Hz), 125.31 (d, J = 4.0 Hz), 119.11 (d, J = 21.2 Hz), 116.02 (d, J = 21.2 Hz), 62.28, 
58.29, 55.09, 53.63, 53.13, 52.73, 42.99, 31.64, 31.41, 24.55, 22.74, 22.23; HRMS (M+H)
+ 
calcd 
for C26H34F4N3O4S
+ (M+H) required 560.2206, found 560.2542. 
180 
 
tert-Butyl 4-(4-fluorophenylamino)piperidine-1-carboxylate (2.31) 
 
To a solution of 1-Boc-4-piperidone (5.28 g, 26.49 mmol) and p-fluoroaniline (2.54 mL, 
26.45 mmol) in CH2Cl2 (60 mL) was added NaBH(OAc)3 (9.73 g, 45.90 mmol) at 0 °C and 
stirred for 2 hrs.  To a reaction mixture was added glacial acetic acid (3 mL, 52.41 mmol) at 0 °C 
and stirred at ambient temperature overnight.  The reaction mixture was washed with saturated 
aqueous NaHCO3 solution.  The mixture was extracted with CH2Cl2 (200 mL X 3) and then the 
combined organic layer was dried over MgSO4, filtered, evaporated, and purified by the ISCO-
Flash column chromatography in 0% to 40% of EtOAc in hexane to get white solid as a product 
2.31 (5.51 g, 71%).  
 
Analytical data for 2.31:  Rf = 0.75 (Sol. EtOAc:Hexane = 1/1); FTIR (neat) 3355, 2982, 
2945, 2923, 2847, 1670, 1612, 1530, 1505, 1419, 1366, 1316, 1233, 1139, 1097, 973, 858, 821, 
773, 645 cm-1; 1H NMR (400 MHz, CD3OD) δ 6.88–6.80 (m, 2H), 6.69–6.59 (m, 2H), 4.85 (s, 
1H), 4.01 (ddd, J = 13.6, 3.4, 3.4 Hz, 2H), 3.38 (tt, J = 10.2, 3.9 Hz, 1H), 2.97-2.91 (m, 2H), 1.96 
(dd, J = 13.3, 3.3 Hz, 2H), 1.45 (s, 9H), 1.29 (dddd, J = 13.0, 11.4, 10.2, 4.2 Hz, 2H); 13C NMR 
(101 MHz, CD3OD) δ 156.83, 154.79 (d, J = 57.6 Hz), 143.83, 114.88 d, J = 22.2 Hz), 114.50 (d, 
J = 7.1 Hz), 79.58, 50.34, 31.63, 27.25; HRMS (M+H)
+ 
calcd for C16H23FN2NaO2
+ (M+H) 
required 317.1336, found 317.1640. 
181 
 
(S)-tert-Butyl 4-((4-fluorophenyl)(N-(1-methoxy-3-methyl-1-oxobutan-2-yl)sulfamoyl) 
amino)-piperidine-1-carboxylate (2.34) 
 
To a solution of sulfuryl chloride (0.30 mL, 3.70 mmol) in CH2Cl2 (20 mL) was added L-
valine methyl ester (0.62 g, 3.70 mmol) in CH2Cl2 (20 mL) slowly at 0 ºC and stirred for 30 
minutes to obtain 2.32.  A solution of 2.31 (0.31 g, 1.06 mmol) and Et3N (1.3 mL, 9.33 mmol) in 
CH2Cl2 (20 mL) was treated with a solution of 2.32 at 0 ºC and stirred for overnight. The reaction 
mixture was evaporated and purified by the ISCO-Flash column chromatography in 0% to 30% 
of EtOAc in hexane to get colorless syrup as a product 2.34 (0.38 g, 73%).  
 
Analytical data for 2.34: Rf = 0.71 (Sol. EtOAc:Hexane = 1/1); []25D = - 4.52 (c = 0.310, 
CH2Cl2); FTIR (neat) 3274, 2969, 2935, 2871, 2383, 2324, 1740, 1682, 15061427, 1365, 1335, 
1275, 1263, 1250, 1210, 1164, 1135, 1092, 1056, 1092, 1056, 955, 935, 869, 822, 737, 703, 642, 
612 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.17 (dd, J = 8.2, 5.1 Hz, 2H), 7.02 (dd, J = 8.8, 8.8 Hz, 
2H), 5.08 (d, J = 9.4 Hz, 1H), 4.14–4.05 (m, 2H), 3.98 (tt, J = 11.9, 3.1 Hz, 1H), 3.74 (dd, J = 9.4, 
5.1 Hz, 1H), 3.71 (s, 3H), 2.71 (dd, J = 11.8, 11.8 Hz, 2H), 2.00 (qd, J = 19.0, 6.3 Hz, 1H), 1.91 
(d, J = 12.4 Hz, 1H), 1.81 (d, J = 12.3 Hz, 1H), 1.36 (s, 9H), 1.29–1.14 (m, 2H), 0.91 (d, J = 6.8 
Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 172.56, 162.66 (d, J = 249.5 
Hz), 154.60, 133.60 (d, J = 9.1 Hz), 132.19 (d, J = 3.0 Hz), 116.14 (d, J = 23.2 Hz), 79.93, 61.73, 
58.11, 53.66, 52.59, 43.37, 32.11, 31.75, 31.45, 28.52, 18.98, 17.96; HRMS (M+Na)
+ 
calcd for 
C22H34FN3NaO6S
 + (M+Na) required 510.2045, found 510.2040. 
182 
 
(S)-Methyl 2-(N-(4-fluorophenyl)-N-(piperidin-4-yl)sulfamoylamino)-3-methylbutanoate  
2HCl (2.36) 
 
To a solution of 2.34 (0.38 g, 0.78 mmol) in CH2Cl2 (40 mL) was added 4N HCl in 1,4-
dioxane (4 mL) at 0 °C and stirred overnight.  A reaction mixture was evaporated to remove 
solvent, and then the mixture was dried under reduced vacuum to furnish a white solid as a 
product 2.36. It used without further purification.   
183 
 
(S)-Methyl 2-(N-(1-(4-fluorobenzyl)piperidin-4-yl)-N-(4-fluorophenyl)sulfamoylamino)-3- 
methylbutanoate (2.38) 
 
To a solution of 2.36 (0.05 g, 0.12 mmol) and 4-fluorobenzaldehyde (14 μL, 0.13 mmol) 
in CH2Cl2 (10 mL) was treated with Et3N (18 μL, 0.13 mmol) and NaBH(OAc)3 (0.08 g, 0.37 
mmol) at 0 °C and stirred overnight.  The reaction mixture was evaporated, and purified by the 
ISCO-Flash column chromatography in 0% to 60% of EtOAc in hexane to get colorless solid oil 
as a product 2.38 (0.04 g, 63%). 
 
Analytical data for 2.38: Rf = 0.43 (Sol. EtOAc:Hexane = 1/1); []25D = - 5.031 (c = 0.318, 
CH2Cl2);  FTIR (neat) 3280, 2958, 2927, 2854, 2383, 2368, 2185, 1738, 1603, 1505, 1454, 1337, 
1208, 1161, 1133, 1057, 960, 871, 823, 740, 622 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.22–7.15 
(m, 4H), 7.03 (t, 2H), 6.94 (t, J = 8.6 Hz, 2H), 5.30 (s, 1H), 4.93 (d, J = 9.4 Hz, 1H), 3.87 (tt, J = 
12.0, 4.0 Hz, 1H), 3.76 (dd, J = 9.5, 5.0 Hz, 1H), 3.73 (s, 3H), 3.39 (s, 2H), 2.86 (d, J = 10.9 Hz, 
2H), 2.09–1.98 (m, 3H), 1.95–1.88 (m, 1H), 1.80 (dq, J = 8.5, 2.6 Hz, 1H), 1.84–1.78 (m, 1H), 
1.41 (dddd, J = 15.6, 12.2, 6.1, 3.1 Hz, 2H), 0.93 (d, J = 6.8 Hz, 3H), 0.88 (d, J = 6.9 Hz, 3H); 
13C NMR (101 MHz, CDCl3) δ 172.37, 162.41 (d, J = 250.5 Hz), 162.11 (d, J = 246.4 Hz), 
133.42, 133.34, 131.96 (d, J = 4.4 Hz), 130.80 (d, J = 8.1 Hz), 115. 87 (d, J = 22.2 Hz), 115.11 
(d, J = 21.2 Hz), 61.56, 61.42, 57.67, 52.57, 52.52, 52.40, 31.91, 31.09, 30.78, 18.76, 17.68; 
HRMS (M+H)
+ 
calcd for C24H32F2N3O4S
+ (M+H) required 496.2076, found 496.2074.  
184 
 
(S)-Methyl 2-(N-(4-fluorophenyl)-N-(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)sulfamoyl- 
amino)-3-methylbutanoate (2.39) 
 
To a solution of 2.36 (0.05 g, 0.12 mmol) and 4-trifluorobenzaldehyde (18 μL, 0.13 
mmol) in CH2Cl2 (10 mL) was treated with Et3N (18 μL, 0.13 mmol) and NaBH(OAc)3 (0.08 g, 
0.37 mmol) at 0 °C and stirred overnight.  The reaction mixture was evaporated, and purified by 
the ISCO-Flash column chromatography in 0% to 60% of EtOAc in hexane to get colorless solid 
oil as a product 2.39 (0.06 g, 83%).  
 
Analytical data for 2.39: Rf = 0.70 (Sol. EtOAc:Hexane = 1/1); []25D = - 3.786 (c = 
0.449, CH2Cl2);  FTIR (neat) 3295, 2956, 2924, 2853, 2342, 2300, 1739, 1619, 1602, 1506, 1454, 
1421, 1323, 1262, 1209, 1161, 1121, 1064, 1018, 959, 931, 871, 822, 740, 621 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.51 (d, J = 8.1 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 7.16–7.11 (m, 2H), 7.01–
6.95 (m, 2H), 4.96 (d, J = 9.4 Hz, 1H), 3.82 (tt, J = 12.1, 3.7 Hz, 1H), 3.69 (dd, J = 9.4, 5.0 Hz, 
1H), 3.66 (s, 3H), 3.41 (s, 2H), 2.79 (d, J = 11.0 Hz, 2H), 2.02 (t, J = 11.2 Hz, 2H), 1.95 (dq, J = 
12.9, 7.1 Hz, 1H), 1.88–1.83 (m, 1H), 1.77–1.72 (m, 1H), 1.36 (ddd, J = 12.3, 8.8, 3.8 Hz, 2H), 
0.87 (d, J = 6.8 Hz, 3H), 0.81 (d, J = 6.3 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 172.48, 162.51 
(d, J = 250.5 Hz), 142.31, 133.52 (d, J = 8.1 Hz), 132.19 (d, J = 4.0 Hz), 129.22, 125.26 (d, J = 
4.4 Hz), 125.19 (d, J = 3.0 Hz), 115.93 (d, J = 22.2 Hz), 62.17, 61.54, 57.96, 53.05, 52.99, 52.46, 
32.01, 31.52, 31.21, 18.84, 17.79; HRMS (M+H)
+ 
calcd for C25H32F4N3O4S
+ (M+H) required 
546.2044, found 546.2049.  
 
185 
 
(R)-tert-Butyl 4-((4-fluorophenyl)(N-(1-methoxy-3-methyl-1-oxobutan-2-yl)sulfamoyl) 
amino)piperidine-1-carboxylate (2.35) 
 
To a solution of sulfuryl chloride (0.48 mL, 5.92 mmol) in CH2Cl2 (40 mL) was added D-
valine methyl ester (1.00 g, 5.97 mmol) in CH2Cl2 (20 mL) slowly at 0 ºC and stirred for 4 hrs to 
furnish 2.33.  To a solution of 2.27 (0.95 g, 3.22 mmol) and Et3N (2.50 mL, 17.94 mmol) in 
CH2Cl2 (20 mL) was added 2.33 solution at 0 ºC and stirred for overnight.  The reaction mixture 
was evaporated and purified by the ISCO-Flash column chromatography in 0% to 30% of EtOAc 
in hexane to get colorless syrup as a product 2.35 (1.50 g, 95%).  
 
Analytical data for 2.35: Rf = 0.68 (Sol. EtOAc:Hexane = 1/1); []25D = - 1.199 (c = 
0.584, CH2Cl2);  FTIR (neat) 3333, 2991, 2924, 2853, 1666, 1611, 1588, 1524, 1448, 1430, 1366, 
1342, 1249, 1233, 1167, 1139, 1099, 1076, 998, 936, 821, 756, 627 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.19–7.14 (m, 2H), 7.07–6.96 (m, 2H), 4.95 (dd, J = 9.0, 4.8 Hz, 1H), 4.15–4.05 (m, 
2H), 3.97 (tt, J = 7.4, 5.0 Hz, 2H), 3.76–3.71 (m, 4H), 2.70 (t, J = 11.5 Hz, 2H), 1.86 (m, 2H), 
1.34 (s, 9H), 1.27–1.16 (m, 2H), 0.91 (t, J = 6.4 Hz, 3H), 0.86 (t, J = 5.7 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ 172.29, 162.44 (d, J = 250.5 Hz), 154.37, 133.34 (d, J = 9.1 Hz), 131.90, 115.92 
(d, J = 22.2 Hz), 79.72, 61.47, 61.12, 57.93, 52.39, 43.14, 31.92, 31.52, 31.23, 28.30, 18.74, 
17.68. 
186 
 
(R)-Methyl 2-(N-(4-fluorophenyl)-N-(piperidin-4-yl)sulfamoylamino)-3-methylbutanoate 
 2HCl (2.37) 
 
To a solution of 2.35 (1.50 g, 3.08 mmol) in CH2Cl2 (60 mL) was added 4N HCl in 1,4-
dioxane (6 mL) at 0 °C and stirred overnight.  A reaction mixture was evaporated to remove 
solvent, and then the mixture was dried under reduced vacuum to furnish a white solid as a 
product 2.37.  It used without further purification.   
187 
 
(R)-Methyl 2-(N-(1-(4-fluorobenzyl)piperidin-4-yl)-N-(4-fluorophenyl)sulfamoylamino)-3- 
methylbutanoate (2.40) 
 
To a solution of 2.37 (0.11 g, 0.26 mmol), 4-fluorobenzaldehyde (0.04 g, 0.32 mmol) and 
Et3N (0.04 mL, 0.29 mmol) in CH2Cl2 (18 mL) was treated with NaBH(OAc)3 (0.17 g, 0.78 
mmol) at 0 °C and stirred overnight.  The reaction mixture was evaporated, and purified by the 
ISCO-Flash column chromatography in 0% to 30% of EtOAc in hexane to get colorless syrup as 
a product 2.40 (0.07 g, 51%). 
   
Analytical data for 2.40: Rf = 0.42 (Sol. EtOAc:Hexane = 1/1); []25D = + 3.767 (c = 
0.584, CH2Cl2); FTIR (neat) 3293, 2956, 2933 2383, 2325, 2299, 1738, 1603, 1505, 1468, 1453, 
1435, 1337, 1259, 1208, 1162, 1132, 1058, 960, 931, 823, 740, 619 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.21–7.16 (m, 4H), 7.05–7.01 (m, 2H), 6.97–6.92 (m, 2H), 4.98 (d, J = 9.4 Hz, 1H), 
3.91–3.82 (m, 1H), 3.75 (ddd, J = 9.8, 5.2, 1.8 Hz, 1H), 3.72 (s, 3H), 3.40 (s, 2H), 2.87 (d, 2H), 
2.08–1.96 (m, 2H), 1.94–1.87 (m, 2H), 1.80 (d, J = 12.4 Hz, 1H), 1.48–1.36 (m, 2H), 0.92 (dd, J 
= 6.8, 1.7 Hz, 3H), 0.87 (dd, J = 6.9, 1.7 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 172.63, 162.64 
(d, J = 250.5 Hz), 162.26 (J = d, 246.4 Hz), 133.68 (d, J = 8.7 Hz), 133.52, 132.32 (d, J = 3.3 
Hz), 130.88 (d, J = 7.9 Hz), 116.05 (d, J = 22.6 Hz), 115.25 (d, J = 21.2 Hz), 61.99, 61.68, 58.12, 
52.95, 52.90, 52.61, 32.16, 31.53, 31.23, 18.99, 17.94; HRMS (M+H)
+ 
calcd for C24H32F2N3O4S
+ 
(M+H) required 496.2081, found 496.2543. 
188 
 
(R)-Methyl 2-(N-(4-fluorophenyl)-N-(1-(4-(trifluoromethyl)benzyl)piperidin-4-yl)sulfamoyl 
-amino)-3-methylbutanoate (2.41) 
 
To a solution of 2.37 (0.12 g, 0.29 mmol) and 4-trifluorobenzaldehyde (0.06 g, 0.32 
mmol) in CH2Cl2 (18 mL) was treated with Et3N (0.04 mL, 0.29 mmol) and NaBH(OAc)3 (0.18 
g, 0.87 mmol) at 0 °C and stirred overnight.  The reaction mixture was evaporated, and purified 
by the ISCO-FlashColumn chromatography in 0% to 30% of EtOAc in hexane to get colorless 
syrup as a product 2.41 (0.0779 g, 50%).  
 
Analytical data for 2.41: Rf = 0.67 (Sol. EtOAc:Hexane = 1/1); []25D = + 2.734 (c = 
0.695, CH2Cl2); FTIR (neat) 3242, 2957, 2804, 2326, 2299, 1739, 1614, 1601, 1574, 1505, 1469, 
1324, 1263, 1209, 1161, 1126, 1066, 1018, 961, 871, 822, 740, 622 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 7.52 (d, J = 8.3 Hz, 2H), 7.35 (d, J = 8.2 Hz, 2H),7.22–7.19 (m, 2H), 7.04 (dd, J = 8.4, 
8.4 Hz, 2H), 4.92 (d, J = 9.4 Hz, 1H), 3.89 (tt, J = 12.0, 3.8 Hz, 1H), 3.77 (dd, J = 9.4, 5.1 Hz, 
1H), 3.73 (d, J = 0.5 Hz, 3H), 3.48 (s, 2H), 2.86 (d, J = 11.5 Hz, 2H), 2.10 (ddd, J = 11.8, 11.8, 
1.8 Hz, 2H), 2.02 (qd, J = 11.4, 4.7 Hz, 1H), 1.94–1.79 (m, 2H), 1.44 (dddd, J = 34.9, 18.7, 14.7, 
10.8 Hz, 2H), 0.95 (d, 6.8 Hz, 3H), 0.89 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
172.48, 162.51 (d, J = 248.9 Hz),, 142.31, 133.52 (d, J = 8.7 Hz), 132.19 (d, J = 3.3 Hz), 129.22, 
125.26 (d, J = 3.7 Hz), 125.18 (d, J = 3.8 Hz), 115.93 (d, J = 22.6 Hz), .62.17, 61.54, 57.96, 
53.05, 52.99, 52.46, 52.45, 32.01, 31.52, 31.21, 18.84, 17.79; HRMS (M+H)
+ 
calcd for 
C25H32F4N3O4S
+ (M+H) required 546.2049, found 546.2187. 
189 
 
(S)-Methyl 2-((N-(1-(4-fluorobenzoyl)piperidin-4-yl)-N-(4-fluorophenyl)sulfamoyl)amino)- 
3-methylbutanoate (2.42) 
 
A solution of 2.36 (0.09 g, 0.22 mmol), Et3N (0.09 mL, 0.65 mmol) and 4-fluorobenzoyl 
chloride (0.04 g, 0.24 mmol) in THF (10 mL) was stirred at room temperature for overnight.  
The reaction mixture was evaporated, and purified by the ISCO-Flash column chromatography 
in 0% to 50% of EtOAc in hexane to get colorless syrup as a product 2.42 (0.09 g, 83%). 
 
Analytical data for 2.42: Rf = 0.35 (Sol. EtOAc:Hexane = 1/1); []25D = - 1.232 (c = 
0.0594, CH2Cl2); FTIR (neat) 3334, 2937, 2863, 2383, 2368, 1737, 1672, 1614, 1505, 1431, 
1366, 1339, 1233, 1167, 1138, 1058, 1014, 961, 936, 845, 822, 759, 737, 663, 617 cm-1; 1H 
NMR (400 MHz, CDCl3) δ 7.24 (dd, J = 8.4, 5.4 Hz, 2H), 7.12 (dd, J = 8.8, 5.0 Hz, 2H), 7.01 (d, 
J = 8.5 Hz, 2H), 6.97 (d, J = 8.6 Hz, 2H), 5.08 (d, J = 9.4 Hz, 1H), 4.06 (ddt, J = 11.0, 7.2, 3.7 
Hz, 1H), 3.69 (dd, J = 9.5, 5.1 Hz, 1H), 3.66 (s, 3H), 3.00 (m, 1H), 2.74 (m, 1H), 1.95 (dt, J = 
13.6, 5.1 Hz, 2H), 1.84 (m, 2H), 1.36–1.25 (m, 2H), 1.18 (t, J = 6.9 Hz, 1H), 0.86 (d, J = 6.8 Hz, 
3H), 0.81 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 172.35, 169.28, 163.37 (d, J = 
251.5 Hz), 162.51 (d, J = 250.5 Hz), 133.61 (d, J = 9.1 Hz), 131.78 (d, J = 3.0 Hz), 131.43 (d, J 
= 4.0 Hz), 129.24 (d, J = 8.1 Hz), 116.12 (d, J = 23.2 Hz), 115.52 (d, J = 22.2 Hz), 61.50, 57.58, 
52.43, 31.86, 18.77, 17.68; HRMS (M+H)
+ 
calcd for C24H30F2N3O5S
+ (M+H) required 510.1874, 
found 510.3023. 
190 
 
(R)-Methyl 2-((N-(1-(4-fluorobenzoyl)piperidin-4-yl)-N-(4-fluorophenyl)sulfamoyl)amino)- 
3-methylbutanoate (2.43) 
 
A solution of 2.37 (0.11 g, 0.27 mmol), Et3N (0.11 mL, 0.79 mmol) and 4-fluorobenzoyl 
chloride (0.03 mL, 0.25 mmol) in THF (10 mL) was stirred at room temperature for overnight.  
The reaction mixture was evaporated, and purified by the ISCO-Flash column chromatography 
in 0% to 50% of EtOAc in hexane to get colorless syrup as a product 2.43 (0.07 g, 51%). 
 
 Analytical data for 2.43: Rf = 0.33 (Sol. EtOAc:Hexane = 1/1); []25D = + 1.146 (c = 
0.584, CH2Cl2); FTIR (neat) 3261, 2961, 2927, 2856, 2366, 1739, 1622, 1604, 1505, 1435, 1336, 
1155, 1138, 1062, 955, 935, 846, 760, 739, 704, 641, 615cm-1; 1H NMR (400 MHz, CDCl3) δ 
7.28 (dd, J = 8.6, 5.4 Hz, 2H), 7.17 (dd, J = 8.8, 4.9 Hz, 2H), 7.04 (q, J = 8.8 Hz, 4H), 5.02 (d, J 
= 9.4 Hz, 1H), 4.72 (s, 1H), 4.11 (tt, J = 11.9, 2.3 Hz, 1H), 3.78–3.73 (dd, J = 9.4, 5.0 Hz, 1H), 
3.71 (s, 3H), 3.20–2.93 (bm, 2H), 2.92–2.63 (bm, 2H), 2.00 (ddd, J = 8.8, 8.8, 6.8 Hz, 2H), 1.95– 
1.76 (bm, 2H), 0.92 (d, J = 6.8 Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 
172.33, 169.30, 163.38 (d, J = 251.5 Hz), 162.52 (d, J = 250.5 Hz), 133.29 (d, J = 9.1 Hz), 
131.73 (d, J = 3.0 Hz), 131.39 (d, J = 3.0 Hz), 129.23 (d, J = 9.1 Hz), 116.22 (d, J = 22.2 Hz), 
115.53 (d, J = 22.2 Hz), 61.48, 57.62, 52.45, 31.88, 29.67, 18.76, 17.64; HRMS (M+H)
+ 
calcd 
for C24H30F2N3O5S
+ (M+H) required 510.1874, found 510.3173. 
191 
 
Piperidin-4-one hydrochloride (2.44) 
 
4N HCl (30 mL) in 1,4-dioxane was added to a solution of 4-Boc-1-piperidone (5.18 g, 
26.00 mmol) at 0 °C and stirred overnight at room temperature.  The mixture was evaporated to 
get white solid as a product 2.44. It was used for next reaction without further purification.  
192 
 
1-(4-Fluorobenzyl)piperidin-4-one (2.45) 
 
 
NaBH(OAc)3 (16.67 g, 78.77 mmol) was added to a solution of 4-fluorobenzaldehyde (3.1 
mL, 28.90 mmol) and 2.44 (3.53 g, 26.00 mmol) in CH2Cl2 (100 mL) at 0 °C and stirred at room 
temperature for overnight.  The mixture was quenched with NaHCO3 and extracted with CH2Cl2 
(200 mL X 3) and the combined organic layer was dried over MgSO4.  The mixture was filtered, 
concentrated, and purified by the ISCO-Flash column chromatography in 0% to 40% of EtOAc 
in hexane to furnish colorless syrup as a product 2.45 (4.29 g, 80%). 
 
Analytical data for 2.45: Rf = 0.29 (Sol. EtOAc:Hexane = 1/1); 
1H NMR (400 MHz, 
CDCl3) δ 7.26 (dd, J = 8.4, 5.5 Hz, 2H), 6.95 (dd, J = 8.7, 8.7, 2H),  3.51 (s, 2H), 2.66 (t, J = 5.9 
Hz, 4H), 2.37 (t, J = 5.9 Hz, 4H); 13C NMR (101 MHz, CDCl3) δ 209.16, 162.26 (d, J = 246.4 
Hz), 134.0 (d, J = 3.0 Hz), 130.62 (d, J = 8.1 Hz), 115.35 (d, J = 21.2 Hz), 61.22, 52.92, 41.33. 
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1-(4-Fluorobenzyl)-N-(3-fluorophenyl)piperidin-4-amine (2.46) 
 
NaBH(OAc)3 (13.45 g, 63.44 mmol) was added to a solution of 2.45 (4.29 g, 20.72 mmol) 
and p-fluoroaniline (2.60 mL, 27.05 mmol) in CH2Cl2 (50 mL) at 0 °C and stirred for 2 hrs.  
Acetic acid (2.40 mL, 41.93 mmol) was treated at 0 °C and stirred for overnight at room 
temperature.  The mixture was transferred to a separatory funnel using CH2Cl2 (100 mL) and 
distilled water (50 mL).  The mixture was extracted with CH2Cl2 (100 mL X 3) and EtOAc (100 
mL) and the combined organic layer was dried over MgSO4.  The mixture was filtered, 
concentrated, and purified by the ISCO-Flash column chromatography in 0% to 40% of EtOAc 
in hexane to furnish white solid as a product 2.46 (4.03 g, 64%).  
 
Analytical data for 2.46: Rf = 0.19 (Sol. EtOAc:Hexane = 1/1); 
1H NMR (400 MHz, 
CDCl3) δ 7.28 (dd, J = 8.7, 5.6 Hz, 2H), 7.07 (ddd, J = 8.1, 8.1, 4.6 Hz, 1H), 7.04–6.98 (dd, J = 
8.7, 8.7 Hz, 2H), 6.35 (ddd, J = 10.6, 8.2, 2.4 Hz, 2H), 6.27 (ddd, J = 11.8, 2.3, 2.3 Hz, 1H), 3.66 
(d, J = 7.8 Hz, 1H), 3.48 (s, 2H), 3.22–3.29 (m, 1H), 2.82 (d, J = 12.0 Hz, 2H), 2.13 (ddd, J = 
11.4, 11.4, 2.9 Hz, 2H), 2.05–2.00 (m, 2H), 1.47 (dddd, J = 10.8, 10.8, 10.8, 3.7 Hz, 2H); 13C 
NMR (101 MHz, CDCl3) δ 164.53 (d, J = 223.2 Hz), 162.11 (d, J = 225.2 Hz), 149.14 (d, J = 
10.1 Hz), 134.37 (d, J = 3.0 Hz), 130.73 (d, J = 8.1 Hz), 130.55 (d, J = 10.1 Hz), 115.24 (d, J = 
21.2 Hz), 109.26 ((d, J =2.0 Hz), 103.67 (d, J = 21.2 Hz), 99.81 (d, J = 25.3 Hz), 62.50, 52.41, 
50.19, 32.62. 
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(S)-Methyl 2-((N-(1-(4-fluorobenzyl)piperidin-4-yl)-N-(3-fluorophenyl)sulfamoyl)amino)-3-
methylbutanoate (2.47) 
N
N
S
N
H
O O
O
MeO
F
F
 
A mixture of L-valine methylester HCl (0.06 g, 0.37 mmol) in CH2Cl2 (20 mL) was 
added slowly to a solution of sulfuryl chloride (0.03 mL, 0.37 mmol) at 0 °C and stirred for 4 hrs.  
A solution of 2.46 (0.07 g, 0.24 mmol) and Et3N (0.15 mL, 1.07 mmol) in CH2Cl2 (20 mL) was 
added to a reaction mixture at 0 °C and stirred at room temperature for overnight.  The mixture 
was evaporated and purified by the ISCO-Flash column chromatography in 0% to 50% of EtOAc 
in hexane to get colorless syrup as product 2.47 (0.06 g, 51%).  
 
Analytical data for 2.47: Rf = 0.33 (Sol. EtOAc:Hexane = 1/1); []25D = - 4.872 (c = 
0.390, CH2Cl2); FTIR (neat) 3284, 2960, 2801, 2762, 2256, 1738, 1669, 1607, 1592, 1508, 1485, 
1468, 1339, 1264, 1220, 1162, 1139, 1055, 981, 908, 861, 828, 728, 691, 646 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 7.30 (ddd, J = 6.9, 6.9, 6.9 Hz, 1H), 7.16 (dd, J = 7.5, 7.5 Hz, 2H), 7.06 
(ddd, J = 8.3, 1.2, 1.2 Hz, 1H), 7.06–7.01 (m, 1H), 6.94 (dd, J = 7.5, 7.5 Hz, 2H), 5.00 (d, J = 9.3 
Hz, 1H), 3.88 (ddd, J = 11.9, 8.7, 3.2 Hz, 1H), 3.76 (ddd, J = 9.4, 2.0, 1.1 Hz, 1H),  3.73 (d, J = 
1.2 Hz, 3H), 3.40 (s, 2H), 2.87 (d, J = 9.5 Hz, 2H), 2.10–1.97 (m, 3H), 1.93 (d, J = 12.2 = Hz, 
1H), 1.82 (d, J = 12.3 Hz, 1H)  1.50–1.38 (m, 2H), 0.94 (d, J = 6.8 Hz, 3H), 0.88 (d, J = 6.9 Hz, 
3H); 13C NMR (101 MHz, CDCl3) δ 172.30, 162.41 (d, J = 249.5 Hz), 161.97 (d, J = 245.4 Hz), 
137.86, 137.77, 130.54 (d, J = 8.1 Hz), 129.84 (d, J = 9.1 Hz), 127.51 (d, J = 4.0 Hz), 118.93 (d, 
J = 22.2 Hz), 115.77 (d, J = 21.2 Hz), 115.00 (d, J = 21.2 Hz), 61.88, 61.42, 58.21, 52.85, 52.79, 
52.40, 31.93, 31.43, 31.16, 18.75, 17.66; HRMS (M+H)
+ 
calcd for C24H32F2N3O4S
+ (M+H) 
required 496.2082, found 496.2135. 
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tert-Butyl 4-(3,5-bis(trifluoromethyl)phenylamino)piperidine-1-carboxylate (2.48) 
 
To a solution of 1-Boc-4-piperidone (5.16g, 25.89 mmol) and 3,5-
bis(trifluoromethyl)aniline (4.0 mL, 25.80 mmol) in CH2Cl2 (100 mL) was added NaBH(OAc)3 
(16.30 g, 76.92 mmol) at 0 °C and stirred for 2 hrs. To a reaction mixture was added glacial 
acetic acid (3 mL, 52.41 mmol) at 0 °C and stirred at ambient temperature overnight.  The 
reaction mixture was washed with saturated aqueous NaHCO3 solution.  The mixture was 
extracted with CH2Cl2 (100 mL X 3) and then the combined organic layer was dried over MgSO4, 
filtered, evaporated, and purified by the ISCO-Flash column chromatography in 0% to 40% of 
EtOAc in hexane to get white solid as a product 2.48 (5.1053 g, 48%).  
 
Analytical data for 2.48: Rf = 0.37 (Sol. EtOAc:Hexane = 1/1); FTIR (neat) 3337, 2941, 
2859, 1671, 1615, 1588, 1477, 1432, 1405, 1367, 1275, 1237, 1167, 1116, 1088, 979, 927, 858, 
822, 731, 683, 624 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.08 (s, 1H), 6.91 (s, 2H), 4.44 (d, J = 
7.1 Hz, 1H), 4.13–4.00 (m, 2H), 3.52–3.40 (m, 1H), 3.47 (s, 1H), 2.95 (t, J = 11.9 Hz, 2H), 2.00 
(d, J = 15.4 Hz, 2H), 1.45 (s, 9H), 1.36 (td, J = 14.3, 4.4 Hz, 2H); 13C NMR (101 MHz, CDCl3) δ 
171.42, 151.39 (d, J = 712.8 Hz), 132.64 (q, J = 32.6 Hz), 123.78 (q, J = 272.6 Hz), 111.04 (dd, 
J = 223.7, 3.3 Hz), 80.02, 49.95, 32.03, 31.74, 28.49.  
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tert-Butyl 4-((3,5-bis(trifluoromethyl)phenyl)(N-(tert-butoxycarbonyl)sulfamoyl)amino) 
piperidine-1-carboxylate (2.49) 
 
To a solution of chlorosulfonyl isocyanate (1.0 mL, 11.49 mmol) in CH2Cl2 (60 mL) was 
added to a solution of tert-butyl alcohol (1.1 mL, 11.50 mmol) in CH2Cl2 (20 mL) at 0 °C.  This 
solution was cannulated to a solution of 2.48 (3.98 g, 9.65 mmol) and Et3N (2.0 mL, 14.35 mmol) 
in CH2Cl2 (40 mL) at 0 °C.  After that, the reaction mixture was stirred at ambient temperature 
for overnight.  The reaction mixture was extracted with CH2Cl2 (100 mL X 2) and dried over 
MgSO4, filtered, evaporated, and purified by the ISCO-Flash column chromatography in 0% to 
40% of EtOAc in hexane to get white solid as a product 2.49 (4.78 g, 84%).  
 
Analytical data for 2.49: Rf = 0.83 (Sol. EtOAc:Hexane = 1/1);
 FTIR (neat) 2981, 2934, 
2866, 2383, 2369, 2325, 1736, 1666, 1436, 1366, 1276, 1247, 1131, 1075, 979, 917, 834, 770, 
734, 705, 674, 610 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.94 (s, 1H), 7.67 (s, 2H), 7.57 (s, 1H), 
4.42 (tt, J = 12.1, 3.8 Hz, 1H), 4.19–4.04 (m, 2H), 2.78 (bt, J = 11.9 Hz, 2H), 2.02–1.98 (m, 2H), 
1.48 (s, 9H), 1.33 (s, 9H), 1.15 (dddd, J = 12.5, 12.3, 12.3, 4.5 Hz, 2H); 13C NMR (101 MHz, 
CDCl3) δ 171.47, 152.13 (d, J = 500.4 Hz), 136.73, 133.12 (q, J = 34.1 Hz), 132.75, 123.59, 
122.78 (q, J = 273.0 Hz), 84.27, 80.23, 59.58, 53.61, 31.85, 28.44, 28.07.  
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(S)-tert-Butyl 4-((3,5-bis(trifluoromethyl)phenyl)(N-(tert-butoxycarbonyl)-N-(3-methoxy-2-
methyl-3-oxopropyl)sulfamoyl)amino)piperidine-1-carboxylate (2.51) 
 
To a solution of 2.49 (0.51 g, 0.86 mmol) and DIAD (0.35 g, 1.73 mmol) in THF (30 mL) 
was added a solution of methyl (s)-(+)-3-hydroxy-2-methylpropionate 2.50 (0.10 mL, 0.86 mmol) 
and PPh3 (0.45 g, 1.72 mmol) in THF (30 mL) at room temperature and stirred at room 
temperature for overnight.  The reaction mixture was extracted with CH2Cl2 (100 mL X 3) and 
the combined organic layer was dried over MgSO4, filtered, evaporated, and purified by the 
ISCO-Flash column chromatography in 0% to 30% of EtOAc in hexane to get colorless oil as a 
product 2.51 (1.22 g, 97%).  
 
Analytical data for 2.51: Rf = 0.34 (Sol. EtOAc:Hexane = 1/1); []25D = - 0.992 (c = 
0.504, CH2Cl2);  FTIR (neat) 2985, 2943, 2882, 2383, 2368, 1672, 1623, 1556, 1478, 1433, 1405, 
1368, 1274, 1238, 1166, 1116, 1088, 1068, 1001, 979, 944, 927, 855, 773, 705, 682, 646 cm-1; 
1H NMR (400 MHz, CDCl3) δ 7.95 (s, 1H), 7.62 (s, 2H), 4.45 (m, 1H), 4.13 (s, 2H), 3.63 (dd, J 
= 12.0, 8.0 Hz, 1H), 3.61 (s, 3H), 3.40 (dd, J = 12.0, 8.0 Hz, 1H), 2.80 (m, 2H), 2.58 (m, 1H), 
2.01 (d, J = 8.0 Hz, 2H), 1.55 (s, 9H), 1.37 (s, 9H), 1.13 (dt, J = 12.9, 7.7 Hz, 2H), 1.02 (d, J = 
7.2 Hz, 3H); HRMS (M+Na)
+ 
calcd for C28H39F6N3NaO8S
 + (M+Na) required 714.2254, found 
714.2257. 
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(S)-Methyl 3-(N-(3,5-bis(trifluoromethyl)phenyl)-N-(piperidin-4-yl)sulfamoylamino)-2- 
methylpropanoate HCl (2.52) 
 
To a solution of 2.51 (0.30 g, 0.44 mmol) in CH2Cl2 (20 mL) was added 4N HCl in 1,4-
dioxane (6 mL) at 0 °C and stirred overnight.  A reaction mixture was evaporated to remove 
solvent, and then the mixture was dried under reduced vacuum to furnish a white solid as a 
product 2.52. It used without further purification.  
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(S)-Methyl 3-(N-(3,5-bis(trifluoromethyl)phenyl)-N-(1-(4-fluorobenzyl)piperidin-4-yl)- 
sulfamoylamino)-2-methylpropanoate (2.53) 
 
To a solution of 2.52 (0.12 g, 0.23 mmol), 4-fluorobenzaldehyde (0.03 g, 0.26 mmol) and 
Et3N (0.1 mL, 0.72 mmol) in CH2Cl2 (10 mL) was added NaBH(OAc)3 (0.15 g, 0.73 mmol) at 
0 °C and stirred for overnight.  The reaction mixture was extracted with CH2Cl2 (100 mL X 2) 
and then the combined organic layer was dried over MgSO4, filtered, evaporated, and purified by 
the ISCO-Flash column chromatography in 0% to 40% of EtOAc in hexane to get white oil as a 
product 2.53 (0.05 g, 37%). 
 
Analytical data for 2.53: Rf = 0.45 (Sol. EtOAc:Hexane = 1/1); []25D = + 1.714 (c = 
0.175, CHCl3); FTIR (neat) 3317, 2945, 2815, 2349, 1727, 1620, 1520, 1475, 1436, 1397, 1372, 
1275, 1221, 1169, 1124, 1087, 1035, 943, 858, 844, 769, 702, 682, 662 cm-1; 1H NMR (400 
MHz, CDCl3) δ 7.30–7.22 (m, 2H), 7.08 (s, 1H), 7.02–6.95 (m, 2H), 6.87 (s, 2H), 5.35 (s, 1H), 
4.29–4.23 (m, 1H), 4.02 (d, J = 7.8 Hz, 1H), 3.70 (s, 1H), 3.65–3.60 (m, 1H), 3.48 (s, 3H), 3.38–
3.29 (m, 1H), 3.27 (d, J = 6.4 Hz, 1H), 2.86–2.77 (m, 2H), 2.16 (td, J = 11.4, 2.7 Hz, 2H), 2.05–
1.96 (m, 2H), 1.49 (dtd, J = 13.6, 10.4, 3.6 Hz, 2H), 1.22 (d, J = 7.3 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ 175.62, 162.22 (d, J = 244.9 Hz), 147.88, 134.07 (d, J = 3.2 Hz), 132.64 (q, J = 
32.6 Hz), 130.75 (d, J = 7.9 Hz), 123.77 (q, J = 272.6 Hz), 115.24 (d, J = 21.2 Hz), 112.18 (d, J 
= 3.0 Hz), 109.99 (p, J = 3.9 Hz), 71.59, 69.62, 69.13, 62.41, 52.32, 52.12, 46.12, 39.43, 32.26, 
14.98. 
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(S)-tert-Butyl 4-((4-fluorophenyl)(N-((1-methoxy-3-methyl-1-oxobutan-2-yloxy)carbonyl) 
sulfamoyl)amino)piperidine-1-carboxylate (2.54) 
 
To a solution of 2.31 (0.93 g, 3.17 mmol) and Et3N (0.66 mL, 4.74 mmol) in CH2Cl2 (20 
mL) was cannulated a solution of chlorosulfonyl isocyanate (0.33 mL, 3.79 mmol) and (S)-
methyl 2-hydroxy-3-methylbutanoate 2.9 (0.50 g, 3.81 mmol) at 0 °C and stirred for overnight.  
The reaction mixture was extracted with CH2Cl2 (100 mL X 2) and then the combined organic 
layer was dried over MgSO4, filtered, evaporated, and purified by the ISCO-Flash column 
chromatography in 0% to 50% of EtOAc in hexane to get white solid as a product 2.54 (0.50 g, 
30 %).  
 
Analytical data for 2.54: Rf = 0.70 (Sol. EtOAc:Hexane = 1/1); []25D = + 33.939 (c = 
0.165, CH2Cl2); FTIR (neat) 3077, 2972, 2936, 2878, 1743, 1667, 1602, 1506, 1452, 1435, 1366, 
1265, 1234, 1212, 1168, 1133, 1093, 1064, 954, 938, 873, 738, 641 cm-1; 1H NMR (400 MHz, 
CDCl3) δ 8.09 (s, 1H), 7.25 (dd, J = 9.0, 4.9 Hz, 2H), 7.07 (dd, J = 5.2, 5.2 Hz, 2H), 4.85 (d, J = 
4.3 Hz, 1H), 4.33 (tt, J = 11.9, 3.6 Hz, 1H), 4.10–3.96 (m, 2H), 3.75 (s, 3H), 2.79–2.59 (m, 2H), 
2.28–2.15 (m, 1H), 1.90 (t, J = 11.5 Hz, 2H), 1.32 (s, 9H), 1.25–1.15 (m 2H), 1.08 (dddd, J = 
12.4, 12.4 12.3, 4.2 Hz, 1H), 0.96 (d, J = 6.9 Hz, 3H), 0.89 (d, J = 6.9 Hz, 3H); 13C NMR (101 
MHz, CDCl3) δ 169.96, 164.36, 161.88, 152.74 (d, J = 378.8 Hz), 134.29 (d, J = 8.9 Hz), 130.12 
(d, J = 3.2 Hz), 116.45 (d, J = 22.7 Hz), 79.97, 78.59, 59.33, 53.64, 52.54, 30.18, 28.49, 18.82, 
17.21.  
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(S)-Methyl 2-(N-(4-fluorophenyl)-N-(piperidin-4-yl)sulfamoylcarbamoyloxy)-3-methyl- 
butanoate hydrochloride (2.55) 
 
To a solution of 2.54 (0.5 g, 0.94 mmol) in CH2Cl2 (20 mL) was added 4N HCl in 1,4-
dioxane (6 mL) at 0 °C and stirred overnight.  A reaction mixture was evaporated to remove 
solvent, and then the mixture was dried under reduced vacuum to furnish a white solid as a 
product 2.55. It used without further purification.   
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(S)-Methyl 2-(N-(1-(4-fluorobenzyl)piperidin-4-yl)-N-(4-fluorophenyl)sulfamoyl 
carbamoyloxy)-3-methylbutanoate (2.56) 
 
To a solution of 2.55 (0.09 g, 0.19 mmol), 4-fluorobenzaldehyde (0.03 mL, 0.22 mmol) 
and Et3N (0.08 mL, 0.22 mmol) in CH2Cl2 (10 mL) was added NaBH(OAc)3 (0.14 g, 0.64 mmol) 
at 0 °C and stirred for overnight.  The reaction mixture was extracted with CH2Cl2 (100 mL X 2) 
and then the combined organic layer was dried over MgSO4, filtered, evaporated, and purified by 
the ISCO-Flash column chromatography in 0% to 40% of EtOAc in hexane to get white oil as a 
product 2.56 (0.0786 g, 76 %).  
 
Analytical data for 2.56: Rf = 0.24 (Sol. EtOAc:Hexane = 1/1); []25D = + 16. 467 (c = 
0.753, CH2Cl2); FTIR (neat) 2956, 2925, 2852, 2383, 2357, 1750, 1661, 1627, 1604, 1505, 1463, 
1264, 1226, 1209, 1089, 918, 874, 838, 791, 739, 626 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.29–
7.23 (m, 2H), 7.15 (dd, J = 8.6, 5.5 Hz, 2H), 7.04 (dd, J = 8.9, 8.9, 2H), 6.96 (dd, J = 8.7, 8.7, 
2H), 4.84 (d, J = 4.6 Hz, 1H), 4.23 (tt, J = 12.0, 3.9 Hz, 1H), 3.75 (s, 3H), 3.49 (d, J = 13.2 Hz, 
1H), 3.41 (d, J = 13.2 Hz, 1H), 3.05–2.91 (m, 3H), 2.28–2.08 (m, 3H), 2.02–1.90 (m, 2H), 1.63–
1.38 (m, 2H), 0.93 (t, J = 6.5 Hz, 3H), 0.86 (d, J = 6.9 Hz, 3H);  13C NMR (101 MHz, CDCl3) δ 
170.35, 162.76 (d, J = 249.2 Hz), δ 162.53 (d, J = 246.7 Hz), 152.77, 134.20 (d, J = 8.7 Hz), 
131.54 (d, J = 8.1 Hz), 131.20, 130.62, 116.10 (d, J = 22.6 Hz), 115.43 (d, J = 21.4 Hz), 77.88, 
60.65, 57.95, 52.22, 52.01, 30.85, 30.37, 30.19, 29.78, 18.68, 17.40; HRMS (M+H)
+ 
calcd for 
C25H32F2N3O6S
+ (M+H) required 540.1980, found 540.2224. 
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(S)-Methyl 2-(N-(1-(4-fluorobenzoyl)piperidin-4-yl)-N-(4-fluorophenyl)sulfamoyl 
carbamoyloxy)-3-methylbutanoate (2.57) 
 
To a solution of 2.55 (0.10 g, 0.21 mmol) and Et3N (0.09 mL, 0.65 mmol) in THF (8 mL) 
was added 4-fluorobenzoyl chloride (0.03 g, 0.22 mmol) at room temperature and stirred for 
overnight.  The reaction mixture was evaporated, and purified by the ISCO-Flash column 
chromatography in 0% to 40% of EtOAc in hexane to get white solid as a product 2.57 (0.0458 g, 
39 %).  
 
Analytical data for 2.57: Rf = 0.30 (Sol. EtOAc:Hexane = 1/1); []25D = + 25.410 (c = 
0.488, CH2Cl2); FTIR (neat) 2964, 2933, 2878, 1741, 1604, 1506, 1449, 1370, 1281, 1213, 1170, 
1151, 1067, 1013, 954, 938, 846, 760, 739, 615 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.27–7.21 
(m, 4H), 7.09 (dd, J = 8.42, 8.42 Hz, 2H), 7.00 (dd, J = 8.6, 8.6 Hz, 2H), 4.85 (d, J = 4.2 Hz, 1H), 
4.69 (s, 1H), 4.48 (tt, J = 12.1, 3.9 Hz, 1H), 3.75 (s, 3H), 2.92 (bd, J = 4.8, 2H), 2.23 (ttd, J = 6.9, 
6.9, 4.2 Hz, 1H), 2.14–1.86 (m, 2H), 1.45–1.00 (m, 4H), 0.97 (d, J = 6.9 Hz, 3H), 0.89 (d, J = 6.8 
Hz, 3H); 13C NMR (101 MHz, CDCl3) δ 169.70, 169.30, 163.36 (d, J = 249.9 Hz), 163.00 (d, J = 
250.7 Hz), 150.64, 133.99 (d, J = 9.0 Hz), 131.35 (d, J = 3.2 Hz), 129.67 (d, J = 3.2 Hz), 129.25 
(d, J = 8.6 Hz), 116.45 (d, J = 22.6 Hz), 115.46 (d, J = 21.7 Hz), 78.43, 58.83, 52.36, 50.92, 
29.93, 29.65, 18.63, 16.95; HRMS (M+H)
+ 
calcd for C25H30F2N3O7S
+ (M+H) required 554.1772, 
found 554.1864. 
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5.3. Appendix A 
Selected 1H and 13C NMR’s 
 
 
 
 
 
 
 
 
 
 
 
1H NMR and 13C NMR of compound 2.4 
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1H NMR and 13C NMR of compound 2.7 
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1H NMR and 13C NMR of compound 2.13
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1H NMR and 13C NMR of compound 2.15
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 and 13C NMR of compound 2.17
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1H NMR and 13C NMR of compound 2.21
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1H NMR and 13C NMR of compound 2.22
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1H NMR and 13C NMR of compound 2.23
214 
 
 
 
1H NMR and 13C NMR of compound 2.24
215 
 
 
 
1H NMR and 13C NMR of compound 2.18
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1H NMR and 13C NMR of compound 2.25
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1H NMR and 13C NMR of compound 2.28
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1H NMR
 
 and 13C NMR of compound 2.30
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1H NMR and 13C NMR of compound 2.31
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1H NMR and 13C NMR of compound 2.34
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 and 13C NMR of compound 2.38
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1H NMR and 13C NMR of compound 2.39
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1H NMR and 13C NMR of compound 2.35
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1H NMR and 13C NMR of compound 2.40
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1H NMR and 13C NMR of compound 2.41
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1H NMR and 13C NMR of compound 2.42
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1H NMR and 13C NMR of compound 2.43
228 
 
 
 
1H NMR and 13C NMR of compound 2.45
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1H NMR and 13C NMR of compound 2.46
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 and 13C NMR of compound 2.47
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1H NMR and 13C NMR of compound 2.48
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1H NMR and 13C NMR of compound 2.49
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1H NMR
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 of compound 2.51 
234 
 
 
1H NMR and 13C NMR of compound 2.53
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1H NMR and 13C NMR of compound 2.54
236 
 
 
 
1H NMR and 13C NMR of compound 2.56
237 
 
 
 
1H NMR and 13C NMR of compound 2.57
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5.4. Appendix B 
One and five dose experimental data from 60 cell line 
-Tdp1 related compounds- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
One dose
 
 experimental data of compound 
240 
2.7 (NSC 750772) 
 
 
One dose
 
 
 experimental data of compound 
241 
2.15 (NSC 750710) 
 
 
One dose
 
 
 experimental data of compound 
242 
2.16 (NSC 750711) 
 
 
One dose
 
 experimental data of compound 
243 
2.21 (NSC 750706) 
 
 
One dose experimental data of compound 
244 
2.22 (NSC 747166) 
 
 
One dose experimental data of compound 
245 
2.23 (NSC 767523) 
 
 
One dose experimental data of compound 
246 
2.24 (NSC 767524) 
 
 
One dose experimental data of compound 
247 
2.25 (NSC 750707) 
 
 
One dose
 
 experimental data of compound 
248 
2.30 (NSC 749205) 
 
 
One dose experimental data of compound 
249 
2.34 (NSC 749201) 
 
 
One dose
 
 experimental data of compound 
250 
2.38 (NSC 750715) 
 
 
One dose
 
 experimental data of compound 
251 
2.40 (NSC 750713) 
 
 
One dose
 
 experimental data of compound 
252 
2.42 (NSC 750714) 
 
 
One dose
 
 experimental data of compound 
253 
2.43 (NSC 750712) 
 
 
One dose
 
 experimental data of compound 
254 
2.47 (NSC 764209) 
 
 
One dose
 
 experimental data of compound 
255 
2.53 (NSC 749204) 
 
 
One dose
 
 experimental data of compound 
256 
2.56 (NSC 749203) 
 
 
One dose experimental data of compound 
257 
2.57 (NSC 749202) 
 
 
Five dos
 
 
e experimental data of compound 
258 
2.53 (NSC 749204) 
 
 
 
 
259 
 
 
260 
 
 
 
 
 
261 
 
262 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.5. Appendix C 
 
One and five dose experimental data from 60 cell line 
-Cyclic sulfamide compounds- 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
One dose
 
 
 experimental data of compound 
263 
4.21 (NSC 764190) 
 
 
One dose
 
 
 experimental data of compound 
264 
4.22 (NSC 751486) 
 
 
One dose
 
 
 experimental data of compound 
265 
4.23 (NSC 751478) 
 
 
One dose
 
 
 experimental data of compound 
266 
4.27 (NSC 751468) 
 
 
One dose
 
 
 experimental data of compound 
267 
4.28 (NSC 751469) 
 
 
One dose
 
 
 experimental data of compound 
268 
4.29 (NSC 751470) 
 
 
One dose
 
 
 experimental data of compound 
269 
4.37c (NSC 764189) 
 
 
One dose
 
 
 experimental data of compound 
270 
4.44 (NSC 751477) 
 
 
One dose
 
 
 experimental data of compound 
271 
4.56 (NSC 751472) 
 
 
One dose
 
 
 experimental data of compound 
272 
4.61 (NSC 751473) 
 
 
One dose
 
 
 experimental data of compound 
273 
4.62a (NSC 751479)  
 
 
One dose
 
 
 experimental data of compound 
274 
4.62b (NSC 751483) 
 
 
One dose
 
 
 experimental data of compound 
275 
4.63 (NSC 751467) 
 
 
One dose
 
 
 experimental data of compound 
276 
4.64 (NSC 764191) 
 
 
One dose
 
 
 experimental data of compound 
277 
4.65 (NSC 764192) 
 
 
One dose
 
 
 experimental data of compound 
278 
4.66 (NSC 764193) 
 
 
One dose
 
 
 experimental data of compound 
279 
4.67 (NSC 764194) 
 
 
One dose
 
 
 experimental data of compound 
280 
4.68 (NSC 764195) 
 
 
One dose
 
 
 experimental data of compound 
281 
4.69 (NSC 764196) 
 
 
One dose
 
 
 experimental data of compound 
282 
4.70 (NSC 764197) 
 
 
One dose
 
 
 experimental data of compound 
283 
4.71 (NSC 767525) 
 
 
One dose
 
 
 experimental data of compound 
284 
4.72 (NSC 767526) 
 
 
One dose
 
 
 experimental data of compound 
285 
4.73 (NSC 767527) 
 
 
One dose
 
 
 experimental data of compound 
286 
4.74 (NSC 767528) 
 
 
One dose
 
 
 experimental data of compound 
287 
4.75 (NSC 767529) 
 
 
One dose
 
 
 experimental data of compound 
288 
4.76 (NSC 767530) 
 
 
One dose
 
 
 experimental data of compound 
289 
4.77 (NSC 767531) 
 
 
One dose
 
 
 experimental data of compound 
290 
4.78 (NSC 767532) 
 
 
Five dos
 
 
 
e experimental data of compound 
291 
4.21 (NSC 764190) 
 
 
 
292 
 
 
 
293 
 
 
 
 
 
 
294 
 
Five dose experimental data of compound 
295 
4.22 (NSC 751486) 
 
 
 
296 
 
 
 
297 
 
 
 
 
 
 
 
298 
 
 
Five dose experimental data of compound 
299 
4.23 (NSC 751478) 
 
 
300 
 
 
 
301 
 
 
 
 
 
 
 
302 
 
Five dos
 
e experimental data of compound 
303 
4.37c (NSC 764189) 
 
 
 
304 
 
 
305 
 
 
 
 
 
 
306 
307 
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